<html lang="en"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <link rel="shortcut icon" href="./favicon.png">
    <link rel="preload" href="./static/media/SourceSansPro-Regular.DZLUzqI4.woff2" as="font" type="font/woff2" crossorigin="">
    <link rel="preload" href="./static/media/SourceSansPro-SemiBold.sKQIyTMz.woff2" as="font" type="font/woff2" crossorigin="">
    <link rel="preload" href="./static/media/SourceSansPro-Bold.-6c9oR8J.woff2" as="font" type="font/woff2" crossorigin="">

    <title>app</title>

    <!-- initialize window.prerenderReady to false and then set to true in React app when app is ready for indexing -->
    <script>
      window.prerenderReady = false
    </script>
    <script type="module" crossorigin="" src="./static/js/index.BlylrL8P.js"></script>
    <link rel="stylesheet" crossorigin="" href="./static/css/index.DpJG_94W.css">
  <style media=""></style><style data-emotion="st-emotion-cache-global" data-s=""></style><style data-emotion="st-emotion-cache" data-s=""></style><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/index.BqlD3NTA.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/index.DW_MHI2K.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/FormClearHelper.UtDFKbpT.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/FileHelper.DV2KuUj6.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/ProgressBar.BtMHwdZZ.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/Hooks.YZgOFmbn.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/UploadFileInfo.C-jY39rj.js"></head>
  <body>
    <noscript>You need to enable JavaScript to run this app.</noscript>
    <div id="root"><div class=""><div class="withScreencast" data-testid="stScreencast"><div class="stApp stAppEmbeddingId-t7j6ukwktirr st-emotion-cache-1r4qj8v ee4bbma0" data-testid="stApp" data-test-script-state="notRunning" data-test-connection-state="CONNECTED"><header tabindex="-1" class="stAppHeader st-emotion-cache-12fmjuu e4hpqof0" data-testid="stHeader"><div class="stDecoration st-emotion-cache-1dp5vir e4hpqof1" data-testid="stDecoration" id="stDecoration"></div><div class="stAppToolbar st-emotion-cache-15ecox0 e4hpqof2" data-testid="stToolbar"><div class="stToolbarActions st-emotion-cache-1p1m4ay e1i26tt72" data-testid="stToolbarActions"></div><span id="MainMenu" class="stMainMenu st-emotion-cache-czk5ss ev04twb8" data-testid="stMainMenu" aria-haspopup="true" aria-expanded="false"><button kind="headerNoPadding" data-testid="stBaseButton-headerNoPadding" aria-label="" class="st-emotion-cache-l1ktzw em9zgd018"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-1pbsqtx ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M12 8c1.1 0 2-.9 2-2s-.9-2-2-2-2 .9-2 2 .9 2 2 2zm0 2c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2zm0 6c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2z"></path></svg></button></span></div></header><div class="stAppViewContainer appview-container st-emotion-cache-1yiq2ps eht7o1d0" data-testid="stAppViewContainer" data-layout="narrow"><section tabindex="0" class="stMain st-emotion-cache-bm2z3a eht7o1d1" data-testid="stMain"><div class="stMainBlockContainer block-container st-emotion-cache-mtjnbi eht7o1d4" data-testid="stMainBlockContainer"><div data-testid="stVerticalBlockBorderWrapper" data-test-scroll-behavior="normal" class="st-emotion-cache-0 eu6p4el5"><div class="st-emotion-cache-b95f0i eu6p4el4"><div class="stVerticalBlock st-emotion-cache-1n76uvr eu6p4el3" data-testid="stVerticalBlock" width="704"><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stHeading" data-testid="stHeading"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 id="olmocr">OLMOCR<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#olmocr" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="st-emotion-cache-8atqhb e1mlolmg0"><div class="stFileUploader st-emotion-cache-0 e17y52ym15" data-testid="stFileUploader" width="704"><label data-testid="stWidgetLabel" aria-hidden="true" class="st-emotion-cache-1s2v671 e1dx5vew0"><div data-testid="stMarkdownContainer" class="st-emotion-cache-wq5ihp e1icttdg0"><p>Upload a PDF or Image</p></div></label><section role="presentation" tabindex="0" data-testid="stFileUploaderDropzone" aria-label="Upload a PDF or Image" class="st-emotion-cache-1gulkj5 e17y52ym0"><input data-testid="stFileUploaderDropzoneInput" accept="application/streamlit,.pdf,.png,.jpg,.jpeg" type="file" style="border: 0px; clip: rect(0px, 0px, 0px, 0px); clip-path: inset(50%); height: 1px; margin: 0px -1px -1px 0px; overflow: hidden; padding: 0px; position: absolute; width: 1px; white-space: nowrap;" tabindex="-1"><div data-testid="stFileUploaderDropzoneInstructions" class="st-emotion-cache-u8hs99 e17y52ym1"><span class="st-emotion-cache-nwtri e17y52ym2"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-6rlrad ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M19.35 10.04A7.49 7.49 0 0012 4C9.11 4 6.6 5.64 5.35 8.04A5.994 5.994 0 000 14c0 3.31 2.69 6 6 6h13c2.76 0 5-2.24 5-5 0-2.64-2.05-4.78-4.65-4.96zM19 18H6c-2.21 0-4-1.79-4-4 0-2.05 1.53-3.76 3.56-3.97l1.07-.11.5-.95A5.469 5.469 0 0112 6c2.62 0 4.88 1.86 5.39 4.43l.3 1.5 1.53.11A2.98 2.98 0 0122 15c0 1.65-1.35 3-3 3zM8 13h2.55v3h2.9v-3H16l-4-4z"></path></svg></span><div class="st-emotion-cache-j7qwjs e17y52ym4"><span class="st-emotion-cache-9ycgxx e17y52ym3">Drag and drop file here</span><small class="st-emotion-cache-1rpn56r ejh2rmr0">Limit 200MB per file • PDF, PNG, JPG, JPEG</small></div></div><button kind="secondary" data-testid="stBaseButton-secondary" aria-label="" class="st-emotion-cache-ocsh0s em9zgd02">Browse files</button></section><div class="st-emotion-cache-fis6aj e17y52ym5"><ul class="st-emotion-cache-14m29r0 e17y52ym6"><li class="st-emotion-cache-1l95nvm e17y52ym7"><div class="stFileUploaderFile st-emotion-cache-12xsiil e17y52ym10" data-testid="stFileUploaderFile"><div class="st-emotion-cache-10ix4kq e17y52ym12"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-4mjat2 ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zM6 20V4h7v5h5v11H6z"></path></svg></div><div class="stFileUploaderFileData st-emotion-cache-1l4firl e17y52ym8"><div class="stFileUploaderFileName st-emotion-cache-1uixxvy e17y52ym9" data-testid="stFileUploaderFileName" title="medical-microbiology-basic immunology and serodiagnosis.pdf">medical-microbiology-basic immunology and serodiagnosis.pdf</div><small class="st-emotion-cache-1rpn56r ejh2rmr0">9.4MB</small></div><div data-testid="stFileUploaderDeleteBtn"><button kind="minimal" data-testid="stBaseButton-minimal" aria-label="" class="st-emotion-cache-8ccstr em9zgd06"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-1pbsqtx ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M19 6.41L17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41z"></path></svg></button></div></div></li></ul></div></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stButton st-emotion-cache-8atqhb e1mlolmg0" data-testid="stButton"><button kind="secondary" data-testid="stBaseButton-secondary" aria-label="" class="st-emotion-cache-ocsh0s em9zgd02"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1hyd1ho e1icttdg0"><p>Submit</p></div></button></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stMarkdown" data-testid="stMarkdown"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><p><strong>Processing file:</strong> medical-microbiology-basic immunology and serodiagnosis.pdf</p></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stMarkdown" data-testid="stMarkdown"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><p>Scanned by CamScanner</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="section-v">Section V<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#section-v" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="medical-microbiology">Medical Microbiology<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#medical-microbiology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Part Five: Basic Immunology and Serodiagnosis</p>
<p>Chapter 1
Introduction</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="terms-commonly-used-in-immunology">TERMS COMMONLY USED IN IMMUNOLOGY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#terms-commonly-used-in-immunology" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><strong>Immunity</strong> Immunity is the defence mechanism or resistance of a host against a foreign body. It involves the recognition and disposal of such ‘foreign’ or ‘non-self’ material that enters the body. This non-self material may be in the form of infectious agents or as life-saving tissue-grafts. Immunity to infection may be natural or acquired through adaptive immune response.</p>
<p><strong>Immunology</strong> Immunology is the study of immunity.</p>
<p><strong>Non-self</strong> This is a very wide term which includes everything which is different from individual’s own constituents. Infectious agents such as bacteria, viruses, fungi, parasites; cells or other material from another individual of same or different species; and occasionally even drugs and food can be regarded as ‘non-self’ to a particular individual.</p>
<p><strong>Natural resistance</strong> This is a non-specific defence mechanism of the body which is mounted against any non-self material without identifying it. This is due to the innate or natural immunity.</p>
<p><strong>Adaptive Immune Response</strong> The adaptive immune response is directed specifically to a particular non-self or antigenic stimulus which may result in the destruction of this antigen in the body. It usually leaves behind a memory of this antigen, so that it can be immediately recognized and eliminated in future. This is also called acquired immunity.</p>
<p><strong>Vaccination</strong> This is a method of stimulating adaptive immune response and memory against a known infectious agent without suffering from the harmful effects of the disease. In case of a future contact with the same agent, the body can mount an immediate immune response due to acquired immunity.</p>
<p><strong>Grafting</strong> If cells or organs from one individual are used to replace defective ones in another individual, the body of the latter mounts an immune response against them, recognizing them as ‘non-self’. This is known as ‘Graft Versus Host’ (GVH) reaction. To suppress this undesirable effect, an immune mechanism is suppressed by using drugs till the new organ is accepted by the recipient body.</p>
<p><strong>Autoimmunity</strong> The body’s own cells and molecules may undergo some variation and are recognised by the host’s immune system as ‘non-self’. An immune response mounted against such cells may lead to the destruction of body’s own cells and tissues. This is known as autoimmunity or autoimmune disease. This is a harmful side of immunity.</p>
<p><strong>Hypersensitivity</strong> Sometimes specific memory to an antigen may lead to harmful or undesirable effect on the body on subsequent contact with the same antigen. The hypersensitivity reaction varies with the type of antigenic stimulus.</p>
<p>Scanned by CamScanner</p>
<p>1112 Basic Immunology and Serodiagnosis</p>
<p>Immunosuppression Some individuals may possess lower levels of immunity due to some defects in their immune mechanism. Immuno-suppression can be induced by certain drugs to control autoimmunity, hypersensitivity and graft rejection; or it can be acquired as a result of chronic infections.</p>
<p>Antigen Antigen is a foreign substance that stimulates adaptive immune response in the body. Example of such adaptive immune response is the production of specific antibody.</p>
<p>Antibody An antibody is a serum immunoglobulin which is produced specifically in response to an antigenic stimulus.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="non-specific-defences">NON-SPECIFIC DEFENCES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#non-specific-defences" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Non-specific defences provide the first line of protection against a diverse array of infectious agents. The degree of this protection varies from individual to individual, and may range from complete insusceptibility to complete susceptibility. The non-specific resistance provided by one individual may make him more susceptible or less susceptible than another individual. This non-specific immunity may be natural or innate.</p>
<p>Natural Immunity Natural immunity is not acquired through previous contact with the antigen, but is largely genetically determined.</p>
<p>Species Immunity A microorganism pathogenic to one species of animals may not be pathogenic to another species. For example, <em>Neisseria gonorrhoeae</em> can infect humans and chimpanzees, but not other animals and <em>Mycobacterium leprae</em> can produce disease in humans but not in monkeys.</p>
<p>Racial Immunity Within one animal species, such as humans, there may be marked differences in susceptibility based on racial and genetic differences. For example, an inherited deficiency of glucose-6-phosphate-dehydrogenase (G6PD) in some individuals makes their red cells much less susceptible to <em>Plasmodium falciparum</em>, a malarial parasite. A similar phenomenon is observed in persons with sickle cell anaemia.</p>
<p>Variation in immunity due to age Some infections are characteristic of certain age groups which can be related to physiological factors. For example, bacterial meningitis during the first month of life is caused by coliform bacteria. The antibodies to these bacteria are IgM which fail to cross the placenta and are not produced by a newborn for the first few months of life. Infections such as rubella or toxoplasma can cause severe disease and/or deformities in the foetus <em>in utero</em> (within the uterus) due to the absence of antibodies where as the mother who is the carrier, suffers from a very mild or asymptomatic infection.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="innate-immunity">Innate Immunity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#innate-immunity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>As with any biological phenomenon, resistance to infection varies from individual to individual, irrespective of species or race, or age. When exposed to the same infectious agent, one individual may develop a severe disease; another may show signs of mild disease; while a third person may not suffer from the disease at all. This is due to the innate resistance of every individual provided by the physiological and chemical barriers at the portal of entry of the pathogen, and other non-specific mechanisms that do not require previous exposure of the host to the infectious agent. Such resistance or defence mechanisms include:</p>
<p>(i) Skin Very few microorganisms can invade an intact skin. The acid pH of sweat and fatty acids secreted by sebaceous glands in the skin have antimicrobial properties.</p>
<p>(ii) Mucous membranes Cells lining the mucous membranes, e.g. ciliated cells of the respiratory tract, are designed to restrict the entry of foreign particles into the body. The mucus secreted by these linings also has antimicrobial activity due to various enzymes such as lysozyme, present in it. The hydrolytic enzymes in saliva and those secreted by the cells lining the mucous membranes, acidity of the gastric juice, acid pH in the vagina, are some examples of body's natural defences.</p>
<p>Scanned by CamScanner</p>
<p>Introduction 1113</p>
<p>(iii) Lysozyme (muramidase) This is an enzyme secreted by macrophages. It attacks the cell walls of many bacteria leading to their lysis and death.</p>
<p>(iv) Interferon This is a family of proteins produced rapidly by many cells in the body in response to any viral infection. It interferes with viral replication.</p>
<p>(v) Phagocytosis Macrophages and polymorphonuclear (PMN) leucocytes are the most active phagocytic cells which are present in the blood and other tissues. A great majority of foreign materials such as bacteria in the tissues are phagocytosed (engulfed) and ultimately eliminated by phagocytosis.</p>
<p>(vi) Inflammation This is a non-specific defense mechanism in which proteins and cells from the blood respond to tissue injury. Irrespective of the cause, such as infection, injury, exposure to chemicals, etc. the basic manifestations of inflammation are very similar and lead to removal of necrotic tissue and foreign material.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="acquired-immunity">ACQUIRED IMMUNITY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#acquired-immunity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="specific-immune-response">Specific Immune Response<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#specific-immune-response" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>There are three parameters of specific immune response:</p>
<ol>
<li>
<p>Recognition This is the ability of the immune system to recognise the antigens of various types and specificities by distinguishing between the 'self' and the 'non-self' in the complex environment of body tissues.</p>
</li>
<li>
<p>Specificity This is the ability of the immune system to direct all its aspects of immune response, individually and separately, to each inducing antigen, without reacting with other antigens.</p>
</li>
<li>
<p>Memory (anamnesia) The immune system has the ability to 'remember' or not to 'forget' an antigen, long after the body's initial contact with that antigen. Because of this faculty, a subsequent exposure to the antigen results in rapid and more aggressive immune response for the destruction of the antigen. This phenomenon provides protection against the recurrence of many infections and is the basis of immunisation by vaccination.</p>
</li>
</ol>
<p>There are two arms of specific immune response:</p>
<ol>
<li>
<p>Humoral or antibody mediated immune response (AMI) AMI is mediated by immunoglobulins called antibodies which are produced by B-lymphocytes and plasma cells as a result of stimulation by a specific antigen.</p>
</li>
<li>
<p>Cell mediated immune response (CMI) The CMI is primarily mediated by T-lymphocytes and their secretory products.</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="types-of-acquired-immunity">Types of Acquired Immunity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#types-of-acquired-immunity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>In general, humoral and cell-mediated immune responses can be acquired in three different ways:</p>
<ol>
<li>
<p>Active Immunity This type of immunity is acquired by direct exposure to an antigen which stimulates individual's own immune system. The exposure to the antigen may be natural, e.g. through infection, or artificial as in vaccination. The disadvantage of this type of immunity is that it takes some time after the exposure to develop. However, once produced, it lasts for a long time because of the phenomenon of 'memory'.</p>
</li>
<li>
<p>Passive immunity As the name suggests, passive immunity is transferred passively from an immune individual to a non-immune or susceptible individual. The transfer can be effected without the induction of any immune response in the recipient. It occurs through soluble mediators of immunity such as antibodies and cytokines.</p>
</li>
</ol>
<p>Passive transfer of immunity occurs naturally from mother to foetus in the form of IgG type of immunoglobulins which can pass through the placenta or as IgA type of antibodies through breast milk. It can also be transferred artificially by administration of a known antibody against an infectious agent e.g. anti-tetanus immunoglobulin for</p>
<p>Scanned by CamScanner</p>
<p>1114 Basic Immunology and Serodiagnosis</p>
<p>treatment of tetanus to neutralize the toxin. The passive immunity provides immediate protection to a non-immune individual, but is short-lived and declines after a few days. There is no ‘memory’ after this immunity.</p>
<ol start="3">
<li>Adaptive Immunity Adaptive immunity is acquired through a passive transfer of lymphocytes from an immune individual to a non-immune individual. The lymphocytes can also be immunised ‘in vitro’. For example, thymic grafts to patients with T-cell immune deficiency. It provides immediate immunity to the recipient and has a long lasting effect.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cells-and-organs-of-the-immune-system">CELLS AND ORGANS OF THE IMMUNE SYSTEM<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cells-and-organs-of-the-immune-system" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The capacity to respond specifically to immunological stimuli is exhibited primarily by the cells of the lymphoid system. During embryonic life, primitive lymphocytes are derived from haemopoietic stem cells in the yolk sac, liver and bone-marrow, along with the cells of myeloid and erythroid series. The lymphoid stem cells which originate from the bone marrow, differentiate to form two distinct lymphocyte subpopulations. One set of populations, called T-cells, require to be differentiated in the thymus before they start functioning as immunologically competent cells. The cells of the other subpopulation, B-cells, are independent of thymus and are differentiated in the Bursa of Fabricius, a lymphoid portion of the hindgut of birds. However, human B-cells are differentiated in the bone marrow. Table 1.1 shows some differences between T- and B-cells.</p>
<p>Primary lymphoid organs of the human immune system, are thymus and bone marrow, from where lymphocytes are developed throughout the life span of an individual. Secondary lymphoid organs, on the other hand, are tissues rich in lymphocytes through which mature lymphocytes are constantly migrating and are being activated for a specific immune response. These secondary lymphoid organs include lymph nodes, white pulp of the spleen and Mucosa associated lymphoid tissue (MALT), e.g. tonsils, Peyer's patches and appendix. T-cells and B-cells occupy areas specific for their development.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="lymphocytes">LYMPHOCYTES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#lymphocytes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Mature lymphocytes in peripheral blood are round in shape, measuring approximately 6–15μm in diameter. The nucleus is large in size giving a high nucleus to cytoplasm ratio. Lymphocytes comprise 20–50% of the white blood cells in a normal adult. When stained with Giemsa or Leishmann stain, the nucleus of a lymphocyte stains intense purple with</p>
<table><thead><tr><th></th><th>T-cells</th><th>B-cells</th></tr></thead><tbody><tr><td>Frequency in Blood</td><td>70%</td><td>20%</td></tr><tr><td>Frequency in spleen</td><td>50%</td><td>50%</td></tr><tr><td>Immunoglobulins on surface</td><td>±</td><td>++++</td></tr><tr><td>Method of counting</td><td>Rosette formation with sheep red cells</td><td>Immunofluorescence with anti-Ig</td></tr><tr><td>Secretion of antibody</td><td>-</td><td>+</td></tr><tr><td>Effector in cell-mediated reactions</td><td>+</td><td>-</td></tr><tr><td>Inactivated by x-ray radiation</td><td>-</td><td>+</td></tr><tr><td>Inactivated by anti-lymphocytic serum</td><td>+</td><td>-</td></tr></tbody></table>
<p>Scanned by CamScanner</p>
<p>Introduction 1115</p>
<p>course masses of chromatin. The cytoplasm appears pale blue without any granules or may contain a few fine azurophilic granules. T- and B-subpopulations of lymphocytes are indistinguishable from each other on the basis of morphology as observed by Giemsa or Leishmann stain.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="t-lymphocytes">T-Lymphocytes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#t-lymphocytes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>T-Lymphocytes constitute approximately 65–80 percent of circulating small lymphocytes in the peripheral blood. They have a long life span extending up to a few months or even years. T-cells require an intact thymus for their functional maturation.</p>
<p>Unlike B-cells, T-cells do not have immunoglobulin molecules on their surfaces, and cannot synthesize antibodies when stimulated by an antigen. They can be identified by their ability to bind sheep red cells on their surfaces, to form rossettes. This property is used to count T-cells in peripheral blood.</p>
<p>T-cells are found to have many surface receptors which can be identified by the use of monoclonal antibodies raised against these receptors. These are called CD (Cluster of Differentiation) markers because one marker may bind with several monoclonal antibodies forming a cluster. Thus, the sheep red cell receptor marker is CD2, and is present on all T-cells. And, CD4 is expressed primarily by T-helper/inducer cells and thought to interact with Class II HLA molecules on the surface of antigen presenting cells.</p>
<p>T-lymphocytes are mainly responsible for mounting a cell-mediated immune response (CMI) in response to an antigenic stimulus. During their migration in the body through various tissues, they recognise ‘non-self’ or antigenic substances and become immunologically ‘activated’. Upon activation, they produce a number of secretory products, known as lymphokines, which participate in effector functions or regulate immune responses. Some T-cells also help B-cells to respond to an antigen.</p>
<p>On the basis of their functions and surface receptors, T-cells can be divided into various subsets. The main subsets are:</p>
<p>(i) T-helper cells (T4) These T-cells are responsible for producing lymphokines that positively regulate or help B-cells in the process of antibody production, especially against haptens. B-cells cannot produce antibodies to haptens until the hapten carrier has interacted with helper T-cells. T-cells also help effector T-cells in cell-mediated immune response.</p>
<p>A large number of helper T-cells have CD4 receptors on their surface.</p>
<p>(ii) T-suppressor cells (Ts) Some T-lymphocytes are able to negatively regulate or suppress the immune responses of both T- and B-lymphocytes. These cells have CD8 surface markers. Overactivity of Ts cells can result in the state of immunodeficiency leading to many intracellular opportunistic infections such as that by <em>Pneumocystis carinii</em>.</p>
<p>(iii) T-inducer cells Generation of T-suppressor cells is induced by T-inducer cells. They also have a CD4 marker on the surface.</p>
<p>(iv) T-cytotoxic cells (Tc) Some T-cells are cytotoxic or lethal for cells that carry specific antigens on their surfaces, e.g. virus infected cells, tumour cells or grafted (transplanted) cells. The Tc cells may also mediate the graft-versus-host (GVH) reaction. A large number of Tc cells have CD8 surface marker.</p>
<p>(v) T-delayed hypersensitivity Cells (TDH) These T-cells secrete lymphokines which produce an inflammatory response in delayed allergic reactions or in defence against infections caused by bacteria, fungi and parasites. All TDH cells have CD4 surface marker.</p>
<p>Scanned by CamScanner</p>
<p>1116 Basic Immunology and Serodiagnosis</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="b-lymphocytes">B-Lymphocytes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-lymphocytes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>B-lymphocytes form about 20 to 25 per cent of the small lymphocytes in peripheral blood. They have a short life span, of only a few days or weeks. Although they originally develop in the bone marrow, when activated by the antigenic stimulus, they undergo differentiation in secondary lymphoid organs. Mature B-cells have a large number of immunoglobulin molecules (about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>10</mn><mn>5</mn></msup></mrow><annotation encoding="application/x-tex">10^{5}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord">1</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">5</span></span></span></span></span></span></span></span></span></span></span></span></span> molecules per cell) on their surface. B-cells can be counted with the help of fluorescent labelled anti-globulin antibody. Resting B-cells are small cells with a thin rim of cytoplasm around the nucleus.</p>
<p>When activated by an antigen, B-cells undergo transformation, enlarge and become lymphoblasts. The lymphoblasts proliferate and quickly increase in number. Some of these lymphoblasts further differentiate into plasma cells. Plasma cells are oval shaped cells, 7 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mi>μ</mi><mi mathvariant="normal">m</mi></mrow><annotation encoding="application/x-tex">15\mu \mathrm{m}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">15</span><span class="mord mathnormal">μ</span><span class="mord mathrm">m</span></span></span></span></span> in diameter, with a round, eccentrically placed nucleus showing a 'cart-wheel' appearance. The plasma cells are seen in the secondary lymphoid organs where they synthesise a large number of immunoglobulin molecules identical to those carried by their B-cell precursors. Sometimes B-cell activation and differentiation may require assistance from helper T-cells.</p>
<p>Some lymphoblasts, revert to a resting stage and form memory cells specific for the antigen which induced its transformation. When re-exposed to the same or related antigen, these memory cells generate a rapid and more intense secondary response.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="9bd3353f">♦ PRIMARY LYMPHOID ORGANS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#9bd3353f" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="thymus">Thymus<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#thymus" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Thymus is a bilobed capsulated organ located in the upper chest cavity. It grows in size till puberty and then atrophies slowly with age. The main function of thymus is to 'educate' T-cells to differentiate between the 'self' and 'non-self' antigens and interact efficiently with the non-self.</p>
<p>T-cell precursors from the bone marrow stem cells (thymocytes) are located in the thymic cortex, the layer of the thymus just below its outer capsule. As they proliferate and mature, these thymocytes pass to the medulla, the inner layer of the thymus. The medulla is much less populated with T-cells than the cortex. The mature educated T-cells from the medulla then migrate to the secondary lymphoid organs.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="the-bursa-of-fabricius">The Bursa of Fabricius<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#the-bursa-of-fabricius" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This is a primary lymphoid organ at the terminal end of the gut in birds. Here precursors of B-lymphocytes develop into mature B-cells. The equivalent of this organ is not yet identified in humans and so bone marrow is considered as the primary organ for B-cell maturation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="da2a17b6">♦ SECONDARY LYMPHOID TISSUES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#da2a17b6" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The main secondary lymphoid tissues in the body are lymph nodes, white pulp of the spleen and mucosa associated lymphoid tissue (MALT) which includes lymphoid tissues in the gut, respiratory system and mammary glands. Most of the B- and T-lymphocytes are present in these lymphoid tissues from where they actively circulate. Each lymphoid tissue has separate T- and B-cell dependent areas.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="lymph-nodes">Lymph nodes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#lymph-nodes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>These are located in several areas of the body, being more numerous in the areas where arms and legs join the trunk of the body. They serve as filters for the tissue fluid, lymph. They also act as stations from where lymphocytes can recirculate between blood and lymph.</p>
<p>Each lymph node has an outer area, cortex, lying beneath the capsule. The cortex contains a large number of dense aggregations of lymphocytes called primary follicles. During an active immune response, they enlarge, appearing less dense and are then known as secondary follicles or germinal centres. These are activated</p>
<p>Scanned by CamScanner</p>
<p>Introduction 1117</p>
<p>proliferating B-lymphocytes undergoing transformation to lymphoblasts and plasma cells.</p>
<p>The innermost portion of the lymph node is the medulla. The paracortex, or the area between the cortex and the medulla, contains diffusely spread out T-lymphocytes. The antibody molecules produced by plasma cells are released into circulation through efferent lymphatics (Fig. 1.1).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="malt">MALT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#malt" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Mucosa associated lymphoid tissues include tonsils, Peyer's patches in the small intestine and appendix in the gut, bronchial and mammary tissue, and salivary and lacrimal glands. Unlike other lymphoid tissues, MALT are not encapsulated, but are scattered diffusely in the mucosa and submucosa. In some sites, follicles of B-cells may be seen.</p>
<p><img src="assets/images/image-20251219-b83b7e62.jpeg" alt="img-0.jpeg">
Fig 1.1 Section of a lymph node (Diagramatic)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="spleen">Spleen<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#spleen" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The spleen is a secondary lymphoid organ located in the left abdominal cavity. The spleen has two main functional areas, the red pulp, which is rich in red blood cells and macrophages, and white pulp which is rich in lymphocytes. The white pulp contains primary and secondary follicles similar to those in the lymph nodes where B-lymphocytes proliferate. The T-cells predominate in the periarterial sheath. The T- and B-cells enter the blood directly from the spleen through the splenic vein (Fig. 1.2).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="the-null-or-natural-killer-nk-cells">The 'Null' or Natural Killer (NK) Cells<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#the-null-or-natural-killer-nk-cells" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In the peripheral blood, 10 per cent of lymphocytes lack traditional T- or B-cell markers. Due to the absence of these two surface markers, these lymphocytes are called 'Null' cells. These large granular lymphocytes mediate rapid lysis of virus infected cells, tumour cells and foreign graf T-cells and so are also called Natural Killer (NK) cells. These NK cells do not require previous</p>
<p>Scanned by CamScanner</p>
<p>1118 Basic Immunology and Serodiagnosis</p>
<p><img src="assets/images/image-20251219-c871d617.jpeg" alt="img-1.jpeg">
Fig. 1.2 Section of spleen (Diagrammatic)</p>
<p>sensitisation to target T-cell antigens in order to perform this function. They achieve cytolysis by.</p>
<p>(i) Directly binding to the target cell.
(ii) Release of cytotoxic factors into the target cell environment.
(iii) Formation of pores in the membrane of the target cell which changes its permeability and leads to the lysis of the target cell.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="recirculation-of-lymphocytes">Recirculation of Lymphocytes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#recirculation-of-lymphocytes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Mature lymphocytes from the primary lymphoid organs are steadily but constantly circulating between body tissues, lymph, blood and the lymphoid organs. Whenever an antigen is detected, T- and B-cells get activated and eventually mount an immune response against it. The process of activation is generally carried out in the same type of lymphoid tissue where the stimulation has occurred. For example, for the antigenic stimulus in the gut, the activation may take place in Peyer's patches, or other MALT.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="fe122d7e">♦ PHAGOCYTES AND PHAGOCYTOSIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#fe122d7e" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Phagocytosis is the process by which microorganisms, tissue debris, inorganic particles or malignant cells are ingested by certain body cells, collectively known as phagocytes. Phagocytes also participate in other processes such as wound repair, inflammation and immune responses. Phagocytes belong to a heterogeneous population of cells arising from the pleuripotent haemopoietic stem cell. Phagocytes belonging to the granulocyte series are neutrophils while those from the monocyte series are mononuclear phagocytes or macrophages.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="polymorphonuclear-neutrophils-pmn">Polymorphonuclear neutrophils (PMN)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#polymorphonuclear-neutrophils-pmn" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Maturation of the polymorphonuclear neutrophil occurs in the bone marrow. It is a multistep sequential process, beginning with stimulation of stem cell. The average time required to produce a mature neutrophil is 6 to 14 days. The mature neutrophils are stored in the bone marrow and are released rapidly into peripheral circulation in response to various stimuli. Under normal condi</p>
<p>Scanned by CamScanner</p>
<p>Introduction 1119</p>
<p>tions, approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>10</mn><mn>11</mn></msup></mrow><annotation encoding="application/x-tex">10^{11}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord">1</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">11</span></span></span></span></span></span></span></span></span></span></span></span></span> mature neutrophils are released into circulation everyday. They form 40 to 75 per cent of the white blood cell population in blood. After a few hours in blood, they migrate to the tissues, where they survive for one to two days.</p>
<p>The activity of neutrophils is mainly directed against bacteria which are killed and degraded. The neutrophils contain primary azurophilic granules and secondary specific granules that contain:</p>
<p>(i) Enzymes such as lysozyme, myeloperoxidase, and acid hydrolases.
(ii) Iron binding and vitamin B₁₂ binding proteins.
(iii) Chemotactic agent for polymorphs and monocytes.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="macrophages-or-mononuclear-phagocytes">Macrophages or mononuclear phagocytes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#macrophages-or-mononuclear-phagocytes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The mononuclear phagocytic system (MPS) is composed of a group of cells arising from a common origin in the bone marrow. They are released from the bone marrow as immature monocytes which circulate in the peripheral blood for one to four days. From blood they migrate to various tissue sites where they reside from months to years. In the tissues MPS cells may be fixed, as in lymph nodes, spleen or liver, or free as in pleural, alveolar or peritoneal spaces and in blood.</p>
<p>The macrophages have a great capacity to respond to a variety of stimuli, including lymphokines produced by T-cells. They contain azurophilic lysosomal granules and many other secretory products such as</p>
<p>(i) Enzymes like lysozyme, myeloperoxidase, acid hydrolases, proteases and non-specific esterases.
(ii) Other secreted products are complement components, coagulation factors, interferon, interleukin-1 etc.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="process-of-phagocytosis">Process of Phagocytosis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#process-of-phagocytosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Mature phagocytic cells which are not fixed, are mobile by a process called diapedesis, which is a movement resembling that of amoeba with a forward extension of cytoplasm, pseudopodium.</p>
<p>Phagocytosis involves a sequence of activities (Fig. 1.3).</p>
<ol>
<li><strong>Chemotaxis</strong> Chemotaxis is a process in which cells tend to move in a certain direction under the influence of chemical substances. These chemical substances are called chemotactic agents. Invasion by bacteria and destruction of tissue stimulates the production of many chemotactic factors. The important chemotactic factors are anaphylatoxins C3a and C5a which are released in the complement pathway, bacterial products and interleukin-8. Antigen-antibody complexes and dead tissue can also act as chemotactic agents.</li>
</ol>
<p><img src="assets/images/image-20251219-5ac23d06.jpeg" alt="img-2.jpeg"></p>
<p>Scanned by CamScanner</p>
<p>1120 Basic Immunology and Serodiagnosis</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="2-adherence-and-opsonisation">2. Adherence and Opsonisation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-adherence-and-opsonisation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>For phagocytosis to occur, the phagocyte and the particle to be phagocytosed must adhere to each other. Particles and cells suspended in body fluids have a negative charge (the zeta potential), due to which they repel each other. The negative charge on the particle can be neutralized by coating it with a positively charged protein. The antibody molecules and the third component of the complement (C3) are examples of such proteins. The particles coated with antibody or C3 have a reduced zeta potential and can adhere to the neutrophils. The molecules that promote phagocytosis by coating the particles in this way are known as opsonins. Antibodies are the most effective opsonins. Adherence between the opsonised particles and neutrophils is enhanced by the presence of specific receptors for antibody and C3 on the surface of neutrophils.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="3-ingestion">3. Ingestion<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-ingestion" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Once the particle is bound firmly to the surface of the phagocyte, engulfment occurs by active amoeboid movement of the cytoplasm. The cytoplasm extends around the particle which is eventually completely enclosed within a vacuole called a phagosome.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="4-destruction">4. Destruction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#4-destruction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Within the phagosome, the ingested particle is exposed to two destructive mechanisms: the respiratory burst and the lysosomal enzyme.</p>
<p>(i) Respiratory burst As soon as the particle such as a bacterium is ingested, the phagocyte increases its oxygen consumption drastically. With the help of oxidative enzymes a large volume of hydrogen peroxide is formed. The main respiratory burst enzyme, myeloperoxidase, converts this hydrogen peroxide into toxic bactericidal products.</p>
<p>(ii) Lysosomal enzymes As the particle is enclosed in a phagosome, the primary granules called lysosomes in the phagocytes migrate towards the phagosome. They fuse with the phagosome (phagolysosome) and release their enzymes into it. These enzymes kill the microorganisms and digest the dead ones.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="inflammation">INFLAMMATION<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#inflammation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Inflammation is a non-specific defense mechanism of the body in response to tissue injury. Blood cells and proteins participate in this process to achieve healing of the injured tissue. The cause of injury can be bacterial infection, exposure to chemicals or radiation, physical changes in the tissue or immunopathological events such as formation of immune complexes. The inflammatory response can occur in any part of the body. Its basic manifestations are the same and are characterised by five classical signs, namely, redness, swelling, heat, pain and loss of function.</p>
<p>The course of inflammatory response can be divided into two phases:</p>
<p>(i) Vascular phase.
(ii) Cellular phase.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="vascular-phase">Vascular phase<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vascular-phase" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>The vascular phase begins immediately after the injury and involves the following processes:</p>
<p>(a) Release of immediate phase products such as histamine from mast cells and basophils and serotonin from platelets, immediately after the injury.
(b) Vasodilatation of small blood vessels in the area due to the above products results in increased blood flow and creates redness and heat.
(c) Increase in vasopermeability brings about leakage of plasma into the extravascular tissue, creating swelling and pain.
(d) Release of later phase products begins 6 to 12 hours after the injury. These products include components of the complement system such as C3a, C4a, C5a etc. kinins, coagulation products, prostaglandins and leukotrienes. These products bring about further increase in vasodilation and vascular permeability. Some products exert a chemotactic effect on phagocytes.</p>
<p>Scanned by CamScanner</p>
<p>Introduction 1121</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cellular-phase">Cellular phase<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cellular-phase" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(a) Migration of neutrophils to the site of injury occurs within 30 to 60 minutes under the influence of chemotactic factors. Vasodilatation and increased vasopermeability allows their passage through the walls of blood vessels. They start active phagocytic activity of ingesting bacteria, cellular debris and immune complexes, if present.</p>
<p>(b) Migration of macrophages begins four to five hours after the injury. These slow moving phagocytic cells are attracted to the site by chemotaxis. In the same way as the neutrophils, macrophages also start resolving the process by active phagocytosis. The process of healing after this stage depends on other factors such as the virulence of infecting bacteria, their number, and the extent and the cause of injury.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="eosinophils-mast-cells-and-basophils">Eosinophils, Mast Cells and Basophils<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#eosinophils-mast-cells-and-basophils" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Eosinophils, basophils and mast cells are functionally related because all have the ability to promote acute inflammatory responses. They serve this function by releasing enzymes which enhance vasodilatation, fluid effusion and tissue damage.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="eosinophils">Eosinophils<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#eosinophils" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Eosinophils are polymorphic nuclear leucocytes. They contain large protein granules which have a high affinity for acid dyes such as eosin. They constitute about 2–6 per cent of leucocytes in the peripheral blood. Eosinophils are phagocytic cells whose primary function is to ingest and destroy foreign particles. Once a particle is bound to the receptors on an eosinophil, it triggers a large number of biochemical reactions, such as the respiratory burst. The eosinophils are more suited to extracellular destruction of large parasites such as helminths than to phagocytosis of small particles. They release the contents of their granules into the surroundings to reach the parasitic worms. These granules contain oxidative and lytic enzymes which bring about destruction of the parasites.</p>
<p>All these factors lead to an inflammatory response called type I hypersensitivity. The presence of eosinophilia (increased number of eosinophils in blood) is characteristic of individuals with severe allergies. This is because the eosinophils are attracted in large numbers where degranulation of mast cells or basophils occurs. Mast cells and basophils release substances such as eosinophil chemotactic factors and histamine which attract the eosinophils at the site of an allergen.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mast-cells-and-basophils">Mast cells and basophils<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mast-cells-and-basophils" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Mast cells are large, round cells, distributed in the connective tissues throughout the body. Their cytoplasm is packed with large acidic granules which stain deeply with basic dyes such as toluidine blue. Basophils are similar to mast cells but are present in the peripheral blood. They constitute about 0.5 per cent of blood leucocytes. Chemical composition of the granules of basophils varies slightly from that of the mast cells. Both mast cells and basophils have receptors for IgE and when two adjacent IgE molecules are bound together by an antigen or an allergen, it triggers the release of the contents of the cytoplasmic granules. These granules contain vasoactive amines which cause capillary dilatation and increased vascular permeability. They also contain histamine, heparin, eosinophils, chemotactic factor and proteases which activate complement to generate anaphylatoxins. All these factors lead to an inflammatory response called type I hypersensitivity.</p>
<p>Scanned by CamScanner</p>
<p>Chapter 2</p>
<p><img src="assets/images/image-20251219-9836d55b.jpeg" alt="img-3.jpeg"></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antigen-antibody-and-complement">Antigen, Antibody and Complement<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antigen-antibody-and-complement" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="antigen">ANTIGEN<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antigen" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>An antigen is a substance which, when introduced into the body, stimulates the production of an antibody, and specifically reacts with it.</p>
<p>Antigenic determinant is the smallest unit of antigenicity in a molecule of antigen. An antigen may possess a number of determinant groups or combining sites, each stimulating the production of an antibody that can bind only at that site. The antigenic determinants can be peptide groups in proteins, or hexasaccharides in polysaccharides.</p>
<p>Haptens are low molecular weight antigens which cannot induce the formation of antibody by themselves, but can react specifically with the antibodies produced against them. Haptens become capable of producing antibodies when they are combined with larger 'carrier' molecules.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="properties-of-antigens">Properties of Antigens<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#properties-of-antigens" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The antigenicity of a substance depends on the following factors:</p>
<p>(i) Molecular weight Substances with high molecular weight are generally more antigenic than those with a low molecular weight. Haptens can induce immune response only when they are adsorbed on high molecular weight carrier.</p>
<p>(ii) Chemical nature With some exceptions, proteins and polysaccharides are highly antigenic as compared to lipids and nucleic acids.</p>
<p>(iii) Foreignness Under normal conditions, the body does not produce antibodies against its own antigens. When this mechanism of recognising self antigens is impaired, it may result in autoimmune disease. The degree of foreignness also influences the antigenicity. Antigens from other individuals of the same species (e.g. man to man) are less antigenic than those from other species (e.g. sheep to man).</p>
<p>(iv) Susceptibility to tissue enzymes When introduced into the body, antigens are degraded by tissue enzymes to expose their antigenic determinants. Therefore, inert substances which are not affected by enzymes are not antigenic e.g. polystyrene latex particles.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="antigenic-specificity">Antigenic Specificity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antigenic-specificity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Antigenic specificity is not absolute. Cross reactions can occur between an antigen with an antibody stimulated by another related antigen. This may occur due to sharing of similar antigenic determinants by different antigens (Fig.2.1).</p>
<p>Based on their specificity, natural tissue antigens can be of various types:</p>
<p>(i) Autoantigens Autoantigens are self-antigens which are ordinarily non-antigenic, because the body recognises self-antigens. However, those antigens which are not found in free circulation or in tissue fluids (e.g. lens protein of the eye); or the</p>
<p>Scanned by CamScanner</p>
<p>Antigen, Antibody and Complement 1123</p>
<p><img src="assets/images/image-20251219-c4ecb51b.jpeg" alt="img-4.jpeg">
Fig. 2.1 The interaction between an antigenic (Ag) determinant and antibody (Ab) combining sites of various specificities</p>
<p>antigens which are not present during the embryonic life, but develop later (e.g. sperm cells), are not recognised as self-antigens. Antibodies are produced against these antigens when they come into circulation accidentally. In autoimmune diseases, the body for one reason or another, fails to recognise autoantigens.</p>
<p>(ii) Isoantigens These are inherited antigens found in some, but not in all members of a species. Members of a species can be grouped depending upon the presence of different isoantigens. For example, blood group antigens (A and B) and human leucocyte antigens.
(iii) Species specific antigens All members of a species have a common antigen on their tissue cells. Members of related species may have some similarities in their antigens which may lead to cross reactions. This specificity is useful in establishing evolutionary relationships among various species.
(iv) Organ specific antigens These antigens are found in the same organ of different species. For example, antirabies vaccine prepared in sheep brain tissue may lead to neurological paralysis when introduced into a human body, due to sharing of the same antigen by the human and sheep brain. Therefore, antibodies produced against sheep brain</p>
<p>antigen may cross-react with human brain causing damage.</p>
<p>(v) Heterophile antigens Some closely related antigens are found to be present in some bacteria, plants and animals. Some such antigens are used for the diagnosis of diseases such as typhus fever caused by rickettsiae (Weil-Felix test). This test uses antigens of some species of Proteus organisms which can react with antibodies produced by rickettsiae.
(vi) Microbial antigens Microorganisms including viruses, bacteria, fungi, protozoa and helminths contain a large number of antigenic substances, which, when introduced into a human body, stimulate immune response. These antigens may be a part of the physical structure of a microorganism, or it may be a chemical, produced or released as a result of metabolism. Detection of these antigens or their specific antibodies is an important tool for the diagnosis of infectious diseases.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="antibody">ANTIBODY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antibody" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Antibody is an immunoglobulin which is produced in the body as a response to a stimulus by an antigen; and reacts specifically with it. Chemically, immunoglobulins are proteins and constitute 20-25 per cent of total serum proteins. The term 'immunoglobulin' is a chemical and structural concept whereas the term 'antibody' is a biological and functional concept. The body can produce various types of antibodies which can react specifically only with the antigens which caused their production.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="structure-of-immunoglobin">Structure of Immunoglobin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#structure-of-immunoglobin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>All immunoglobulins have a similar basic structure. However, they can show a great diversity in the capacity to produce specific antigen combining sites. Each immunoglobulin (Ig) molecule consists of two unequal pairs of polypeptide chains held together by disulphide (-s-s-) bonds. The two short</p>
<p>Scanned by CamScanner</p>
<p>Basic Immunology and Serodiagnosis</p>
<p>chains are called light chains (L) whereas the two long chains are called heavy chains (H). Each chain has a constant region called 'carboxy terminal' (C) and a variable region called 'amino terminal' (V) (Fig.2.2).</p>
<p>The domains at the amino terminal (V) are variable while those at the carboxy terminal (C) are constant. Each domain has a specific biological activity such as antigen binding, complement activation or monocyte binding (Fig. 2.3).</p>
<p><img src="assets/images/image-20251219-1a4efbf0.jpeg" alt="img-5.jpeg">
Fig. 2.2 A schematic diagram of an immunoglobulin molecule</p>
<p>The H and L chains are folded in three dimensions by disulphide bonds to construct 'domains'.</p>
<p><strong>Heavy (H) chains</strong> The long or heavy (H) chains are not identical in all immunoglobulins. Based on structural and antigenic differences in</p>
<p><img src="assets/images/image-20251219-44f869fd.jpeg" alt="img-6.jpeg">
Fig. 2.3 Immunoglobulin domains</p>
<p>Scanned by CamScanner</p>
<p>Antigen, Antibody and Complement 1125</p>
<p>heavy chains, immunoglobulins are divided into five groups or subclasses. These are designated as IgG, IgM, IgA, IgD and IgE. The H-chain specificity of each of the above classes is symbolised as γ (gamma) for IgG, μ (mu) for IgM, α (alpha) for IgA, δ (delta) for IgD and ε (epsilon) for IgE.</p>
<p>The portion of the H-chain which is not involved in the antibody combining site i.e. Fc fragment of the constant region (see fragments of immunoglobulin below), carries the sites for various biological activities such as complement fixation, attachment to phagocytic cells, placental transfer, degranulation of mast cells and skin fixation.</p>
<p><strong>Light (L) chains</strong> The light chains do not vary according to the immunoglobulin subclass. They always belong to one of the two types, kappa (κ) and lambda (λ). Both may occur in all classes of immunoglobulins; but any one molecule contains either kappa or lambda chains, not both. The kappa and lambda chains occur in a ratio of 2:1 in human serum.</p>
<p><strong>Combining sites</strong> The antigen combining sites of each antibody molecule are located at the aminoterminal end within the variable regions of both heavy (V_H) and light (V_L) chains (Fig.2.3). This is the main biological activity of an antibody molecule. The specificity of an antibody is determined by the sequence of amino acids and its 3-dimensional configuration of domains achieved by disulphide bonds in this variable region. On the other hand, the constant region at the carboxyterminal has a constant or non-variable sequence of amino acids in the H chain, and, either kappa or lambda sequence on the L chain. In the L chain, the constant and variable regions are of equal length, whereas in the H chain the variable region constitutes about one-fifth of the chain. The constant region on the L-chain is called C_L; and that on the heavy chains is called C_H. The C_H region is further divided into three to four regions (C_H1, C_H2, etc.). Differences in the constant regions of H chains have been used to divide immunoglobulins into classes and sub-classes.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="fragments-of-immunoglobulin">Fragments of Immunoglobulin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#fragments-of-immunoglobulin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Enzymes papain and pepsin are used to digest immunoglobulin molecules into discrete fragments.</p>
<p>Papain cleaves the antibody molecule just above the disulphide bonds which hold the two heavy chains together. This creates two identical Fab (fragment antigen binding) fragments, at the aminoterminal (Fig. 2.4). At the carboxy terminal, a fragment Fc (fragment crystallisable), which crystallises spontaneously at 4 °C, is formed. The Fc fragment is responsible for many biological functions of the immunoglobulin molecule, except antigen binding.</p>
<p>Pepsin cleaves the molecule just below the disulphide bonds connecting the two heavy chains (Fig. 2.4), which results in the production of one major fragment F(ab')_2, containing two antigen binding sites. The Fc portion is digested by pepsin into minor fragments.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="classes-of-immunoglobulin">Classes of Immunoglobulin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classes-of-immunoglobulin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>There are five major immunoglobulin classes, IgG, IgM, IgA, IgD and IgE. The structure and function of each is described below. Some of their characteristics are shown in Table 2.1.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="immunoglobulin-g-igg">Immunoglobulin G (IgG)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#immunoglobulin-g-igg" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>IgG is the predominant immunoglobulin in the adult, constituting about 75% of the total immunoglobulins in serum (8–16 mg/ml). It has a molecular weight of approximately 150,000 daltons and a sedimentation coefficient of 7 S.</p>
<p>&gt; <strong>Note</strong>
&gt; Sedimentation coefficient is the sedimentation rate in an ultracentrifuge, expressed in Svedberg units of time i.e. 10⁻¹³ seconds.</p>
<p>Each molecule of IgG consists of two L-chains and two H-chains of γ-specificity, linked by 20–25</p>
<p>Scanned by CamScanner</p>
<p>Basic Immunology and Serodiagnosis</p>
<p><img src="assets/images/image-20251219-19830205.jpeg" alt="img-7.jpeg">
Fig. 2.4 Fragments of immunoglobulin molecule after enzyme treatment</p>
<p>disulphide bonds. There is only one type of L-chain and one type of H-chain in each molecule.</p>
<p>There are four sub-classes of IgG (IgG1 to IgG4), each with a different type of gamma chain.</p>
<p>Functions of IgG While the antigen specificity of an IgG molecule lies within the Fab portion; the Fc portion is responsible for many biological activities:</p>
<ol>
<li>Binding of complement Complement is a group of proteins present in the blood and other</li>
</ol>
<p>body fluids, which interacts with antigen-antibody complexes in a series of steps (Fig. 2.5A). In an antigen-antibody complex, the Fc portion of the IgG molecule combines with the complement to bring about destruction of the antigen.</p>
<ol start="2">
<li>Opsonisation When IgG serves as a bridge between the antigen and the phagocytic cell, the phagocytic activity of the cell is enhanced. This is called opsonisation. This is achieved when the Fab</li>
</ol>
<p>Scanned by CamScanner</p>
<p>Scanned by CamScanner</p>
<p>Table 2.1 Some characteristics of immunoglobulins</p>
<table><thead><tr><th></th><th>IgG</th><th>IgM</th><th>IgA</th><th>IgD</th><th>IgE</th></tr></thead><tbody><tr><td>Sedimentation coefficient</td><td>7S</td><td>19S</td><td>7S or 11S*</td><td>7S</td><td>8S</td></tr><tr><td>Molecular weight</td><td>150,000</td><td>900,000</td><td>170,000 or 400,000*</td><td>180,000</td><td>190,000</td></tr><tr><td>Heavy chain symbol</td><td>γ</td><td>μ</td><td>α</td><td>δ</td><td>ε</td></tr><tr><td>Average concentration in normal serum (mg/dL)</td><td>1000-1500</td><td>60-180</td><td>100-400</td><td>3-5</td><td>0.03</td></tr><tr><td>Half-life in serum (days)</td><td>23</td><td>5</td><td>6</td><td>3</td><td>2.5</td></tr><tr><td>Prominent in external secretions</td><td>-</td><td>-</td><td>++</td><td>-</td><td>+</td></tr><tr><td>Crosses placenta</td><td>+</td><td>-</td><td>-</td><td>?</td><td>-</td></tr><tr><td>Fixes complement</td><td>+</td><td>+</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Examples of antibodies</td><td>Many antibodies to toxins, bacteria, viruses, especially late in antibody response</td><td>Many antibodies to infectious agents, especially early in antibody response; antipolysaccharide antibody; cold agglutinins</td><td>Important as secretory antibody on mucous membranes</td><td>No proven antibody activity; main immunoglobulin on surface of B lymphocytes in newborn</td><td>Binds to mast and basophil cells, raised in allergic conditions and parasitic infections</td></tr></tbody></table>
<p>*11S: molecular weight 400,000 IgA in external secretions; 7S: molecular weight 170,000 IgA in serum</p>
<p>1128 Basic Immunology and Serodiagnosis</p>
<p>portion of IgG binds to the antigen and Fc portion binds to the Fc receptor on the phagocytic cell (Fig. 2.5B).</p>
<ol start="3">
<li>
<p>Cellular cytotoxicity When the Fc portion of the IgG is attached to the Fc receptor on the phagocyte or natural killer (NK) cell, enzymes are released from the granules of these cells. These enzymes destroy the antigen (Fig. 2.5C).</p>
</li>
<li>
<p>Neutralization of toxins When a specific IgG antibody (anti-toxin) binds to a bacterial (toxin) antigen, it neutralises the toxic activity (Fig. 2.5D).</p>
</li>
</ol>
<p><img src="assets/images/image-20251219-0d693f6c.jpeg" alt="img-8.jpeg">
Fig. 2.5 Some function of IgG</p>
<p>Scanned by CamScanner</p>
<p>Antigen, Antibody and Complement 1129</p>
<ol start="5">
<li>
<p>Crossing the placenta IgG is the only immunoglobulin which is capable of crossing the placenta. This helps in the transfer of passive immunity from the mother to the foetus. This immunity lasts for about six months after birth. The infant's own immune system begins to function by this time.</p>
</li>
<li>
<p>Feedback suppression When IgG antibody specific for an antigen is passively administered into an individual, it suppresses the homologous antibody synthesis by a feedback process. This property of IgG is used for the suppression of anti-Rh (D) antibodies in an Rh-negative mother who has delivered an Rh-positive child. Synthesis of anti-Rh (D) antibodies is suppressed by passive administration of anti-Rh (D) IgG, immediately after delivery.</p>
</li>
<li>
<p>Precipitation and agglutination IgG antibodies are capable of precipitating soluble antigens and agglutinating particulate antigens by forming lattice-like complexes, thus rendering the antigens inactive. IgG is more effective in tissue fluids.</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="immunoglobulin-m-igm">Immunoglobulin M (IgM)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#immunoglobulin-m-igm" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>IgM is the largest of the immunoglobulins, with a molecular weight of about 900,000 to 1,000,000 (therefore called a 'millionaire molecule'). The sedimentation coefficient is 19S. It constitutes 5-10% of serum immunoglobulins (0.5 to 2 mg/ml).</p>
<p>IgM is a pentamer, made up of five basic subunits i.e. five units of two μ-chains bound to two L-chains. These units are linked together by a protein called the 'J' or joining chain (Fig. 2.6a). The heavy chains are called μ (mu) chains, and are longer than the γ (gamma) heavy chains of IgG, because they contain an additional domain, C_H4, located at the carboxyterminal of the H-chain. Since each IgM molecule has ten Fab segments, it can combine with up to ten antigenic sites. However, with antigens of a large size, this valency may fall to five, probably due to stearic hindrance.</p>
<p>IgM molecules are the earliest antibodies synthesised in response to antigenic stimulation. It is synthesised by the foetus from about 20 weeks of age. The presence of IgM antibodies in a foetus or a neonate indicates intrauterine infection because IgM cannot cross through the placenta. Congenital infections such as syphilis, rubella or toxoplasmosis can be diagnosed by detection of IgM antibodies in the newborn.</p>
<p>IgM antibodies are also the first to be produced in response to any antigenic stimulus, even in adult life. They are shortlived as compared to IgG. Therefore, their detection in the serum indicates a recent or current infection. IgM is selectively destroyed by 2-mercaptoethanol (O.12M), which does not affect IgG. This provides a simple method for estimating IgG and IgM separately.</p>
<p>There are two subclasses of IgM; IgM1 and IgM2.</p>
<p>Functions of IgM 1. Binding of complement IgM is the most efficient in performing this function among all the immunoglobulins due to its multiple Fc portion.</p>
<ol start="2">
<li>
<p>Neutralization of toxins (Fig. 2.5D) This function also is similar to that of IgG.</p>
</li>
<li>
<p>Agglutination IgM is much more efficient than other immunoglobulins in bringing about agglutination of particulate antigens such as those of bacteria, since it has ten functional antigen binding sites. Most of IgM (80%) is intravascular in distribution. Therefore it protects the blood stream against microbial invasion. IgM deficiency is often associated with septicaemias. It is present in the acute phase of infection.</p>
</li>
<li>
<p>Opsonisation IgM is more effective in opsonisation than IgG.</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="immunoglobulin-a-iga">Immunoglobulin A (IgA)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#immunoglobulin-a-iga" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>IgA is the second most abundant class of immunoglobulins after IgG. It constitutes about 10% of total serum immunoglobulins (0.6 to 4.2 mg/ml).</p>
<p>IgA occurs in two forms. In the serum, it is present as a monomer i.e. one basic unit of two heavy chains bound to two light chains. The molecular weight of the monomer is about 170,000</p>
<p>Scanned by CamScanner</p>
<p>1130 Basic Immunology and Serodiagnosis</p>
<p><img src="assets/images/image-20251219-12da6f68.jpeg" alt="img-9.jpeg">
Fig. 2.6 Structures of (A) IgM and (B) IgA molecules</p>
<p>daltons, with a sedimentation coefficient of 7 S. The heavy chains of IgA are called α (alpha) chains (Fig. 2.6b). Unlike other immunoglobulins, the disulphide bonds in IgA link its light chains together, and not the heavy chains.</p>
<p>Besides occurring in the serum, IgA is a predominant immunoglobin in body's secretions such as saliva, tears, sweat and breast milk. The mucous membranes of respiratory, intestinal and genital tracts are also rich in IgA. In the body secretions, IgA occurs mainly as a dimer i.e. it has two basic subunits held together by the J-chain (Fig. 2.6b). The molecular weight of the dimer is about 400,000 daltons and has a sedimentation coefficient of 11 S. In addition, the dimer contains a protein known as the secretory or transport (T) piece. The T-piece is synthesised by the epithelial cells in the mucous membrane. The T-piece protects the IgA from the proteolytic enzymes and helps in its transport through the mucous membranes into the secretions.</p>
<p>There are two subclasses of IgA: IgA1 and IgA2.</p>
<p>Functions of IgA 1. Protection of body surfaces and mucous membranes Because it is predominant in body secretions, it protects the body against the entry of pathogens and from adherence to the mucous membranes. It forms an 'antibody paste' on the mucous surfaces which plays an important role in local immunity against respiratory and intestinal pathogens.</p>
<ol start="2">
<li>Phagocytosis It promotes phagocytosis in the same way as the IgG and IgM.</li>
<li>Passive immunity Ingestion of IgA in breast milk confers passive immunity from a mother to an infant. It does not cross through the placenta.</li>
<li>Activation of complement Although it cannot fix complement, it can activate the alternate complement pathway.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="immunoglobulin-d-igd">Immunoglobulin D (IgD)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#immunoglobulin-d-igd" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Structurally, IgD resembles IgG. It exists as a monomer, with δ(delta) heavy chains. It is mostly intravascular in distribution (3-5mg/100ml). Its concentration in serum is very low (0.03-0.05mg/ml).</p>
<p>Very little is known about the functions of IgD. It is active against antigens such as insulin, milk protein, nuclear and thyroid antigens, and penicillin. It is believed to be associated with lymphocyte activation and suppression.</p>
<p>Scanned by CamScanner</p>
<p>Antigen, Antibody and Complement 1131</p>
<p>There are two subclasses: IgD1 and IgD2.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="immunoglobulin-e-ige">Immunoglobulin E (IgE)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#immunoglobulin-e-ige" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>IgE exists as a monomer with ε (epsilon) heavy chains, has a molecular weight of about 200,000 daltons and sedimentation coefficient of 8S. It is present in very low concentration, about 0.02mg/ml. The ε chain contains an additional C₁₁₄ domain in the constant region, similar to that of IgM. This C₁₁₄ region is capable of binding to Fc receptors on mast cells and basophils. This interaction stimulates the development of Type I allergic reactions. IgE levels are also elevated in the serum of individuals with parasitic infections and may play a role in defence against parasites.</p>
<p>IgE is mostly extravascular in distribution. It does not fix complement or pass through the placenta.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="complement">COMPLEMENT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#complement" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Complement is a complex system of proteins and other factors found in body fluids or on cell membranes of vertebrates. These components are capable of specific, sequential interactions leading to a number of physiological effects. Some of them have enzymatic activity, while others are activators or inhibitors of certain processes. Lysis of cells such as microorganisms or immunogenic red cells is the mainstay of this system. In addition, the complement system also plays a major role in the mediation of inflammation, in metabolism of immune complexes and in regulating the phagocytic activity.</p>
<p>At least 11 distinct components of human complement have been identified. Complement gets deteriorated very fast in vitro therefore it should either be used fresh or kept frozen. It can also be preserved by chemical methods such as Richardson method. Complement activity is destroyed by heating serum at 56°C for 30 minutes, when it is said to be 'inactivated'.</p>
<p>Complement (C) is normally present in the body in an inactive form. When it is activated by antigen-antibody complexes, the components of C react in a specific sequence, which is called the complement cascade. Several biologically active fragments and components are released as byproducts during the reaction cascade. The preceding components act as enzymes on the succeeding components, cleaving them into unequal fragments. Generally, larger fragments join the cascade, smaller ones perform other biological functions.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="activation-of-complement">Activation of Complement<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#activation-of-complement" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>There are two ways in which the complement can be activated; the classical pathway and the alternate pathway. Complement is activated by the classical pathway when an antigen-antibody complex initiate the reaction sequence by binding with the first component of C, namely C1. C1 exists in serum as a calcium ion (Ca²⁺) dependant complex of three subunits, C1q, C1r and C1s.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="classical-pathway">Classical pathway<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#classical-pathway" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>The sequence of the complement cascade by classical pathway can be summarised as follows:</p>
<p>(i) Immunoglobulins IgG and IgM have receptors for C1q on their constant region of heavy chains, which are exposed when the immunoglobulin attaches to the specific antigen. In the presence of Ca++, C1q binds to the antigen-antibody (Ag-Ig) complex. C1q is sufficiently changed when it binds to the Ag-Ig complex to induce C1r, which in turn splits C1s resulting in the formation of Ag-Ig-C1qrs (Fig. 2.7).</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">g</mi><mo>−</mo><mi mathvariant="normal">I</mi><mi mathvariant="normal">g</mi><mo>+</mo><mi mathvariant="normal">C</mi><mn>1</mn><mi mathvariant="normal">q</mi><mover><mo stretchy="true" minsize="3.0em">→</mo><mpadded width="+0.6em" lspace="0.3em"><mrow><mi mathvariant="normal">C</mi><msup><mi mathvariant="normal">a</mi><mrow><mn>2</mn><mo>+</mo></mrow></msup></mrow></mpadded></mover><mi mathvariant="normal">A</mi><mi mathvariant="normal">g</mi><mo>−</mo><mi mathvariant="normal">I</mi><mi mathvariant="normal">g</mi><mi mathvariant="normal">C</mi><mn>1</mn><mi mathvariant="normal">q</mi></mrow><annotation encoding="application/x-tex">\mathrm{Ag - Ig + C1q \xrightarrow{Ca^{2+}} Ag - IgC1q}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.4404em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Ag</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord mathrm" style="margin-right: 0.01389em;">Ig</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord mathrm">C1q</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel x-arrow"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.2459em;"><span style="top: -3.322em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight x-arrow-pad"><span class="mord mtight"><span class="mord mathrm mtight">C</span><span class="mord mtight"><span class="mord mathrm mtight">a</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8913em;"><span style="top: -2.931em; margin-right: 0.0714em;"><span class="pstrut" style="height: 2.5em;"></span><span class="sizing reset-size3 size1 mtight"><span class="mord mtight"><span class="mord mathrm mtight">2</span><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span><span class="svg-align" style="top: -2.689em;"><span class="pstrut" style="height: 2.7em;"></span><span class="hide-tail" style="height: 0.522em; min-width: 1.469em;"><svg xmlns="http://www.w3.org/2000/svg" width="400em" height="0.522em" viewBox="0 0 400000 522" preserveAspectRatio="xMaxYMin slice"><path d="M0 241v40h399891c-47.3 35.3-84 78-110 128
-16.7 32-27.7 63.7-33 95 0 1.3-.2 2.7-.5 4-.3 1.3-.5 2.3-.5 3 0 7.3 6.7 11 20
 11 8 0 13.2-.8 15.5-2.5 2.3-1.7 4.2-5.5 5.5-11.5 2-13.3 5.7-27 11-41 14.7-44.7
 39-84.5 73-119.5s73.7-60.2 119-75.5c6-2 9-5.7 9-11s-3-9-9-11c-45.3-15.3-85
-40.5-119-75.5s-58.3-74.8-73-119.5c-4.7-14-8.3-27.3-11-40-1.3-6.7-3.2-10.8-5.5
-12.5-2.3-1.7-7.5-2.5-15.5-2.5-14 0-21 3.7-21 11 0 2 2 10.3 6 25 20.7 83.3 67
 151.7 139 205zm0 0v40h399900v-40z"></path></svg></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.011em;"><span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mord mathrm" style="margin-right: 0.01389em;">Ag</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord mathrm">IgC1q</span></span></span></span></span></span></div>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mover><mo stretchy="true" minsize="3.0em">→</mo><mpadded width="+0.6em" lspace="0.3em"><mrow><mi>C</mi><mn>1</mn><mi>r</mi><mo>+</mo><mi>C</mi><mn>1</mn><mi>s</mi></mrow></mpadded></mover><mi>A</mi><mi>g</mi><mo>−</mo><mi>I</mi><mi>g</mi><mo>−</mo><mi>C</mi><mn>1</mn><mi>q</mi><mtext>.r.s.</mtext></mrow><annotation encoding="application/x-tex">\xrightarrow{C1r + C1s} Ag - Ig - C1q \text{.r.s.}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.1113em; vertical-align: -0.011em;"></span><span class="mrel x-arrow"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.1003em;"><span style="top: -3.322em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight x-arrow-pad"><span class="mord mtight"><span class="mord mathnormal mtight" style="margin-right: 0.07153em;">C</span><span class="mord mtight">1</span><span class="mord mathnormal mtight" style="margin-right: 0.02778em;">r</span><span class="mbin mtight">+</span><span class="mord mathnormal mtight" style="margin-right: 0.07153em;">C</span><span class="mord mtight">1</span><span class="mord mathnormal mtight">s</span></span></span></span><span class="svg-align" style="top: -2.689em;"><span class="pstrut" style="height: 2.7em;"></span><span class="hide-tail" style="height: 0.522em; min-width: 1.469em;"><svg xmlns="http://www.w3.org/2000/svg" width="400em" height="0.522em" viewBox="0 0 400000 522" preserveAspectRatio="xMaxYMin slice"><path d="M0 241v40h399891c-47.3 35.3-84 78-110 128
-16.7 32-27.7 63.7-33 95 0 1.3-.2 2.7-.5 4-.3 1.3-.5 2.3-.5 3 0 7.3 6.7 11 20
 11 8 0 13.2-.8 15.5-2.5 2.3-1.7 4.2-5.5 5.5-11.5 2-13.3 5.7-27 11-41 14.7-44.7
 39-84.5 73-119.5s73.7-60.2 119-75.5c6-2 9-5.7 9-11s-3-9-9-11c-45.3-15.3-85
-40.5-119-75.5s-58.3-74.8-73-119.5c-4.7-14-8.3-27.3-11-40-1.3-6.7-3.2-10.8-5.5
-12.5-2.3-1.7-7.5-2.5-15.5-2.5-14 0-21 3.7-21 11 0 2 2 10.3 6 25 20.7 83.3 67
 151.7 139 205zm0 0v40h399900v-40z"></path></svg></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.011em;"><span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord mathnormal">A</span><span class="mord mathnormal" style="margin-right: 0.03588em;">g</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.07847em;">I</span><span class="mord mathnormal" style="margin-right: 0.03588em;">g</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span><span class="mord">1</span><span class="mord mathnormal" style="margin-right: 0.03588em;">q</span><span class="mord text"><span class="mord">.r.s.</span></span></span></span></span></span></div>
<p>(ii) Activated C1 acquires esterase activity (C1s) and acts on C4, splitting it into C4a and C4b.</p>
<p>Scanned by CamScanner</p>
<p>1132 Basic Immunology and Serodiagnosis</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi><mi mathvariant="normal">s</mi></mrow><mo>+</mo><mrow><mi mathvariant="normal">C</mi><mn>4</mn></mrow><mover><mo stretchy="true" minsize="3.0em">→</mo><mpadded width="+0.6em" lspace="0.3em"><mrow><mi mathvariant="normal">C</mi><mn>4</mn><mi mathvariant="normal">a</mi></mrow></mpadded></mover><mrow><mi mathvariant="normal">C</mi><mn>4</mn><mi mathvariant="normal">b</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{Cls} + \mathrm{C4} \xrightarrow{\mathrm{C4a}} \mathrm{C4b}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7778em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord mathrm">Cls</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1.1113em; vertical-align: -0.011em;"></span><span class="mord"><span class="mord mathrm">C4</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel x-arrow"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.1003em;"><span style="top: -3.322em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight x-arrow-pad"><span class="mord mtight"><span class="mord mtight"><span class="mord mathrm mtight">C4a</span></span></span></span></span><span class="svg-align" style="top: -2.689em;"><span class="pstrut" style="height: 2.7em;"></span><span class="hide-tail" style="height: 0.522em; min-width: 1.469em;"><svg xmlns="http://www.w3.org/2000/svg" width="400em" height="0.522em" viewBox="0 0 400000 522" preserveAspectRatio="xMaxYMin slice"><path d="M0 241v40h399891c-47.3 35.3-84 78-110 128
-16.7 32-27.7 63.7-33 95 0 1.3-.2 2.7-.5 4-.3 1.3-.5 2.3-.5 3 0 7.3 6.7 11 20
 11 8 0 13.2-.8 15.5-2.5 2.3-1.7 4.2-5.5 5.5-11.5 2-13.3 5.7-27 11-41 14.7-44.7
 39-84.5 73-119.5s73.7-60.2 119-75.5c6-2 9-5.7 9-11s-3-9-9-11c-45.3-15.3-85
-40.5-119-75.5s-58.3-74.8-73-119.5c-4.7-14-8.3-27.3-11-40-1.3-6.7-3.2-10.8-5.5
-12.5-2.3-1.7-7.5-2.5-15.5-2.5-14 0-21 3.7-21 11 0 2 2 10.3 6 25 20.7 83.3 67
 151.7 139 205zm0 0v40h399900v-40z"></path></svg></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.011em;"><span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord"><span class="mord mathrm">C4b</span></span></span></span></span></span></div>
<p>C4a is released in the surrounding medium.</p>
<p>(iii) C1s also cleaves C2 into two fragments, C2a and C2b</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi><mi mathvariant="normal">s</mi></mrow><mo>+</mo><mrow><mi mathvariant="normal">C</mi><mn>2</mn></mrow><mover><mo stretchy="true" minsize="3.0em">→</mo><mpadded width="+0.6em" lspace="0.3em"><mrow><mi mathvariant="normal">C</mi><mn>2</mn><mi mathvariant="normal">b</mi></mrow></mpadded></mover><mrow><mi mathvariant="normal">C</mi><mn>2</mn><mi mathvariant="normal">a</mi></mrow><mover><mo stretchy="true" minsize="3.0em">→</mo><mpadded width="+0.6em" lspace="0.3em"><mrow><mn>4</mn><mi>b</mi></mrow></mpadded></mover><mrow><mi mathvariant="normal">C</mi><mn>4</mn><mi mathvariant="normal">b</mi><mn>2</mn><mi mathvariant="normal">a</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{Cls} + \mathrm{C2} \xrightarrow{\mathrm{C2b}} \mathrm{C2a} \xrightarrow{4b} \mathrm{C4b2a}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7778em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord mathrm">Cls</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1.1191em; vertical-align: -0.011em;"></span><span class="mord"><span class="mord mathrm">C2</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel x-arrow"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.1081em;"><span style="top: -3.322em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight x-arrow-pad"><span class="mord mtight"><span class="mord mtight"><span class="mord mathrm mtight">C2b</span></span></span></span></span><span class="svg-align" style="top: -2.689em;"><span class="pstrut" style="height: 2.7em;"></span><span class="hide-tail" style="height: 0.522em; min-width: 1.469em;"><svg xmlns="http://www.w3.org/2000/svg" width="400em" height="0.522em" viewBox="0 0 400000 522" preserveAspectRatio="xMaxYMin slice"><path d="M0 241v40h399891c-47.3 35.3-84 78-110 128
-16.7 32-27.7 63.7-33 95 0 1.3-.2 2.7-.5 4-.3 1.3-.5 2.3-.5 3 0 7.3 6.7 11 20
 11 8 0 13.2-.8 15.5-2.5 2.3-1.7 4.2-5.5 5.5-11.5 2-13.3 5.7-27 11-41 14.7-44.7
 39-84.5 73-119.5s73.7-60.2 119-75.5c6-2 9-5.7 9-11s-3-9-9-11c-45.3-15.3-85
-40.5-119-75.5s-58.3-74.8-73-119.5c-4.7-14-8.3-27.3-11-40-1.3-6.7-3.2-10.8-5.5
-12.5-2.3-1.7-7.5-2.5-15.5-2.5-14 0-21 3.7-21 11 0 2 2 10.3 6 25 20.7 83.3 67
 151.7 139 205zm0 0v40h399900v-40z"></path></svg></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.011em;"><span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1.1191em; vertical-align: -0.011em;"></span><span class="mord"><span class="mord mathrm">C2a</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel x-arrow"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.1081em;"><span style="top: -3.322em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight x-arrow-pad"><span class="mord mtight"><span class="mord mtight">4</span><span class="mord mathnormal mtight">b</span></span></span></span><span class="svg-align" style="top: -2.689em;"><span class="pstrut" style="height: 2.7em;"></span><span class="hide-tail" style="height: 0.522em; min-width: 1.469em;"><svg xmlns="http://www.w3.org/2000/svg" width="400em" height="0.522em" viewBox="0 0 400000 522" preserveAspectRatio="xMaxYMin slice"><path d="M0 241v40h399891c-47.3 35.3-84 78-110 128
-16.7 32-27.7 63.7-33 95 0 1.3-.2 2.7-.5 4-.3 1.3-.5 2.3-.5 3 0 7.3 6.7 11 20
 11 8 0 13.2-.8 15.5-2.5 2.3-1.7 4.2-5.5 5.5-11.5 2-13.3 5.7-27 11-41 14.7-44.7
 39-84.5 73-119.5s73.7-60.2 119-75.5c6-2 9-5.7 9-11s-3-9-9-11c-45.3-15.3-85
-40.5-119-75.5s-58.3-74.8-73-119.5c-4.7-14-8.3-27.3-11-40-1.3-6.7-3.2-10.8-5.5
-12.5-2.3-1.7-7.5-2.5-15.5-2.5-14 0-21 3.7-21 11 0 2 2 10.3 6 25 20.7 83.3 67
 151.7 139 205zm0 0v40h399900v-40z"></path></svg></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.011em;"><span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord"><span class="mord mathrm">C4b2a</span></span></span></span></span></span></div>
<p>(C3 convertase)</p>
<p>4b and 2a form a reversible complex. C4b2a which is known as C3 convertase. C2b is released.</p>
<p><img src="assets/images/image-20251219-350cc210.jpeg" alt="img-10.jpeg"></p>
<p>Fig. 2.7 Activation sequence of the classical complement pathway</p>
<p>Scanned by CamScanner</p>
<p>Antigen, Antibody and Complement 1133</p>
<p>(iv) C4b2a (C3 convertase) rapidly activates and cleaves many molecules of C3 into C3a, C3b joins the cascade.</p>
<p><img src="assets/images/image-20251219-e94cbff7.jpeg" alt="img-11.jpeg"></p>
<p>(v) C5 convertase splits C5 into C5a, which is released into the environment.</p>
<p><img src="assets/images/image-20251219-813394e6.jpeg" alt="img-12.jpeg"></p>
<p>C5b initiates the formation of Terminal Complement Complex (TCC).</p>
<p>(vi) C6 and C7 are then added.</p>
<p>C5b + C6 → C5b,6 + C7 → C5b,6,7.</p>
<p>C5b,6,7 is a heat stable trimolecular complex which binds to the cell membranes of target cells and prepares them for lysis by subsequent components C8 and C9. The unbound C5,6,7 complex has chemotactic and leucocyte activating properties.</p>
<p>(vii) Membrane bound C5b,6,7 constitutes receptor for C8 and allows its insertion into the target cell membrane.</p>
<p>C5b,6,7 + C8 → C5b,6,7,8.</p>
<p>(viii) The C5b,6,7,8 complex forms small transmembrane channels in the target cell, and also facilitate polymerisation of C9 into an unfolding tubular structure. Poly C9. The polymerised C9 can insert into the cell membrane and form channels or holes into the target cell membrane. This disrupts the osmotic integrity of the membrane, followed by lysis of the cell. (Fig 2.7).</p>
<p>The alternate pathway While the 'classical' pathway of complement activation starts by attachment of C1q to the antigen-antibody complex, an 'alternate' pathway exists which starts by activation of C3. In the classical pathway, C3 is activated by the C3 convertase (C4b2a). A variety of substances can bring about the formation of C3 activator that cleaves C3 in the similar way to that of C3 convertase in the classical pathway. This 'alternative pathway' then proceeds from C3 to C9, as in the classical pathway.</p>
<p>The alternate pathway of complement activation provides a natural defence mechanism against invasion by microorganisms, before the formation of antibodies. Activators of this pathway include</p>
<p>(i) Lipopolysaccharides from gram negative bacteria.
(ii) Teichoic acid from the cell wall of gram positive bacteria.
(iii) Zymosan from the cell walls of fungi and yeast.
(iv) Some viruses and virus infected cells.
(v) Certain parasites such as trypanosomes.
(vi) Some tumour cells.
(vii) Therapeutic sulphydryl compounds.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="biological-activities-of-complement-and-its-components">Biological Activities of Complement and its Components<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#biological-activities-of-complement-and-its-components" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><strong>Cytolysis</strong> Activation of complement results in cytolysis and bacteriolysis. Lysis of red cells coated with antigen by complement forms the basis of complement fixation test for the detection of either antigen or antibody.</p>
<p>Cytolysis may cause injury to normal tissues in allergic reactions or in autoimmune diseases.</p>
<p><strong>Effects of C4a, C3a and C5a</strong> These smaller fragments are released in the environment during the formation of the complement cascade. Collectively, these fragments have effects on phagocytosis, anaphylaxis and inflammation. As anaphylotoxins they cause smooth muscle contraction, enhance mucus secretion, increase vascular permeability and induce release of histamine from basophils and mast cells.</p>
<p><strong>Opsonization and Immune adherence</strong> The fragments C4b, C3b and iC3b (inactive 3b) promote adherence of antigen-antibody complexes to leucocytes or platelets, which can then be easily phagocytosed by macrophages. They also enhance phagocytosis of antibody-coated (opsonised) microorganisms by leucocytes and macrophages.</p>
<p>Scanned by CamScanner</p>
<p>Scanned by CamScanner</p>
<p>1134 Basic Immunology and Serodiagnosis</p>
<p>Hereditary deficiencies of C and Low serum C levels Deficiency or low level of complement may lead to increased susceptibility to infection and diseases like systemic lupus erythematosus (SLE) or acute glomerulonephritis.</p>
<p>Chapter 3</p>
<p>Specific Immune Response</p>
<p>Specific immune response can be either antibody mediated or cell mediated.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="2185a636">♦ ANTIBODY MEDIATED IMMUNE RESPONSE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2185a636" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Specific antibody mediated immune response is also referred to as humoral immune response. The cells responsible for the synthesis of antibody molecules are B-lymphocytes. Each immunocompetent B-lymphocyte has an immunoglobulin of appropriately coded specificity on its surface, before its exposure to the antigen. The specificity of the antibody molecule for a particular antigen is determined at the level of the gene.</p>
<p>The undifferentiated stem cell has a set of genes capable of coding for 106 to 108 different types of antibody molecules. These immunoglobulin genes occur on widely separated fragments of DNA. For example, the set of genes for heavy (H) chain coding are separate from those coding for light (L) chains.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="activation-of-b-lymphocytes">Activation of B-lymphocytes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#activation-of-b-lymphocytes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Activation of B-lymphocytes by an antigen can be either dependent or independent of T-cells, which, in turn, depends on the nature of the antigen.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="t-cell-independent-activation-of-b-lymphocytes">T-cell Independent activation of B-lymphocytes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#t-cell-independent-activation-of-b-lymphocytes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Antigens that are made up of large polymers with repeating identical subunits can directly induce B-lymphocytes to produce specific antibodies. Such antigens have many antigenic determinants or epitopes and are capable of stimulating many clones of B-lymphocytes. These are called polyclonal activators, e.g. lipopolysaccharide.</p>
<p>The subunits of the antigen bind to the binding sites on the specific surface immunoglobulin molecules on B-lymphocytes. This stimulates the B-lymphocytes to proliferate into a clone of identical cells. They subsequently mature into plasma cells which produce and secrete antibody molecules into the body fluids. The T-cell independent antibody response has three characteristic features:</p>
<p>(i) It can produce only IgM antibody.
(ii) Help from T-helper (Th) cell is not required.
(iii) There is no memory of the antibody response.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="t-cell-dependent-activation-of-b-lymphocytes">T-cell dependent activation of B-lymphocytes<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#t-cell-dependent-activation-of-b-lymphocytes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>This is the mechanism by which most of the antigens stimulate production of antibodies. The characteristics of this type of response are:</p>
<p>(i) It can produce antibody of any immunoglobulin class.</p>
<p>Scanned by CamScanner</p>
<p>Basic Immunology and Serodiagnosis</p>
<p>(ii) It depends on the help from T-helper (Th) lymphocytes.
(iii) The antibody response also results in the induction of 'memory'.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism-of-antibody-mediated-immunity-ami">Mechanism of Antibody Mediated Immunity (AMI)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-antibody-mediated-immunity-ami" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This mechanism can be briefly explained as follows:</p>
<p>(i) When an antigen comes in contact with a macrophage, it is phagocytosed.
(ii) Within the macrophage, the enzymes partially degrade the antigen in such a way that the antigenic determinants are exposed.
(iii) This partially degraded antigen is then placed on the surface of the macrophage next to the HLA-D or Ia marker, which is a genetically determined Class II antigen of the HLA system.
(iv) The T-helper (Th) cells have a specific T-cell receptor (TcR), specific for each antigen, on their surface in association with the CD3 (Cluster of Differentiation 3) molecule. When such 'resting' or non-activated Th cells come in contact with the macrophage with the antigen-Ia complex on its surface, these two complexes bind with each other (Fig. 3.1).</p>
<p>(v) At this stage, the resting Th cell is activated by a monokine (Interleukin-1, IL-1) produced by the macrophage. The activated Th undergoes a series of biochemical changes resulting in self stimulatory response by:</p>
<p>(a) production of large quantities of lymphokines, including interleukin-2 (IL-2).
(b) acquiring surface membrane receptors for IL-2.</p>
<p>(vi) Binding of IL-2 to its receptor on the activated Th leads to the proliferation of Th to produce a clone of identical Th cells specific for the inducing antigen. Thus the response is amplified at this stage.</p>
<p><img src="assets/images/image-20251219-e2953ff8.jpeg" alt="img-13.jpeg"></p>
<ul>
<li>Antigen presentation to B cell can be: (i) directly (ii) by contact with Th, macrophages or B cells with bound antigen</li>
</ul>
<p>Fig. 3.1 T-cell dependant activation of B-lymphocytes</p>
<p>Scanned by CamScanner</p>
<p>Specific Immune Response 1137</p>
<p>(vi) The activated Th cells also produce Interleukins 4, 5 and 6 (IL-4, IL-5 and IL-6) among other lymphokines, which participate later in B-cell proliferation and differentiation.</p>
<p>(vii) B-lymphocytes can come in contact with the antigen in three different ways:</p>
<p>(a) Direct binding of the antigen to the specific surface Ig molecule on the B-cell.</p>
<p>(b) Presentation of the antigen by an activated Th cell to B-cell.</p>
<p>(c) Presentation of the antigen by macrophages or other B-cells possessing bound antigen on their surface.</p>
<p>(ix) At this stage, only those antigens capable of initiating B-cell proliferation without the influence of Th cells can induce antibody production independently. All other antigens can induce proliferation of B-cells into a clone of identical cells only under the influence of IL-4 and IL-5, released by Th.</p>
<p>(x) After proliferation of B-cells, IL-5 and IL-6 produced by activated Th trigger differentiation of B-cells into plasma cells to secret antibody molecules specific for the inducing antigen (Fig. 3.1).</p>
<p>(xi) Instead of differentiating into plasma cells, some of the stimulated B-cells develop into mature memory cells with very long life. These can be activated rapidly upon subsequent exposure to the same antigen.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="primary-antibody-response">Primary Antibody Response<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#primary-antibody-response" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>When an individual is exposed to an antigen for the first time, it results in the primary antibody response. Characteristically, in the primary response, there is a lag period before any antibody is produced. This is due to the time required for the activation of B-cells after the first exposure to the antigen. This lag period depends on the type and dose of antigen, its route of entry, as well as host related factors. Generally, the lag period is for three-four days before detectable levels of antibody appear. The first immunoglobulin to be produced is IgM, which rises to a peak in one to ten weeks, then starts dropping below detectable levels over the next few weeks (Fig. 3.2).</p>
<p>The production of IgG is slower, and begins about one to two weeks after exposure, reaches a peak within a few weeks and gradually decreases over the next few months. Some IgG antibodies may be present in the body for years.</p>
<p><img src="assets/images/image-20251219-08380b27.jpeg" alt="img-14.jpeg">
Fig. 3.2 Primary (first dose) and secondary (second dose) antibody response to antigen</p>
<p>Scanned by CamScanner</p>
<p>Specific Immune Response 1139</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cell-mediated-immune-response-cmi">CELL MEDIATED IMMUNE RESPONSE (CMI)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cell-mediated-immune-response-cmi" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>CMI is another type of specific immune response and does not involve antibody. This is an important group of responses mediated by T-lymphocytes, in which B-lymphocytes do not play any role. CMI was originally identified by its role in immunity to tuberculosis and viral infections. It was also found to be involved in graft rejection, chronic inflammation, tumour immunity, and in delayed type hypersensitivity.</p>
<p>CMI is regulated by many suppressor cells and factors which are able to limit the damaging effect of CMI. However, in some diseases, this regulatory activity can impair the protective aspect of the system.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cytokines">Cytokines<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cytokines" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The process of cell mediated immunity (CMI) is carried out by T-lymphocytes and their products, lymphokines, with the help of monokines secreted by the cells of the mononuclear phagocytic system, namely, monocytes and macrophages. The lymphokines and monokines are grouped together as cytokines. Some cytokines are produced as an integral part of the immune response and are antigen specific, while others, although induced by the presence of an antigen, are antigen non-specific in function.</p>
<p>Depending on their role in the immune response, cytokines are classified into two groups.</p>
<p>Afferent cytokines have a role in the induction of primary immune responses. Efferent cytokines play a part in the suppression of immune responses.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="afferent-cytokines">Afferent cytokines<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#afferent-cytokines" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Interleukin-1 (IL-1) IL-1 is primarily produced by the cells of mononuclear phagocytic system (MPS), and also by T- and B-cells, natural killer (NK) cells and many other nucleated cells. The secretion of IL-1 is generally induced by antigen, injury, toxins or inflammation, and is considered to be a primary mediator of acute phase reactions.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="functions-of-il-1">Functions of IL-1<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#functions-of-il-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>(a) Activation of resting T-cells. It activates resting T-cells and stimulates production of lymphokines such as Interleukin-2.</p>
<p>(b) Chemotaxis: It causes chemotaxis and increased metabolism in phagocytes.</p>
<p>(ii) Interleukin-2 (IL-2) IL-2 is also known as T-cell growth factor (TCGF). It is a lymphokine produced by T-helper cells activated by IL-1. Activated T-cells produce IL-2, and at the same time receptors for IL-2 appear on their surface. (Fig. 3.1).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="functions-of-il-2">Functions of IL-2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#functions-of-il-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>(a) Proliferation of Th cells. When IL-2 interacts with the IL-2 receptor on the surface of T-helper (Th) cell, it results in proliferation of Th cells, which in turn, amplify the immune response. The activated T-cells subsequently produce other interleukins (IL-4, IL-5, IL-6), which induce activation, proliferation and differentiation of B-cells.</p>
<p>(b) Enhancement of killer cell activities. IL-2 rapidly enhances natural killer (NK) cell activity. It increases specific killing ability of cytotoxic lymphocytes in the presence of antigen. It also acts on null (non-T, Non-B) cells which are then capable of lysing NK-resistant tumour cells.</p>
<p>(iii) Interleukin-3 (IL-3) or Colony stimulating Factors (multi-CSF). Colony Stimulating Factors (CSFs) are known to induce differentiation and proliferation of pleuripotent haematopoietic stem cells in vitro. IL-3 is produced by activated T-cells and perhaps by the bone marrow.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="function-of-il-3">Function of IL-3<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#function-of-il-3" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>IL-3 is capable of supporting proliferation and differentiation of pleuripotent stem cells of the erythroid, lymphocytic, megakaryocytic series and mast cells.</p>
<p>Scanned by CamScanner</p>
<p>Specific Immune Response 1139</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cell-mediated-immune-response-cmi">CELL MEDIATED IMMUNE RESPONSE (CMI)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cell-mediated-immune-response-cmi" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>CMI is another type of specific immune response and does not involve antibody. This is an important group of responses mediated by T-lymphocytes, in which B-lymphocytes do not play any role. CMI was originally identified by its role in immunity to tuberculosis and viral infections. It was also found to be involved in graft rejection, chronic inflammation, tumour immunity, and in delayed type hypersensitivity.</p>
<p>CMI is regulated by many suppressor cells and factors which are able to limit the damaging effect of CMI. However, in some diseases, this regulatory activity can impair the protective aspect of the system.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cytokines">Cytokines<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cytokines" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The process of cell mediated immunity (CMI) is carried out by T-lymphocytes and their products, lymphokines, with the help of monokines secreted by the cells of the mononuclear phagocytic system, namely, monocytes and macrophages. The lymphokines and monokines are grouped together as cytokines. Some cytokines are produced as an integral part of the immune response and are antigen specific, while others, although induced by the presence of an antigen, are antigen non-specific in function.</p>
<p>Depending on their role in the immune response, cytokines are classified into two groups. Afferent cytokines have a role in the induction of primary immune responses. Efferent cytokines play a part in the suppression of immune responses.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="afferent-cytokines">Afferent cytokines<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#afferent-cytokines" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Interleukin-1 (IL-1) IL-1 is primarily produced by the cells of mononuclear phagocytic system (MPS), and also by T- and B-cells, natural killer (NK) cells and many other nucleated cells. The secretion of IL-1 is generally induced by antigen, injury, toxins or inflammation, and is considered to be a primary mediator of acute phase reactions.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="functions-of-il-1">Functions of IL-1<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#functions-of-il-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>(a) Activation of resting T-cells It activates resting T-cells and stimulates production of lymphokines such as Interleukin-2.</p>
<p>(b) Chemotaxis: It causes chemotaxis and increased metabolism in phagocytes.</p>
<p>(ii) Interleukin-2 (IL-2) IL-2 is also known as T-cell growth factor (TCGF). It is a lymphokine produced by T-helper cells activated by IL-1. Activated T-cells produce IL-2, and at the same time receptors for IL-2 appear on their surface. (Fig. 3.1).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="functions-of-il-2">Functions of IL-2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#functions-of-il-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>(a) Proliferation of Th cells When IL-2 interacts with the IL-2 receptor on the surface of T-helper (Th) cell, it results in proliferation of Th cells, which in turn, amplify the immune response. The activated T-cells subsequently produce other interleukins (IL-4, IL-5, IL-6), which induce activation, proliferation and differentiation of B-cells.</p>
<p>(b) Enhancement of killer cell activities IL-2 rapidly enhances natural killer (NK) cell activity. It increases specific killing ability of cytotoxic lymphocytes in the presence of antigen. It also acts on null (non-T, Non-B) cells which are then capable of lysing NK-resistant tumour cells.</p>
<p>(iii) Interleukin-3 (IL-3) or Colony stimulating Factors (multi-CSF) Colony Stimulating Factors (CSFs) are known to induce differentiation and proliferation of pleuripotent haematopoietic stem cells in vitro. IL-3 is produced by activated T-cells and perhaps by the bone marrow.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="function-of-il-3">Function of IL-3<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#function-of-il-3" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>IL-3 is capable of supporting proliferation and differentiation of pleuripotent stem cells of the erythroid, lymphocytic, megakaryocytic series and mast cells.</p>
<p>Scanned by CamScanner</p>
<p>1140 Basic Immunology and Serodiagnosis</p>
<p>(iv) Interleukin-4 (IL-4) Interleukin-4 is also known as B-cell growth factor I (BCGF I). It is produced by activated T-cells. Receptors for IL-4 are found on both T- and B-lymphocytes.</p>
<p><strong>Functions of IL-4</strong></p>
<p>(a) IL-4 participates in B-cell activation, differentiation, proliferation, immunoglobulin secretion, and later, also in the switch in immunoglobulin class (e.g. IgM to IgG).</p>
<p>(b) IL-4 promotes the growth of T-helper (Th) cells, although to a lesser extent than IL-2.</p>
<p>(c) It co-stimulates mast cells along with IL-3.</p>
<p>(v) Interleukin-5 (IL-5) Interleukin-5 is alternatively known as B-cell growth factor II (BCGFII). It is also produced by activated T-cells.</p>
<p><strong>Function of IL-5</strong></p>
<p>IL-5 brings about final maturation of B-cells which are already proliferating, and promotes production and secretion of immunoglobulins. IL-5 cannot induce proliferation of resting B-cells.</p>
<p>(vi) Interleukin-6 (IL-6) IL-6 is also commonly known as interferon β2 (IFNβ2). IL-6 is primarily produced by fibroblasts.</p>
<p><strong>Function of IL-6</strong></p>
<p>IL-6 induces secretion of immunoglobulins within individual cells.</p>
<p>(vii) Interferon (IFN) Interferons is a group of cytokines that show antiviral and immunoregulatory activity. There are three main types of interferons.</p>
<p>Alpha interferon (IFNα) is produced primarily by leukocytes. Beta interferon (IFNβ) is produced by fibroblasts and Gamma interferon (IFNγ) by immune cells, mainly stimulated lymphocytes. T-helper (Th) cells, T-suppressor (Ts) cells and natural killer (NK) cells.</p>
<p>IFNα and IFNβ are structurally related polypeptides and have anti-viral activity and anti-proliferative and immunoregulatory activities against immune cells. IFNα and IFNβ—together with IL-2 enhance NK cell activity.</p>
<p>IFNγ is mainly immunoregulatory in function. It can enhance or suppress immune response depending upon dosage and timing. IFNγ also inhibits growth of normal and neoplastic cells, and can either stimulate or inhibit haematopoiesis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="efferent-cytokines">Efferent cytokines<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#efferent-cytokines" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Soluble immune response suppressors (SIRS) These are immunosuppressive cytokines produced by T-suppressor (Ts) cells. When SIRS are oxidized by hydrogen peroxide from the macrophage, macrophage function is suppressed by inhibition of cell division and immune responses.</p>
<p>(ii) Immunoglobulin binding factors Immunoglobulin binding factors inhibit <em>in vitro</em> antibody production.</p>
<p>(iii) DNA synthesis inhibitors These inhibitors bind to DNA polymerase to arrest synthesis of DNA.</p>
<p>(iv) Lymphotoxins Lymphotoxins are a group of proteins produced by activated T-cells. They act as efferent cytokines by exerting cytostatic and cytolytic effects on transformed cells.</p>
<p>(v) Cytokines acting on macrophages</p>
<p>(a) Macrophage migration inhibition factor (MIF) prevents the movement of macrophages.</p>
<p>(b) Macrophage activating factor (MAF) enhances the bactericidal and tumouricidal activity of macrophages.</p>
<p>(c) Macrophage chemotactic factors have affinity for macrophages.</p>
<p>(vi) Cytokines acting on leukocytes</p>
<p>(a) Leukocyte inhibition factor inhibits random and directional movement of neutrophils.</p>
<p>(b) PMN activating factor and eosinophil activating factor stimulate neutrophils and eosinophils respectively.</p>
<p>(vii) Other cytokines</p>
<p>Fibroblast activating factor induces wound healing and fibrosis. Efferent monokines include, among others, chemotoxins, prostaglandins, and plasminogen activator.</p>
<p>Scanned by CamScanner</p>
<p>Specific Immune Response 1141</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-cell-mediated-immunity">Mechanism of Cell Mediated Immunity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-cell-mediated-immunity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Cell mediated immunity (CMI) provides a specific immune response against infectious organisms. It also plays a role in tumour immunity, rejection of foreign grafts and delayed type hypersensitivity reactions. Cytotoxic killer cells (Tcx) are the principal effectors of CMI, except in delayed hypersensitivity reactions. When activated, they bring about the lysis of target cells such as virus infected cells, tumour cells or graft tissue.</p>
<p>The initiation of the immune response is the same as that for T-cell dependent activation of B-lymphocytes for the antibody mediated immune response.</p>
<p>Steps (i) to (v) of the mechanism of antibody mediated immunity are common to both AMI and CMI. Other steps in the mechanism of CMI are as follows:</p>
<p>(vi) Maturation of Tcx The IL-2 produced by activated Th leads to maturation of Tcx precursor.
(vii) Direct contact between Tcx and target cell
Contact occurs between antigen specific T-cell receptor (TcR) on Tcx surface membrane and the appropriate antigen on the target cell, resulting in the binding of the two cells. This binding is strengthened by simultaneous binding between the CD8 molecule on the Tcx surface membrane and a Class I HLA molecule on the target cell surface.
(viii) Cytolysis When bound to the target cell, Tcx is stimulated to produce cytolytic proteins from its cytoplasmic granules into the environment of the target cell. These proteins bring about target cell lysis by producing pores in its cell membrane. This alters the cell permeability causing osmotic swelling and lysis.</p>
<p>Figure 3.3 summarises the mechanism of CMI.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="regulation-of-immunity">REGULATION OF IMMUNITY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#regulation-of-immunity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The adaptive immune responses must be 'switched on' as a result of an antigenic stimulus and switched off when they are no longer required, so that a balance between help and suppression is achieved. The regulation of the immune system is achieved through a variety of mechanisms, such as:</p>
<p>T-helper (Th) and T-suppressor (Ts) cells These two types of cells act as a check and balance system for each other. Their functions are</p>
<p><img src="assets/images/image-20251219-1fa23648.jpeg" alt="img-15.jpeg">
Fig. 3.3 Mechanism of cell mediated immunity (CMI)</p>
<p>Scanned by CamScanner</p>
<p>1142 Basic Immunology and Serodiagnosis</p>
<p>regulated by a complex network of cellular interactions and soluble mediators.</p>
<p><strong>Cytokines</strong> These soluble products, secreted by cells such as lymphocytes, macrophages, neutrophils, and NK cells, have both positive and negative effects on the immune response. Afferent cytokines such as interleukins, interferons and B-cell stimulating factors help in building up the immune response whereas efferent cytokines, such as macrophages inhibition factor (MIF), leukocyte inhibition factor and lymphotoxins help in the suppression of the immune response.</p>
<p><strong>Anti-idiotypic antibodies</strong> Idiotypes are unique amino acid sequences in the variable regions of the heavy and light chains of immunoglobulins which contribute directly to the antigen binding specificity of another antibody molecule (anti-idiotypes). Activation of the immune response may also result in the production of antibodies to the idiotype portion of the newly formed antibody molecules. These anti-idiotype antibodies may bind to the surface receptors on B-cells or to TcR on T-cells. Depending on the structure of anti-idiotypes, their attachment may have one of two consequences, namely:</p>
<p>(a) Inhibition of the immune response by blocking the attachment of antigen to these receptors, or
(b) Enhancement of the immune response by producing the same effect as bound antigen.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="immunotolerance">Immunotolerance<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#immunotolerance" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Immunotolerance or immunological unresponsiveness is the condition in which contact with an antigen specifically destroys the capacity of the immune system to mount an immune response against that particular antigen. This tolerance is specific for that antigen only, the response to other antigens is unaffected. Immunotolerance is very undesirable in most infections, but is very useful in the case of an organ or tissue transplant.</p>
<p>The induction of immunotolerance depends on the following factors:</p>
<p><strong>Immunological maturity of the host</strong> Immunological unresponsiveness of the host to the ‘self’ antigens is due to the contact of immature immunological system with these antigens during embryonic life. Similarly, any antigen which comes in contact with the immune system during embryonic life would be identified as the ‘self’ antigen and would not induce any immune response. For this reason, if animals of one strain are injected with the cells from a second strain <em>in utero</em>, the injected animal will accept these cells as self antigens. Another example of this type of immunotolerance is the vertical transmission of some tumour viruses from mother to foetus. The viruses multiply in the foetus and continue to persist after birth, without inducing any immune response as they are recognised as self-antigens.</p>
<p><strong>Physical state and dose of the antigen</strong> Tolerance, instead of immune response, can be induced if very low or very high doses of an antigen are administered. Intravenous injection of huge doses may lead to immune paralysis. The immune response may revive when most of the antigen is degraded or excreted.</p>
<p>The physical state of the antigen is also significant. Generally, soluble antigens and haptens are more likely to lead to immunotolerance than particulate antigens. Tolerance to an antigen may end spontaneously or by administration of a cross reacting antigen.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="b0a099">♦ HARMFUL EFFECTS OF IMMUNITY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b0a099" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Immune response may sometimes have an undesirable effect on the host. These harmful effects of immunity are:</p>
<p>I. Hypersensitivity reactions.
II. Autoimmunity.
III. Transplantation immunity.</p>
<p>Scanned by CamScanner</p>
<p>Specific Immune Response 1143</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="hypersensitivity-reactions">Hypersensitivity Reactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hypersensitivity-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Hypersensitivity reactions are characterised by an altered state of immune responsiveness. Allergy is a commonly used synonym for hypersensitivity, and the antigen which causes allergy is called allergen. For hypersensitivity to occur, the host must receive an initial or sensitizing dose of the allergen. Subsequent contact with the same or related antigen, the shocking dose, results in the hypersensitivity reaction.</p>
<p>Hypersensitivity reactions are basically divided into two groups:</p>
<ol>
<li>Antibody mediated or immediate type reactions and</li>
<li>Cell mediated, delayed type reactions.</li>
</ol>
<p>Some important differences in the two groups are listed in Table 3.1</p>
<p>The basic mechanisms underlying hyper-sensitivity reactions are designed for host defense. However, direction of these mechanisms towards an inappropriate antigen or chronic activation of the mechanisms can lead to pathological consequences. On the basis of pathogenesis, hypersensitivity reactions have been classified into four major types by Gell and Coombs. Out of these, types I, II and III are antibody mediated. These are manifested within a few minutes to a few hours after exposure to the inducing antigen. Type IV hypersensitivity, on the other hand, is cell mediated. This is observed 24 to 48 hours after exposure to the antigen.</p>
<p>Mechanisms of the hypersensitivity reactions are discussed briefly here.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="type-i-hypersensitivity-anaphylactic-shock">Type I Hypersensitivity: Anaphylactic shock<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#type-i-hypersensitivity-anaphylactic-shock" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="mechanism">Mechanism<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>(i) The inducing antigen, allergen, induces the production of specific IgE antibody.</p>
<table><thead><tr><th></th><th>Ab-Mediated or Immediate Type</th><th>Cell-Mediated or Delayed Type</th></tr></thead><tbody><tr><td>Clinical examples</td><td>Anaphylactic shock; allergy to pollen with asthma; serum sickness; some allergies to antibiotics; asthmatic reaction</td><td>Tuberculin hypersensitivity; allergy to fungi (Histopalsma), parasites (Trichinella), Rhus plants (poison ivy or oak), chemicals (nickel); skin graft rejection.</td></tr><tr><td>Timing</td><td>The reaction begins immediately, i.e. within minutes after contact with the allergen, and disappears within 1 hour</td><td>The reaction is delayed. It begins several hours after contact with the allergen and may last for days.</td></tr><tr><td>Histology</td><td>The main pathological reaction consists of dilation of capillaries and arterioles, erythema and oedema and only limited polymorphonuclear leukocyte infiltration</td><td>The main pathological reaction consists of inflammatory change with predominant mononuclear cell infiltration and tissue induration.</td></tr><tr><td>Passive transfer</td><td>The reaction is associated with circulating antibodies and can be transferred passively by means of serum</td><td>The reaction is not associated with circulating antibodies and cannot be transferred passively by means of serum. It can often be transferred passively by means of lymphoid cells or their extracts.</td></tr></tbody></table>
<p>Scanned by CamScanner</p>
<p>1144 Basic Immunology and Serodiagnosis</p>
<p>(ii) The specific IgE binds to Fc receptors on mast cells and basophils.</p>
<p>(iii) On subsequent exposure, the allergen binds to the cell-bound IgE molecules, causing cross linking of the IgE receptors.</p>
<p>(iv) Granules within the mast cells and basophils are released to discharge chemical mediators like histamine, leukotrienes, bradykinin etc.</p>
<p>(v) Chemical mediators act on various tissues leading to increased permeability of blood vessels, increased smooth muscle contractions and increased mucous secretions.</p>
<p>The anaphylactic reaction can be induced by a stinging insect, parenteral administration of antibiotic such as penicillin, rupture of hydatid cyst, or inhalation or ingestion of allergens. The systemic manifestations can develop within five to ten minutes and may appear as nausea, itching, wheezing, cyanosis, abdominal pain, urticaria or hypotension.</p>
<p><strong>Atopy</strong>: Some type I hypersensitivity are inherited and run in families. Such a hypersensitivity is called atopy. The allergens commonly involved in atopy are characteristically inhalants, such as pollen or house dust, or ingestants such as eggs. Hay fever and asthma are typical examples.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="type-ii-hypersensitivity-cytotoxic-reaction">Type II Hypersensitivity: Cytotoxic Reaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#type-ii-hypersensitivity-cytotoxic-reaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Type II reactions are intermediate between hypersensitivity and autoimmunity.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism">Mechanism<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) The inducing antigen stimulates the production of IgM and IgG antibodies.</p>
<p>(ii) The production of antibodies may lead to:
(a) Agglutination of antigen particles.
(b) Opsonisation and subsequent phagocytosis of the antigen.
(c) Binding of complement to the antigen antibody complex resulting in lysis of antigen.</p>
<p>(d) Antibody dependent cellular cytotoxicity (ADCC).</p>
<p>All the effects listed above lead to the destruction of the cell containing the target antigen. If the antigen is a cell surface receptor, or is intimately associated with the cell, binding of antibody may cause destruction of the cell.</p>
<p>Cytolytic reactions are significant in immunohaematology and can cause transfusion reactions, haemolytic disease of the newborn and autoimmune anaemias. Other examples are idiopathic thrombocytopenic purpura and Goodpasture’s disease.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="type-iii-hypersensitivity-immune-complex-disease">Type III Hypersensitivity: Immune Complex Disease<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#type-iii-hypersensitivity-immune-complex-disease" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Immune complex disease can occur when a soluble antigen combines with its antibody. The antigen-antibody complex may precipitate locally in a tissue, in and around small blood vessels or spread systemically via the blood stream. The deposition of the immune complexes at these sites causes local inflammation and massive complement activation, leading to tissue damage.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism">Mechanism<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Antigen-antibody complexes are formed by induction of antibody mediated immunity (AMI) by antigen.</p>
<p>(ii) Complement is bound to the immune complexes.</p>
<p>(iii) Activation of complement results in the release of the components of the complement cascade and manifestation of their biological activities.</p>
<p>(iv) Immune complexes are bound to platelets forming aggregates of platelets and releasing vasoactive amines and increasing vasopermeability.</p>
<p>(v) Phagocytic cells (neutrophils and macrophages) are attracted to the site by chemotaxis where immune complexes are deposited.</p>
<p>Scanned by CamScanner</p>
<p>Specific Immune Response 1145</p>
<p>(vi) Lysosomal enzymes are released by living and dead phagocytes, mediating destruction of the surrounding tissue.</p>
<p>Arthus reaction and serum sickness are two well-known examples of immune complex disease.</p>
<p><strong>Arthus reaction</strong> Arthus reaction is observed when repeated injections of horse serum are given subcutaneously. The initial injection has no effect, but after subsequent injections, an intense local reaction occurs. This consists of oedema, induration and haemorrhagic necrosis. This is known as the Arthus reaction. The localised tissue necrosis is due to the formation of immune complexes on the walls of blood vessels.</p>
<p><strong>Serum sickness</strong> This is a systemic immune complex disease resulting from a single injection into an individual of a high concentration of serum from another species such as a horse. The symptoms appear 7–12 days after the injection and may include fever, lymphadenopathy, splenomegaly, arthritis, endocarditis, vasculitis, glomerulonephritis, urticarial rashes, nausea and vomiting. This hypersensitivity reaction occurs when the antibody to a large dose of foreign serum reaches high levels. Immune complexes are formed on the walls of blood vessels in various parts of the body. The symptoms are resolved when the immune complexes are phagocytosed.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="type-iv-hypersensitivity-delayed-hypersensitivity">Type IV Hypersensitivity: Delayed Hypersensitivity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#type-iv-hypersensitivity-delayed-hypersensitivity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The mechanism of delayed type hypersensitivity is independent of antibody and is closely associated with cell mediated immunity and activated T-lymphocytes. These hypersensitivity reactions are provoked by specific antigens, evolve slowly and involve lymphocytes, macrophages and neutrophils.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism">Mechanism<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) The antigen is processed by macrophages and presented to T-helper (Th) cells.
(ii) The macrophages release Interleukin-1 (IL-1), which activates Th which, in turn, secretes IL-2.</p>
<p>(iii) IL-2 activates T-delayed type hypersensitivity cells (Td) and T-cytotoxic (Tcx) cells.</p>
<p>(a) Td promotes inflammatory response by releasing lymphokines which attract, activate and retain macrophages and neutrophils.
(b) Tcx activation leads to subsequent binding and lysis of target cells containing the surface antigen that induced the immune response.</p>
<p><strong>Delayed type skin reaction</strong> As opposed to the immediate hypersensitivity reactions, delayed hypersensitivity reactions begin several hours after contact with the antigen, and reach a peak 24 to 72 hours later. The reactivity can be transferred by lymphoid cells, but not by serum.</p>
<p>The prototype of delayed hypersensitivity is the typical skin reaction seen in hypersensitivity to tuberculin, the protein derivative obtained from <em>Mycobacterium tuberculosis</em>. A small dose of tuberculin is injected intradermally into a person previously sensitized to tuberculoprotein either by infection or immunisation. There is no immediate reaction. Redness, oedema and induration appear which tend to increase for 48 to 72 hours. Histologically, the lesion is characterised by vasodilation, oedema and polymorphonuclear infiltration. Later, lymphoid cells and macrophages also appear. The intensity of the reaction is not related to the level of antibodies in the host. Reactivity can be transferred to a skin-test-negative person by transferring lymphoid cells from a skin-test-positive person.</p>
<p>Tuberculin-type of hypersensitivity is developed in many other infections with bacteria, fungi, viruses and parasites. It is more pronounced when the pathogen is intracellular, and the infection is subacute or chronic. A similar hypersensitivity is also observed in some autoimmune diseases and in allograft reactions.</p>
<p>Figure 3.4 summarises the mechanisms of different types of hypersensitivity reactions.</p>
<p>Scanned by CamScanner</p>
<p>1146 Basic Immunology and Serodiagnosis</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="autoimmunity">AUTOIMMUNITY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#autoimmunity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Autoimmunity is a condition in which immune responses are directed toward self-antigens with consequent structural and functional damage to the host. These immune responses may involve both humoral immunity with production of auto-antibodies, and cell-mediated immunity.</p>
<p>Tissue antigens present during foetal and neonatal life are recognized as ‘self’ and the host develops ‘tolerance’ towards them. On the other hand, antigens which are not present during foetal or neonatal life are considered as ‘non-self’ and “auto-antibodies” develop against them. This differentiation between ‘self’ and ‘non-self’ is an important homeostatic function. ‘Autoimmunity’ is a failure of this homeostatic mechanism.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanisms-of-autoimmunity">Mechanisms of autoimmunity<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanisms-of-autoimmunity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Autoimmunity may result under various conditions, some of which are listed below:</p>
<p><strong>Altered antigen theory</strong> Alteration in the surface antigens of the tissues or cells can occur as a result of physical, chemical or biological influences. Such altered antigens are considered as ‘non-self’ and an immune response is mounted against them. Mutation, infection with viruses and exposure to ultraviolet light are examples of some factors which can alter surface antigens.</p>
<p><strong>Cross-reactive antigen theory</strong> Some complex foreign structures may possess structural parts</p>
<p><img src="assets/images/image-20251219-2d95acc9.jpeg" alt="img-16.jpeg"></p>
<p>(Contd.)
Scanned by CamScanner</p>
<p>Specific Immune Response 1147</p>
<p><img src="assets/images/image-20251219-312f5b84.jpeg" alt="img-17.jpeg">
<img src="assets/images/image-20251219-4e6337cf.jpeg" alt="img-18.jpeg"></p>
<p>Fig. 3.4 Mechanisms of four types of hypersensitivity reactions</p>
<p>which are similar or related to self-antigens. This results in immunological cross-reactivity. The immune response mounted against the foreign complex antigen may also cross-react with similar self-antigen. For example, antibodies against some strains of Group A streptococci may cross-react with heart muscle, causing rheumatic heart disease.</p>
<p>Hidden or sequestered antigen theory Some self-antigens are 'hidden' in the circulation in normal healthy individuals. Such a self-antigen may come in contact with the immune system only at a later stage in life, when it is treated as non-self. Such antigens are known as hidden or sequestered antigens. The lens tissue of the eye, spermatozoa, central nervous tissue are examples of sequestered antigens. These antigens come in contact with cells of the immune system only after organ damage, such as eye injury.</p>
<p>Forbidden clone theory Breakdown of immunoregulatory mechanism may lead to the loss of 'tolerance'. Under such conditions, antigen presentation by cells which are not normally specialised for this role, may give rise to self reactivity. For example, Class II antigens of the HLA system which are normally only expressed on antigen presenting cells such as macrophages and B-lymphocytes, appear on the thyrocytes in thyroiditis, and on liver cells in biliary cirrhosis. They stimulate autoreactive T-cells to induce cytotoxic T-cells and B-lymphocytes to respond against them.</p>
<p>Scanned by CamScanner</p>
<p>1148 Basic Immunology and Serodiagnosis</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="examples-of-autoimmune-diseases">Examples of autoimmune diseases<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#examples-of-autoimmune-diseases" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><strong>Systemic lupus erythematosus (SLE)</strong> SLE is a systemic disease which occurs mainly in women and has a strong hereditary tendency. Patients develop a variety of autoantibodies directed against the cell nuclei, intracytoplasmic constituents, immunoglobulins and some organ specific antigens. The LE cell phenomenon is observed in SLE (see Haematology section).</p>
<p><strong>Rheumatoid arthritis (RA)</strong> This is a chronic inflammatory disease, primarily affecting joints and surrounding tissues. The striking feature of the disease is the presence of several abnormal proteins circulating in the blood. These are a group of immunoglobulins which interact specifically with the antigenic determinants on the Fc fragment of the IgG molecules, i.e. they act as anti-antibodies to immunoglobulins. These proteins are collectively known as rheumatoid factor (RA factor).</p>
<p>Other examples of autoimmune diseases include myasthenia gravis, Addison's disease and pernicious anaemia</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="transplant-immunity">TRANSPLANT IMMUNITY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#transplant-immunity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>When an organ or a tissue is irreparably damaged, defective or absent, its function can be restored by organ transplant or tissue grafting. Transplants or grafts survive better only when the organ or tissue is taken from the recipient himself or from an identical twin. The grafts from other individuals of the same species or different species would be rejected. The speed and vigour with which these transplants are rejected depends on their mutual degree of foreignness. This is related to the genetic relationship between the donor and the recipient.</p>
<p>There are four different types of transplants:</p>
<p><strong>Autograft</strong> An organ or tissue taken from an individual and grafted on himself.</p>
<p><strong>Isograft</strong> An organ or tissue taken from one individual (donor) and grafted on genetically identical individual (recipient) e.g. identical twins or highly inbred strains of animals.</p>
<p><strong>Allograft</strong> Grafts between genetically non-identical members of the same species, e.g. human donor and recipient.</p>
<p><strong>Xenografts</strong> Grafts between members of different species, e.g. mouse donor and guinea-pig recipient.</p>
<p>Generally, autografts and isografts are accepted because the grafts are genetically and antigenically compatible with the host-tissues. Allografts and xenografts are rejected due to genetic and antigenic incompatibility.</p>
<p>The main cause of incompatibility is the major histocompatibility complex (MHC) of each species, such as HLA (Human Leucocyte Antigen) system in man. The MHC is gene coded and has two types of cell surface glycoproteins. Class I are present on all nucleated cells and Class II are present on the cells of the immune system which are involved in antigen recognition (macrophages, T-helper cells, B-cells). Thelper (Th) cells recognise antigen only when it is presented by macrophages in association with Class II MHC antigen. Cytotoxic T-cells (Tcx) recognize an antigen when it is associated with Class I MHC antigen on any nucleated cell in the body. When identified in the donor tissue, the immune system of the recipient mounts an immune response, especially of the cell mediated type, to destroy the antigens and consequently reject the graft. Only if the MHC antigens of the donor and the recipient are the same or closely related, will the graft be tolerated and eventually accepted by the recipient.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="survival-of-the-allograft">Survival of the Allograft<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#survival-of-the-allograft" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Successful allografts rely on</p>
<p>(i) Matching donor and recipient MHC antigens as far as possible. Siblings or relatives are more likely to share these antigens.</p>
<p>(ii) Immunosuppression of the recipient which can be non-specific or specific.</p>
<p>Scanned by CamScanner</p>
<p>Specific Immune Response 1149</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="non-specific-immunosuppression">Non-specific Immunosuppression<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#non-specific-immunosuppression" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Non-specific immunosuppression is achieved by interfering with multiplication or functions of T- and B-lymphocytes by:</p>
<ol>
<li>Use of anti-lymphocyte serum (ALS) obtained by immunising horses or rabbits with human lymphocytes.</li>
<li>Total body irradiation with X-rays.</li>
<li>Corticosteroids such as cortisone, prednisone mainly affect neutrophil and macrophage activity, but may also act on T-cells.</li>
<li>Drugs, e.g Cyclosporin A act against dividing T-cells, perhaps by interfering with the production of lymphokines and presentation of antigen.</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="specific-immunosuppression">Specific Immunosuppression<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#specific-immunosuppression" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Specific immunosuppression is achieved by administration of specific antibody against the target antigens or by elimination of clones of cells which react specifically with the allograft antigens.</p>
<p>&gt; <strong>Note</strong>
&gt; Besides transplantation, immunosuppression is also valuable in cases of severe hypersensitivity and autoimmunity.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="graft-versus-host-gvh-reaction">Graft Versus Host (GVH) Reaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#graft-versus-host-gvh-reaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>A grafted tissue may be rejected by the host due to the reaction of the host to the grafted tissue i.e. host versus graft response. On the other hand, when the graft tissue mounts an immune response against the antigens of the host, it is called graft versus host (GVH) reaction. GVH reaction can occur when the graft contains immunocompetent T-cells, the host has transplantation antigens which are absent in the graft and the graft is not rejected by the host.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="b0c15fde">♦ IMMUNODEFICIENCY DISEASES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b0c15fde" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Deficiency in one or more components of the immune system leads to a condition known as immunodeficiency disease. Basic components involved are</p>
<p>(i) T-lymphocytes</p>
<p>(ii) B-lymphocytes
(iii) Phagocytic cells
(iv) Complement system.</p>
<p>Immunodeficiency may be primary or secondary.</p>
<p>Primary immunodeficiency is congenitally derived due to genetic defects. Many of these are X-linked i.e. inherited by boys from their mothers. The defect may be due to the interruption of differentiation of immunocompetent cells at some stage of development, or due to missing gene products, e.g. individual components of the complement system.</p>
<p>Secondary immunodeficiency is acquired as a result of other factors such as</p>
<p>(i) Malnutrition Reduced intake of proteins, carbohydrates, and minerals such as iron and zinc can lead to defects in antibody formation or T-cell development.
(ii) Infections Many infections lead to immunosuppression. The acquired immune deficiency syndrome (AIDS) is mainly due to a viral infection of Th cells.
(iii) Tumours Tumours such as Hodgkin's disease, myeloma, leukaemias etc. are often associated with immunodeficiency
(iv) Opportunistic infections Severely immunocompromised patients may develop infections with different types of 'opportunistic' organisms. These are usually organisms of low pathogenicity and can cause serious infections mainly when host's defence mechanisms are impaired. Opportunistic infections are the usual cause of death in patients with AIDS, malignancy or in recipients of organ transplants. Examples of opportunistic pathogens are:</p>
<ul>
<li>Bacteria e.g. <em>Pseudomonas aeruginosa</em>, <em>Mycobacterium tuberculosis</em></li>
<li>Viruses e.g. <em>Herpes simplex</em>, cytomegalovirus</li>
<li>Fungi e.g. <em>Candida albicans</em>, <em>Histoplasma capsulatum</em></li>
<li>Protozoa e.g. <em>Cryptosporidium</em>, <em>Pneumocystis carinii</em></li>
</ul>
<p>(v) Drugs Drugs can cause immunodeficiency either intentionally as in</p>
<p>Scanned by CamScanner</p>
<p>Basic Immunology and Serodiagnosis</p>
<p>transplantation, hypersensitivity or autoimmunity; or unintentionally.</p>
<p>(vi) Age Immunity is weaker during infancy and in old age.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="immunoproliferative-diseases">Immunoproliferative Diseases<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#immunoproliferative-diseases" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Malignant proliferation of one or more key cells of the immune system results in immunoproliferative diseases. These diseases include:</p>
<p>(i) Leukaemias involving T- or B-lymphocytes, null cells or monocytes.
(ii) Lymphomas involving lymphoid cells within a solid tissue.
(iii) Monoclonal gammopathies which are a result of proliferation of malignant plasma cells that produce large quantities of a homogeneous immunoglobulin, for example multiple myeloma.</p>
<p>Scanned by CamScanner</p>
<p>Chapter 4</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antigen-antibody-reaction-in-vitro">Antigen-Antibody Reaction in Vitro<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antigen-antibody-reaction-in-vitro" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Antigen and its homologous antibody react with each other specifically. The main purpose of this reaction, occurring in vivo, is to protect the body from the harmful effects of antigens such as pathogenic bacteria and viruses. Antibodies bring about this destruction of antigens by various biological activities such as opsonisation, lysis, neutralization of toxins and viruses etc. This is the basis of antibody mediated immunity (AMI). However, sometimes antibodies may lead to tissue damage as in hypersensitivity reactions and autoimmune diseases.</p>
<p>In the laboratory, the specificity of antigen-antibody reactions is employed either for the detection and/or identification of antigens, which may be in the form of infectious agents or their metabolic products; or for the detection of antibodies produced by the host in response to a stimulus by a specific antigen. Antigen-antibody reactions performed in vitro for the purpose of diagnosis are known as serological tests.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="measurement-of-antigen-and-antibody">MEASUREMENT OF ANTIGEN AND ANTIBODY<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#measurement-of-antigen-and-antibody" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The reactions between antigens and antibodies can occur at various levels. Initially, the specific antigen and antibody may bind with each other without any visible effects. Such reactions can be made visible using various types of markers such as enzymes, fluorescent dyes and radioactive isotopes.</p>
<p>In some cases, antigen-antibody reaction may be demonstrable in the form of precipitation, agglutination, lysis of cells, killing of live organisms, neutralisation of toxic activity or enhancement of phagocytic activity. The technique used for the detection of antigen-antibody reaction depends on the type and level of activity.</p>
<p>Serological techniques can be divided into two main groups:</p>
<p><strong>Antigen tests</strong> These tests employ known, specific antibodies (antisera) to detect and identify antigens in the specimens or in the causative agent isolated from the specimens.</p>
<p><strong>Antibody tests</strong> In these tests, known antigens are used to detect and measure specific antibodies in patient's serum in response to a suspected infection. The amount of antibody in the serum or any other body fluid is expressed as its titre. The antibody titre of a serum is the highest dilution of the serum which reacts with known specific antigen in an observable manner.</p>
<p>The technique for the measurement of an antibody in patient's serum, in its simplest form, involves:</p>
<p>(i) Preparation of serial dilutions of the serum e.g. 1:2, 1:4, 1:8, 1:16 ..., etc.
(ii) Addition of a constant volume of the known antigen suspension to each dilution.</p>
<p>Scanned by CamScanner</p>
<p>1152 Basic Immunology and Serodiagnosis</p>
<p>(iii) Incubation of the antigen-antibody mixture under optimum conditions, for the reaction to occur.</p>
<p>(iv) Detection of the reaction either directly or with the help of markers or indicator systems, in each dilution of the serum.</p>
<p>(v) Interpretation of the antibody titre i.e. the highest dilution of the serum which shows evidence of antigen-antibody reaction. For example, the antibody titre is '16' if the highest dilution of the serum showing a positive reaction is 1:16 as shown in Figure 4.1.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="9d760df7">♦ PREPARATION OF SIMPLE AND SERIAL DILUTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#9d760df7" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="simple-dilution">Simple Dilution<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#simple-dilution" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>To prepare a simple dilution, a given volume of the substance to be diluted, e.g. serum, is added to a constant volume of a diluent e.g. saline. A given volume of a desired dilution of serum may be prepared using the formula:</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mfrac><mtext>Volume&nbsp;of&nbsp;serum</mtext><mtext>Total&nbsp;volume</mtext></mfrac><mo>=</mo><mtext>Dilution</mtext></mrow><annotation encoding="application/x-tex">\frac{\text{Volume of serum}}{\text{Total volume}} = \text{Dilution}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 2.0574em; vertical-align: -0.686em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3714em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">Total&nbsp;volume</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">Volume&nbsp;of&nbsp;serum</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.686em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord text"><span class="mord">Dilution</span></span></span></span></span></span></div>
<p>where dilution is expressed as a fraction (1/x). For example, to prepare 2 ml (Total volume) of 1:20 dilution, the volume of serum required is</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mfrac><mtext>Volume&nbsp;of&nbsp;serum</mtext><mrow><mn>2.0</mn><mtext>&nbsp;ml</mtext></mrow></mfrac><mo>=</mo><mfrac><mn>1</mn><mn>20</mn></mfrac></mrow><annotation encoding="application/x-tex">\frac{\text{Volume of serum}}{2.0 \text{ ml}} = \frac{1}{20}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 2.0574em; vertical-align: -0.686em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3714em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">2.0</span><span class="mord text"><span class="mord">&nbsp;ml</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">Volume&nbsp;of&nbsp;serum</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.686em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 2.0074em; vertical-align: -0.686em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3214em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">20</span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">1</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.686em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span></div>
<p>i.e. Volume of serum = <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mfrac><mn>2</mn><mn>20</mn></mfrac><mo>=</mo><mfrac><mn>1</mn><mn>10</mn></mfrac><mtext>&nbsp;ml</mtext><mo>=</mo><mn>0.1</mn><mtext>&nbsp;ml</mtext></mrow><annotation encoding="application/x-tex">\frac{2}{20} = \frac{1}{10} \text{ ml} = 0.1 \text{ ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.1901em; vertical-align: -0.345em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.8451em;"><span style="top: -2.655em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">20</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.394em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.345em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1.1901em; vertical-align: -0.345em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.8451em;"><span style="top: -2.655em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">10</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.394em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.345em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mord text"><span class="mord">&nbsp;ml</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">0.1</span><span class="mord text"><span class="mord">&nbsp;ml</span></span></span></span></span></span></p>
<p>i.e. 0.1 ml of serum, when diluted to a total volume of 2.0 ml, will give 1:20 dilution.</p>
<p>Therefore, volume of diluent (e.g. saline) needed</p>
<p>= Total volume – volume of patient’s serum
= 2.0 ml – 0.1 ml</p>
<p><img src="assets/images/image-20251219-b40c26ee.jpeg" alt="img-19.jpeg">
Fig. 4.1 Titration of antibodies</p>
<p>Scanned by CamScanner</p>
<p>Antigen-Antibody Reaction in Vitro 1153</p>
<p>= 1.9 ml.</p>
<p>To prepare 2.0 ml of 1:20 dilution of serum, add 1.1 ml of serum to 1.9 ml of saline.</p>
<p>The formula <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mfrac><mrow><mi>R</mi><mi>V</mi></mrow><mi>O</mi></mfrac></mrow><annotation encoding="application/x-tex">\frac{RV}{O}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.2173em; vertical-align: -0.345em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.8723em;"><span style="top: -2.655em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight" style="margin-right: 0.02778em;">O</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.394em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight" style="margin-right: 0.00773em;">R</span><span class="mord mathnormal mtight" style="margin-right: 0.22222em;">V</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.345em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span> can also be used for making dilutions</p>
<p>Where
R = Required concentration (dilution)
V = Total volume required
O = Original concentration (Refer to Section I)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="serial-dilution">Serial Dilution<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#serial-dilution" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Serial dilutions are dilutions in progressive, regular increments, resulting in a series of dilutions in which, each dilution is less concentrated than the preceding one by a constant amount.</p>
<p>For example, a two-fold or doubling dilution series consists of</p>
<table><thead><tr><th>Tube No.</th><th>1</th><th>2</th><th>3</th><th>4</th><th>5</th></tr></thead><tbody><tr><td>Dilution</td><td>1:2</td><td>1:4</td><td>1:8</td><td>1:16</td><td>1:32</td></tr></tbody></table>
<p>i.e. tube No.2 is 1:2 dilution of tube No.1; tube No.3 is 1:2 dilution of tube No.2 and so on.</p>
<p>Two-fold dilutions can be prepared as shown in the table below*.</p>
<p>Variations The volume of a dilution may be changed to the desired volume e.g. 0.1ml, 1.0ml, 2.0 ml etc. while keeping the proportion constant. The dilutions may be carried out in the same way up to any desired dilution e.g. up to tube 10. Sometimes, instead of starting from the first dilution (e.g. 1:2), the test may be started from the third (1:8) or fourth (1:16) dilutions.</p>
<p>The dilutions of the serum can be prepared in tubes or in wells of a microtitre plate where much smaller volumes can be used.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="characteristics-of-antigen-antibody-reactions">CHARACTERISTICS OF ANTIGEN-ANTIBODY REACTIONS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#characteristics-of-antigen-antibody-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Generally, antigens and antibodies observe the following rules when they react:</p>
<p>(i) The reaction is specific: The antigen reacts only with its specific antibody, and vice-versa. However, this specificity is not absolute and cross-reactions do occur between related antigens and antibodies.</p>
<p>(ii) Reaction occurs at surface: The combining groups of antigen and antibody are present on the surface of these molecules. Therefore, surface antigens are immunologically most relevant.</p>
<p>(iii) Entire molecules, and not the fragments, take part in the reaction, even when the antigen or antibody is absorbed on a carrier molecule.</p>
<p>(iv) The combination of antigen-antibody is firm, but reversible. The firmness depends on two factors; affinity, or the intensity of attraction; and avidity, or the strength of the bond between them.</p>
<p>(v) There is no chemical change or denaturations in either the antigen or the antibody molecule after the reaction.</p>
<p>(vi) Unlike chemical reactions with reactants, antigens and antibodies can react in varying</p>
<table><thead><tr><th>Tube No.</th><th>1</th><th>2</th><th>3</th><th>4</th><th>5</th></tr></thead><tbody><tr><td>Saline</td><td>0.5 ml</td><td>0.5 ml</td><td>0.5 ml</td><td>0.5 ml</td><td>0.5 ml</td></tr><tr><td>Serum</td><td>0.5ml</td><td>Mix 0.5ml</td><td>Mix 0.5ml</td><td>Mix 0.5ml</td><td>Mix 0.5ml</td></tr><tr><td>Dilutions</td><td>1:2</td><td>1:4</td><td>1:8</td><td>1:16</td><td>1:32</td></tr></tbody></table>
<p>Scanned by CamScanner</p>
<p>Basic Immunology and Serodiagnosis</p>
<p>proportions. However, to result in a visual effect such as precipitation and agglutination, they must be in optimal proportions.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="monoclonal-antibodies">MONOCLONAL ANTIBODIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#monoclonal-antibodies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>One of the requirements for a highly sensitive and specific antigen-antibody reaction is to obtain pure antibody molecules, with high affinity and avidity for the antigen. Earlier techniques involved immunisation of animals with several repeated doses of antigen, followed by repeated bleeding to obtain the desired quantity of pure antibody.</p>
<p>Technologies have been developed to obtain monoclonal antibodies which are produced by the daughter cells (clones) of a single cell. One technique for the production of a pure, specific antibody by such a clone of cells is called a hybridoma technique. A hybrid of two types of cells is obtained which has a dual quality of being able to multiply indefinitely like a malignant cell; and to produce a specific antibody, like B-lymphocyte.</p>
<p>The two types of cells used for the hybrid are:</p>
<p><strong>Multiple myeloma cells</strong> Multiple myeloma is a malignant tumour of antibody producing plasma cells, usually of undetermined specificity. The multiple myeloma cells selected for this technique, which can multiply indefinitely, also possess a very important defect. They are deficient in the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT). Due to this defect they are unable to survive in the medium containing hypoxanthine, aminopterin and thymidine (HAT).</p>
<p><strong>Splenic cells of a mouse immunised with the specific antigen</strong> A mouse is immunised with the antigen for which the antibody is to be produced. The mouse responds by producing antibodies to many determinants or epitopes on the antigen injected. The mouse spleen is removed, minced and prepared as a single cell suspension. This should include the B-cell population which produces antibodies to the injected antigen. These B-cells cannot multiply indefinitely, but possess the enzyme HGPRT and can grow in HAT medium for some time.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="fusion-of-splenic-b-cells-with-multiple-myeloma-cells">Fusion of Splenic B-cells with Multiple Myeloma Cells<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#fusion-of-splenic-b-cells-with-multiple-myeloma-cells" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>When these two types of cells are suspended in HAT medium in the presence of surfactants such as polyethelyne glycol (PEG), a spontaneous fusion occurs between some cells, resulting in a hybrid with the desired qualities of each type of cell. Only the hybrid cells are capable of growing indefinitely in HAT medium and produce antibodies to the desired antigen. The unfused myeloma cells will not be able to grow in the HAT medium because they lack HGPRT. The unfused antibody forming cells can grow for a short time in HAT medium, but die eventually. The hybrids formed by the fusion will be the only cells surviving indefinitely. This is the hybridoma technique (Fig. 4.2).</p>
<p>The hybrid cells are then screened to identify clones which produce the desired antibody. The selected cells or hybridomas may be maintained in cell culture or may be injected into the peritoneal cavity of a mouse for growth and subsequent antibody harvest.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="antigen-antibody-reactions-in-vitro">ANTIGEN-ANTIBODY REACTIONS IN VITRO<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antigen-antibody-reactions-in-vitro" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="precipitation">Precipitation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precipitation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>There are four essential factors that must be present for precipitation to occur. These are: antigen, antibody, an electrolyte and a means of mixing.</p>
<p>When a soluble antigen reacts with its antibody in the presence of an electrolyte such as normal saline, and then mixed by shaking, a visible antigen-antibody complex appears in the form of an insoluble precipitate.</p>
<p>Precipitation is perhaps the simplest method of detecting antigen-antibody reactions. Most antibodies are capable of precipitation. If the precipitate remains suspended in the form of floccules, the reaction is known as flocculation.</p>
<p>Scanned by CamScanner</p>
<p>Antigen-Antibody Reaction in Vitro 1155</p>
<p><img src="assets/images/image-20251219-81201c91.jpeg" alt="img-20.jpeg">
Mouse immunised with specific antigen</p>
<p>Mouse spleen removed</p>
<p>Antibody producing spleen cells (can not multiply continuously)</p>
<p><img src="assets/images/image-20251219-57839590.jpeg" alt="img-21.jpeg">
Mouse myeloma cells grown in cell culture (These cells die in HAT medium)</p>
<p>Myeloma cells capable of continuous multiplication</p>
<p><img src="assets/images/image-20251219-500a558d.jpeg" alt="img-22.jpeg"></p>
<p><img src="assets/images/image-20251219-c7e4d6e5.jpeg" alt="img-23.jpeg">
Fusion of cells in polyethelene glycol (hybrids formed)</p>
<p><img src="assets/images/image-20251219-48e44177.jpeg" alt="img-24.jpeg">
Assay for specific antibody
Positive hybrids recloned
Hybridoma frozen for storage
Propagation of selected clones
Monoclonal antibodies</p>
<p>Only hybrids multiply in HAT medium</p>
<p>Cloning of hybrids</p>
<p>Fig. 4.2 Production of monoclonal antibodies by hybridoma technique</p>
<p>Scanned by CamScanner</p>
<p>1156 Basic Immunology and Serodiagnosis</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mechanism-of-precipitation">Mechanism of precipitation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-precipitation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>By the lattice theory of precipitation, the precipitate is formed as a result of random, reversible reactions, where each antibody binds to more than one antigen, and vice versa; eventually forming a 'lattice' of antigen and antibody. Because it exceeds the critical volume for solubility, it appears as an 'insoluble precipitate'.</p>
<p>For an antigen-antibody reaction to result in the formation of a precipitate, several conditions are necessary:</p>
<p>(i) Binding sites Both antigen and antibody molecules must possess multiple binding sites specific for each other.
(ii) Optimal concentration The relative concentration of antigen and antibody in the mixture must be optimal for that system. Usually it corresponds to approximately equivalent amounts of an antigen and antibody.
(iii) Other factors The degree of precipitation also depends on the electrolyte concentration, time and temperature of reaction, pH and mobility of the reactants in solution.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="prozone-phenomenon">Prozone phenomenon<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#prozone-phenomenon" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>If increasing quantities of antigen are added to the same amount of antibody in different tubes, precipitation is found to occur most rapidly and abundantly in the middle tubes, in which antigen and antibody are present in optimal or equivalent proportions (Fig. 4.3).</p>
<p><img src="assets/images/image-20251219-fa2defc1.jpeg" alt="img-25.jpeg">
Fig. 4.3 Prozone (A), Zone of equivalence (B), and Postzone (C)</p>
<p>Similar results are obtained if varying amounts of antibody are added to a constant amount of antigen. If the amounts of precipitate in the different tubes in Fig. 4.3 are plotted on a graph, the resulting curve will show three phases (Fig. 4.4)</p>
<p>(i) The ascending portion called prozone or zone of antibody excess.
(ii) A peak, where antigen and antibody are in equivalent proportions. This zone is called the zone of equivalence.
(iii) The descending portion is called postzone or zone of antigen excess.</p>
<p>Prozone is important in some serological reactions when antibody is present in very high titres in the serum. If the test is performed by serially diluting the antibody and adding a constant amount of antigen, the first few tubes may not show precipitation due to excess of antibody molecules.</p>
<p>In such a test, the results may appear as</p>
<table><thead><tr><th>Serum dilution</th></tr></thead><tbody><tr><td>1:20 1:40 1:80 1:160 1:320 1:640 1:1280 1:2560</td></tr><tr><td>Precipitation</td></tr><tr><td>- - - ++ ++++ ++++ ++ -</td></tr></tbody></table>
<p>Therefore, if sufficiently wide range of antibody dilutions is not used, it may be wrongly interpreted as a negative test.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="types-of-precipitation-reaction">Types of Precipitation Reaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#types-of-precipitation-reaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Precipitation tests can be carried out either in solution or in gels.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="precipitation-in-solution">Precipitation in solution<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#precipitation-in-solution" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Ring test In this simplest type of precipitation, antigen in solution is layered over a solution of antibody in a narrow tube or a capillary. Appearance of a precipitate at the junction of the two liquids indicates a positive test. Unknown antigens such as C-reactive proteins or streptococci can be identified and typed by using known antisera.
(ii) Slide test A drop of antigen and of antibody are mixed on a slide either on a shaker or manually for a few minutes. A positive test is indicated by</p>
<p>Scanned by CamScanner</p>
<p>Antigen-Antibody Reaction in Vitro 1157</p>
<p><img src="assets/images/image-20251219-d414cfee.jpeg" alt="img-26.jpeg">
Fig. 4.4 Precipitation curve</p>
<p>the presence of floccules. This is known as slide flocculation test and is a common technique for VDRL (Venereal Disease Research Laboratory) test used in the diagnosis of syphilis. It can be used as a qualitative or quantitative test.</p>
<p>(iii) Tube test The tube test has a similar principle as the slide test. It can be used for quantitative estimation of antigen or antibody by serially diluting the unknown entity. The Kahn test for syphilis is an example of tube flocculation test. However, this test is outdated due to the advent of more specific and simpler tests. The tube flocculation test is also used for standardisation of toxins or toxoids.</p>
<p>Precipitation in gel or Immunodiffusion Gels such as agar, agarose and polyacrylamide give good precipitation reaction because they help to stabilize liquids and prevent the formation of convection currents. The gels do not take part in the reaction and provide a mesh-like structure which allows free diffusion of soluble substances. When precipitate forms, the size of the complex exceeds the dimensions of the pore size of the gel, and the diffusion stops, leading to the formation of bands of precipitation.</p>
<p>When antigen and antibody are allowed to diffuse through a gel, the formation of precipitate indicates that both the reactants are homologous and are present in optimal proportions at the point of precipitation. This technique is known as immunodiffusion. There are two types of immunodiffusion: Passive and active. In passive immuno-diffusion, the reactions take place without the addition of electric field. They are simple to perform and do not require expensive equipment. However, they are slow and less sensitive. On the other hand, active immunodiffusion conducts immunodiffusion in an electric field which increases the sensitivity and reduces the time required for results, but requires special equipment.</p>
<p>Scanned by CamScanner</p>
<p>1158 Basic Immunology and Serodiagnosis</p>
<p>Agar consists of a mixture of two polysaccharides, agarose and agaropectin, and is obtained by partial hydrolysis of a seaweed. The pore size of the medium depends on the concentration of agar. About 0.3 to 1.5 per cent agar gel concentrations are found to be optimum for most precipitation reactions. Agarose is prepared by removing agaropectin from agar.</p>
<p><strong>Preparation of gel</strong> Immunodiffusion can be carried out either in a tube or on a flat surface such as a microscope slide or a flat glass plate.</p>
<ul>
<li>For a tube test, 0.6 per cent concentration of agar or agarose is used either in saline or in phosphate buffer (0.2 mol/litre) at pH 7.2. The mixture is boiled to dissolve agar or agarose and poured in a tube and allowed to set.</li>
<li>For a slide test, agar or agarose is used at 1 per cent concentration in saline or phosphate buffer.</li>
<li>Pour the molten agar on the slide or any other flat surface of desired dimensions and allow to set. A microscope slide requires about 2.0 to 2.5 ml of agar solution.</li>
</ul>
<p><strong>Single diffusion techniques</strong> In single diffusion techniques, only one reactant, usually antigen, is allowed to diffuse into a medium containing a lower concentration of corresponding antibody. The single diffusion can be either in one dimension or two dimensions.</p>
<p><strong>Single diffusion in one dimension (Oudin technique)</strong> This technique is performed in a tube. The antibody is mixed with agar at 60° C and allowed to cool in a tube. Antigen in solution, as the diffusing reactant, is overlaid on the cooled agar. In this system, the antigen can move only in one direction, downward. A band of precipitation will form where the antigen-antibody meet at optimal proportions. (Fig. 4.5) If the reactants contain more than one antigen or antibody, multiple precipitation bands appear independent of each other.</p>
<p><strong>Single diffusion in two dimensions (Radial immunodiffusion, RID)</strong> This involves the incorporation of one reagent, usually antibody, into the agar which is poured onto a flat plate. The corresponding reactant, the antigen, is placed in a circular well cut in the agar surface (Fig. 4.6). The antigen diffuses radially from the well into the surrounding agar, producing an advancing circular gradient. Ring shaped bands of precipitation form concentrically around the well. The diameter of the precipitation bands (haloes) is proportional to the concentration of the antigen in the well.</p>
<p><strong>Double diffusion techniques</strong> Double immunodiffusion techniques are those where both the antigen and the antibody are allowed to diffuse through a matrix of neutral gel. Like single diffusion, it can be in one dimension (in tubes) or two dimensions (on a plate).</p>
<p><img src="assets/images/image-20251219-3ead0b89.jpeg" alt="img-27.jpeg">
Fig. 4.5 Oudin technique—Single diffusion in one dimension</p>
<p>Scanned by CamScanner</p>
<p>Antigen-Antibody Reaction in Vitro 1159</p>
<p><img src="assets/images/image-20251219-6c8211dc.jpeg" alt="img-28.jpeg">
Fig. 4.6 Radial immunodiffusion</p>
<p>Double diffusion in one dimension In this technique, the antibody is incorporated in gel and allowed to set in a tube. Above this is placed a column of plain agar. Antigen in gel is layered on top of the plain agar. The antigen and antibody move towards each other through the column of plain agar. A band of precipitation is formed where they meet at optimum proportion (Fig. 4.7).</p>
<p>Double diffusion in two dimensions (Ouchterlony Technique) This is a highly versatile system for identifying and characterising antigen-antibody systems. A 1% agarose gel is prepared on a flat surface. Wells are cut into this medium, the distance and configuration of wells varies with each system. In its simplest form, two wells are cut as shown in Figure 4.8. Reacting antigen and antibody solutions are placed in respective wells. The plate is then placed in a moist chamber either at 4°C or 37°C. The reaction is faster at 37°C, but the bands are sharper at 4°C. During incubation, each reactant diffuses radially from the point of application. The precipitin bands appear at approximately the point of equivalence, perpendicular to the axis line between the points of application (Fig. 4.8 (i)).</p>
<p>One of the advantages of this technique is that the reactants in the wells diffuse radially, and therefore, are capable of reacting in any direction. This helps to compare different antigens or antisera directly for their identity, non-identity or relatedness (Fig. 4.8 (ii)). Various different sizes, shapes and configurations of wells can be used in this technique. A circular central well and equidistant satellite wells around it is the most commonly used pattern.</p>
<p>The selected pattern, the template, is drawn on a paper which is placed under the gel plate. The wells are then cut according to the template, and filled with the desired reactants. For example, a known antiserum in the centre and antigen solution</p>
<p><img src="assets/images/image-20251219-fe1e63d9.jpeg" alt="img-29.jpeg"></p>
<p>Scanned by CamScanner</p>
<p>1160 Basic Immunology and Serodiagnosis</p>
<p>to be tested in the surrounding wells. At the end of appropriate incubation period, the plate is examined for the lines of precipitation. The lines are very fine and should be observed in diffused light (Fig. 4.9).</p>
<p>The types of precipitation bands commonly observed are:</p>
<p>(i) The reaction of identity where the lines are continuous from one well to the next (Fig. 4.8 ii A).
(ii) The reaction of non-identity where the lines cross each other (Fig. 4.8 ii B) and
(iii) The reaction of partial identity where a spur is formed at the junction of the precipitation bands (Fig. 4.8 ii C).</p>
<p>Elek's test is a modification of the Ouchterlony technique. It is used to detect toxin producing strains of <em>Corynebacterium diphtheriae</em>. A strip of filter paper impregnated with diphtheria antitoxin (500 to 1000 units/ml) is embedded in the centre of an agar gel. A known toxin producing strain of <em>C. diphtheriae</em> and the strain isolated from a patient are streaked separately at right angle to the filter paper strip. If the isolate produces toxin, a line of precipitation is seen which merges with that produced by the control strain, proving identity.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="electroimmunodiffusion-or-active-immunodiffusion-techniques">Electroimmunodiffusion or Active Immunodiffusion Techniques<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#electroimmunodiffusion-or-active-immunodiffusion-techniques" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Electroimmunodiffusion or active immunodiffusion combines electrophoresis with immunodiffusion techniques. Electrophoresis is the use of electric current to induce the migration and separation of charged ions in an electric field. The reactants in these procedures are stabilized by a porous material such as agar, agarose or cellulose acetate. Agarose and cellulose acetate are stabilized by a porous material such as agar, agarose or cellulose acetate.</p>
<p><img src="assets/images/image-20251219-c6b07d94.jpeg" alt="img-30.jpeg">
(i) With single antigen and antibody</p>
<p><img src="assets/images/image-20251219-340019b0.jpeg" alt="img-31.jpeg">
Line of precipitation</p>
<p><img src="assets/images/image-20251219-7bfb9f2b.jpeg" alt="img-32.jpeg">
(ii) With multiple antigens and antibodies
A. Identity: Antigen A (AgA) and antigen B(AgB) react identically with antibody (Ab)</p>
<p><img src="assets/images/image-20251219-0c6d8f73.jpeg" alt="img-33.jpeg">
B. Non-identity: AgA and AgB react independently with their respective antibodies AbA, AbB</p>
<p><img src="assets/images/image-20251219-1901b83f.jpeg" alt="img-34.jpeg">
C. Partial identity: AgA and AgB both react with AbA, but with partial identity (cross reactivity)</p>
<p>Fig. 4.8 Ouchterlony technique</p>
<p>Scanned by CamScanner</p>
<p>Antigen-Antibody Reaction in Vitro 1161</p>
<p><img src="assets/images/image-20251219-eca13651.jpeg" alt="img-35.jpeg">
Fig. 4.9 Viewing box for immunodiffusion</p>
<p>lulose acetate are electrically inert whereas agar possesses an electronegative charge in relation to the buffer, and is useful when endosmosis is desired.</p>
<p>Migration of proteins in an electric field is affected by the charge, size and shape of particles; the concentration and pH of the solvent; the temperature and viscosity of the medium; and intensity of the electric field. Like immunodiffusion, electroimmunodiffusion can occur as single or double diffusion in one or two dimensions. The various techniques are briefly described here.</p>
<p>Counterimmunoelectrophoresis (CIEP) This is a double diffusion in one dimension which is based on the principle of endosmosis. Commercially available agar forms a gel with a negative electrical charge. When such a gel is used for electrophoresis, a current is established in the direction opposite to the electrophoretic migration. In a gel at pH 8.2, immunoglobulins which are electrically almost neutral, move in the direction opposite to that of the electric current, because of this electro-endosmotic flow. If the antigen is placed near the cathode as compared to the antiserum, the antigen will move towards the anode (+) along with the electric current and the antibody will move towards the cathode (-) due to endosmosis (Fig. 4.10). A precipitate will form as they meet.</p>
<p>The test is carried out in a 1% agar gel on a microscope slide in a buffer at pH 8.2. Two wells (1.5 mm in diameter) are cut about 1 cm apart along the long axis of the slide. The well closest to the cathode is filled with antigen and the other with antiserum. Electrophoresis is carried out at 8 volts/cm for 30 minutes.</p>
<p>The advantage of this technique over simple immunodiffusion is that the result can be obtained within one hour, and less quantities of the reactants are needed. Examples of CIEP application are the detection of bacterial antigens in CSF or hepatitis B antigen in serum.</p>
<p>Immunoelectrophoresis Immunoelectrophoresis is an ingenious method of analyzing and identifying serum proteins by a combination of electrophoretic protein separation followed by immunodiffusion. Serum is placed in a well in an appropriate medium such as cellulose acetate, agar or agarose; at a suitable pH (usually 0.05 M Veronal buffer, pH 8.6). It is electrophoresed at about 50 volts, 2.5 milliamperes per slide for a period of 45 minutes to 4 hours. This separates the constituents of the serum according to their electrophoretic mobilities. Albumin, the most negatively charged in basic buffers, moves the farthest distance towards the anode, followed by α1, α2, β and γ globulins (Fig. 4.11).</p>
<p>After electrophoresis, troughs are cut on each side of, and parallel to, the line of electrophoresis. The troughs are filled with antibody to human serum, for the detection of an abnormal component in the serum. During incubation, double immuno-diffusion</p>
<p>Scanned by CamScanner</p>
<p>1162 Basic Immunology and Serodiagnosis</p>
<p><img src="assets/images/image-20251219-c8500f82.jpeg" alt="img-36.jpeg">
Fig. 4.10 Counterimmunoelectrophoresis (CIEP)</p>
<p>fusion takes place. The antiserum diffuses perpendicular to the trough, and each serum protein diffuses outward from its point of electrophoresis. Precipitation bands appear at the equivalence points, and can be identified by their shape and position (Fig. 4.11).</p>
<p>The most useful clinical application of immunoelectrophoresis is in detection and identification of abnormal proteins in multiple myeloma and other lympho-proliferative disorders. It is also useful in detecting changes in globulin levels in diseases such as viral hepatitis and cirrhosis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="rocket-electrophoresis-and-crossed-immunoelectrophoresis">Rocket Electrophoresis and Crossed Immunoelectrophoresis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#rocket-electrophoresis-and-crossed-immunoelectrophoresis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>These are two more modifications of immunoelectrophoresis. In rocket electrophoresis, serum is separated electrophoretically into its components. In the second stage, it is allowed to diffuse into the antibody incorporated in the gel to form precipitation peaks. Since the pattern resembles a spike or a rocket, it is called rocket electrophoresis.</p>
<p>In crossed electrophoresis, an electric current is applied at right angles to the first run to form precipitation peaks in the antibody containing gel. The area of the peak is proportional to the concentration of the antigen (Fig. 4.12).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="agglutination">Agglutination<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#agglutination" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Agglutination is the observable clumping which occurs when a particulate antigen is mixed with its antibody. This reaction takes place at a suitable temperature and pH, and in presence of an electrolyte such as sodium chloride.</p>
<p><img src="assets/images/image-20251219-8f6bb79a.jpeg" alt="img-37.jpeg">
Fig. 4.11 Immunoelectrophoresis</p>
<p>Scanned by CamScanner</p>
<p>Antigen-Antibody Reaction in Vitro 1163</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanism-of-agglutination">Mechanism of agglutination<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanism-of-agglutination" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The mechanism of agglutination is based on the same principle as that of precipitation i.e. the formation of lattice by antigen and antibody combining in optimal proportions. However, due to the particulate nature of the antigen in agglutination, the reaction takes place in two phases, primary and secondary.</p>
<p>In the primary phase, an antibody molecule binds with the antigenic determinant on the particulate antigen. In the secondary phase, the same antibody molecule must bind to an antigenic determinant on another particle of the antigen to facilitate formation of a lattice (Fig. 4.13). Viscosity of the environment and better exposure of antigenic determinants enhance the secondary phase of agglutination. Therefore, addition of agents such as albumin or enzymes (e.g. papain) may be needed to improve the secondary reaction.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="role-of-an-electrolyte-in-agglutination">Role of an electrolyte in agglutination<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#role-of-an-electrolyte-in-agglutination" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Because particulate antigens have net electrostatic charges on their surface, they tend to repel each other. The net effect of this is that the particles are kept apart. An antibody molecule, therefore, may find it difficult to bind to two particles at the same time. Electrolytes such as saline neutralise negative charges and tend to nullify the repulsive forces between antigen molecules. This allows them to come closer and facilitate multiple binding by one antibody molecule.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="complete-and-incomplete-blocking-antibodies">Complete and Incomplete (blocking) antibodies<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#complete-and-incomplete-blocking-antibodies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Antibodies involved in <em>in vitro</em> agglutination reactions are regarded to be complete if they are capable of both primary and secondary stage interactions with antigen in a normal saline solution. IgM antibodies act as complete antibodies due to their high valency and high molecular weight. Incomplete antibodies bring about primary but not secondary binding. Most incomplete antibodies are IgG by nature. The presence of IgG in test samples may have the effect of blocking the agglutinating ability of IgM by occupying the necessary binding sites on the antigen (Fig. 4.14).</p>
<p>As in precipitation, prozone phenomenon is also observed in agglutination reactions due to the presence of antibodies in high concentration. The prozone phenomenon can however, be overcome by using a wider range of dilutions of antibody in the test. This eliminates false negative results.</p>
<p>The presence of blocking antibodies in low titres may also be responsible for the absence of agglutination. The effect of blocking or incomplete antibodies may be overcome by using hypertonic</p>
<p><img src="assets/images/image-20251219-4005d03e.jpeg" alt="img-38.jpeg"></p>
<p>Crossed immunoelectrophoresis</p>
<p>Scanned by CamScanner</p>
<p>Basic Immunology and Serodiagnosis</p>
<p><img src="assets/images/image-20251219-1c5416db.jpeg" alt="img-39.jpeg">
Fig. 4.13 Primary and secondary phases of agglutination reaction</p>
<p>(5%) saline instead of isotonic (0.85%) normal saline, by the addition of albumin (22% bovine albumin in saline) to the test or by the use of antiglobulin (Coomb's) reagent.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="types-of-agglutination-tests">Types of Agglutination Tests<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#types-of-agglutination-tests" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Agglutination reactions have the advantage of being (i) simple to perform (ii) relatively sensitive (iii) having a wide range of applications. Agglutination tests can be qualitative or quantitative.</p>
<p><strong>Slide agglutination tests</strong> These are rapid techniques which can be easily performed on a slide or agglutination tile. The reaction can be read within seconds or minutes. The slide tests are classically qualitative but can be adapted for quantitative estimations.</p>
<p>These tests may be either active or passive agglutination reactions. Active (or direct) agglutination tests are those which use the antigen where the antigenic determinant is inherent to the particle itself. Passive (or indirect) agglutination tests use inert particles coated with soluble antigens. By</p>
<p>passive agglutination, even soluble antigens can be used for agglutinations tests. The inert particles commonly employed are polystyrene latex, bentonite, charcoal or red blood cells.</p>
<p><strong>Active agglutination</strong> When a smooth, uniform suspension of a particulate antigen, such as bacteria, prepared in a drop of saline on a slide or a tile, is mixed with a drop of antiserum, agglutination takes place if the antigen and antibody are homologous. Gently rocking the slide facilitates the reaction, which appears instantly or within a few seconds. Care should be taken to see that the clumping is not due to autoagglutination which is false clumping not due to antigen-antibody reaction. A control consisting of the antigen suspension in saline should also be prepared on the same slide.</p>
<p>Direct slide agglutination is a routine procedure for the identification and serotyping of bacterial isolates from clinical specimens using known specific antisera. Examples are <em>Salmonella</em> and <em>Shigella</em> slide agglutination tests.</p>
<p><strong>Passive agglutination</strong> Examples of passive agglutinators slide tests are:</p>
<p>Scanned by CamScanner</p>
<p>Antigen-Antibody Reaction in Vitro 1165</p>
<p><img src="assets/images/image-20251219-6167109a.jpeg" alt="img-40.jpeg">
Fig. 4.14 Effect of blocking antibodies</p>
<p>(i) Tests using latex particles Passive agglutination can be used for the diagnosis of arthritis. In rheumatoid arthritis, (RA) an autoantibody called RA factor appears in the patient's serum and acts as an antibody to gamma globulin. In the test, latex particles coated with gamma globulin are mixed with patient's serum. Agglutination indicates the presence of RA factor in patient's serum. Polystyrene latex particles are used in many other tests such as test for the detection of antibody to streptolysin O of streptococci by coating the latex particles with the streptococcal antigen.</p>
<p>(ii) Tests using red blood cells Tests using red blood cell agglutination are called haemagglutination tests. Treponema pallidum haemagglutination (TPHA) test uses chicken erythrocytes coated with an extract of T. pallidum. These red cells are agglutinated by antibody in the serum of a patient with syphilis.</p>
<p>(iii) Tests using carbon particles Carbon particles mixed with cardiolipin antigen are used in the rapid plasma reagin (RPR) card test. Patient's serum is mixed with this antigen. Agglutination reaction is rendered easily visible by the presence of carbon particles and indicates the presence of antibodies in patient's serum. This is a screening test for cardiolipin antibodies in the sera of patients suffering from syphilis. It is a non-specific screening test.</p>
<p>Tube agglutination test This is a standard method for the quantitative estimation of antibodies. It is more sensitive than slide test. To serial dilutions of patient's serum in tubes, a constant amount of known antigen is added. The highest dilution showing agglutination indicates the antibody titre for the antigen tested. Tube agglutination tests are routinely employed for serodiagnosis of typhoid, brucellosis and typhus fever. A four fold rise in antibody titre in paired sera indicates active infection and is more diagnostic than a single result.</p>
<p>Reversed passive agglutination test Reversed passive agglutination involves adsorption of antibody, instead of antigen, on to inert carrier particles. The tests are useful for the detection of antigens, using known antisera on carrier particles. For example, reversed passive haemagglutination (RPHA) assays are available for the detection of antigens such as rubella and measles. Inert particles such as polystyrene latex can be used for the detection of soluble bacterial antigens in clinical specimens such as CSF or for viral antigens in specimens such as stool.</p>
<p>Figure 4.15 shows the mechanisms of the passive and the reversed passive agglutination reactions</p>
<p>Coagglutination (COAG) tests Coagglutination is a modification of reversed passive ag</p>
<p>Scanned by CamScanner</p>
<p>Basic Immunology and Serodiagnosis</p>
<p><img src="assets/images/image-20251219-febc8f51.jpeg" alt="img-41.jpeg"></p>
<p><img src="assets/images/image-20251219-f8e66ab1.jpeg" alt="img-42.jpeg">
Fig. 4.15 (A) Passive and (B) Reversed passive agglutination</p>
<p>glutination where a pretreated, 'stabilized' cell of Staphylococcus aureus is used as a carrier particle for antibodies. COAG is based on the principle that most strains of Staphylococcus aureus possess on their surfaces a substance called protein A which is capable of binding IgG molecules nonspecifically through the Fc region. When mixed with the specific antigen, it will bind with the antibody molecules attached to protein A on staphylococci, resulting in clumping of bacteria. This indicates a positive test (Fig. 4.16). Reagents for coagglutination are commercially available.</p>
<p>Antiglobulin mediated agglutination test (Coomb's test) The Coomb's test was originally devised for the detection of incomplete Rh-antibodies which do not agglutinate Rh-positive</p>
<p><img src="assets/images/image-20251219-ef8d5279.jpeg" alt="img-43.jpeg">
Fig. 4.16 Coagglutination</p>
<p>erythrocytes in saline. When the serum of Rh-negative mother, containing such incomplete IgG antibodies to Rh-antigen are mixed with Rh-positive red cells, the Rh-antibody binds to the surface of the red cells, without agglutinating them. Such red cells are called 'sensitised' red cells. When such</p>
<p>Scanned by CamScanner</p>
<p>Antigen-Antibody Reaction in Vitro 1167</p>
<p>sensitised cells are treated with antiglobulin or Coomb's serum, the cells coated with Rh-antibody are agglutinated by this 'antibody to the antibody' (Fig. 4.17).</p>
<p><img src="assets/images/image-20251219-ad6d6c8c.jpeg" alt="img-44.jpeg">
Fig. 4.17 Antiglobulin test</p>
<p>The Coomb's reagent is an antibody to human immunoglobulin raised in animals such as rabbit. It can be used to detect incomplete or non-agglutinating antibodies against many antigens. It can also detect false negative tests due to blocking antibodies.</p>
<p>The Coomb's test can be either direct or indirect. The direct Coomb's test can detect the cells which are 'sensitised' with the blocking antibodies 'in vivo'. Addition of a drop of the Coomb's reagent to such sensitised cells shows visible agglutination. The red cells sensitised with incomplete Rh-antibodies are present in neonates suffering from haemolytic disease of the new born (HDN) due to Rh incompatibility.</p>
<p>The indirect Coomb's tests detects incomplete antibodies in patient's serum. The sensitisation of a known antigen is performed 'in vitro' by the antibody in the patients serum. Addition of the Coomb's reagent results in agglutination. The indirect Coomb's test is useful for the detection of incomplete antibodies in cases such as an Rh-negative mother or in brucellosis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="complement-fixation-test-cft">Complement Fixation Test [CFT]<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#complement-fixation-test-cft" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Complement is 'activated' in vivo when it is 'fixed' to an antigen-antibody complex. When activated, the complement can initiate a series of biological reactions in the body through the activities of various components of the complement cascade. These activities include lysis of antigens such as bacteria or red cells, killing of bacteria, immobilization of motile bacteria and promotion of phagocytosis.</p>
<p>In the complement fixation test, complement is fixed to an antigen-antibody complex without any observable biological activity. For this reason, an indicator system is included in the test to detect fixation or non-fixation of complement. In the absence of either antigen or antibody, complement will not be fixed. The CFT is mainly used for the detection of antibodies in patient samples.</p>
<p><strong>Principle of CFT</strong> Complement fixation test involves a test system and an indicator system, both of which are capable of activating complement. The test system consists of patient's serum and a known antigen. The indicator system consists of sheep red cells coated with antibody to sheep red cells. These cells will lyse in presence of complement.</p>
<p>CFT consists of the following steps:</p>
<p>(i) A known antigen and patient's serum (which may contain antibody to the antigen) are reacted with standardized, limited amount of reagent complement. If specific, complement activating antibody is present in the serum, complement will be activated or 'fixed' by the antigen-antibody complex. On the other hand, if there is no antibody in the patient's serum, there will be no antigen-antibody complex, and therefore, complement will not be 'fixed', but will remain free.</p>
<p>(ii) In the second step, the indicator system is added to the test. If complement is fixed in the first step due to the presence of antibody</p>
<p>Scanned by CamScanner</p>
<p>1168 Basic Immunology and Serodiagnosis</p>
<p>in patient's serum, there will be no complement left to 'fix' to the indicator system. If there is no antibody in patient's serum, there will be no antigen-antibody complex, and therefore, complement will not be fixed. This 'unfixed' complement will bring about the lysis of red cells. Therefore, no lysis of sheep red cells indicates presence of antibody in the test serum; and lysis of sheep red cells shows a negative test for antibody in the serum. (Fig. 4.18).</p>
<p>CFT is a complex procedure which requires five reagents. Accurate results depend on appropriate standardization of each reagent involved.</p>
<p><strong>Antigen</strong> The antigen may be soluble or particulate.</p>
<p><strong>Antiserum</strong> The patient's serum, which has to be tested for the presence of antibody, should be inactivated at 56 °C for 30 minutes to destroy its complement activity so that it will not interfere in the test. The inactivation also removes non-specific inhibitors of complement which may be present.</p>
<p><strong>Complement</strong> The commonest source of fresh complement is the guinea-pig-serum. As complement is easily destroyed by heat, the serum should be collected just before use. It can be preserved either by freezing or chemically by Richardson's method. Complement is also available commercially. Complement should be standardised for its haemolytic activity. One unit of minimum haemolytic dose (MHD) of complement is the highest dilution of the complement that lyses one unit volume of washed sheep red cells in the presence of excess of haemolysin (amboceptor) in 30 or 60 minutes, at 37°C.</p>
<p><strong>Sheep red cells</strong> A washed, 5% suspension of fresh sheep red cells should be used.</p>
<p><strong>Haemolysin (amboceptor)</strong> This is an antibody to sheep red cells raised in rabbit. This is standardised as MHD which is the highest dilution of the inactivated amboceptor that lyses one unit volume of sheep red cells in the presence of excess of complement within 30 or 60 minutes at 37 °C.</p>
<p>&gt; <strong>Note</strong> It is necessary to run known positive and negative controls with each CFT.</p>
<p><img src="assets/images/image-20251219-9463a99c.jpeg" alt="img-45.jpeg">
Positive test: No haemolysis
Antibody present in patient's serum
Complement fixed by test system</p>
<p>Key:
Test system → Antigen
Antibody in patient's serum
Complement</p>
<p><img src="assets/images/image-20251219-fa273255.jpeg" alt="img-46.jpeg">
Negative test: Haemolysis
No antibody in patient's serum
Complement not fixed by test system
Causes lysis of red cell in indicator system</p>
<p>☐ Sheep red cell
☐ Antibody to sheep red cell
→ Indicator system</p>
<p>Fig. 4.18 Complement fixation test
Scanned by CamScanner</p>
<p>Antigen-Antibody Reaction in Vitro 1169</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="applications-of-cft">Applications of CFT<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#applications-of-cft" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Complement fixation tests are more cumbersome to perform, but much more sensitive than precipitation and agglutination tests. They are less sensitive than other serological tests such as radioimmunoassays, enzyme immunoassays or immunofluorescence tests. They are very valuable in the diagnosis of some viral, rickettsial and mycotic infections.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="neutralisation-tests">Neutralisation Tests<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#neutralisation-tests" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Neutralisation tests are based on the principle that specific antibodies are able to neutralize biological effects of viruses, toxins and enzymes. They can be used for the detection of either antigen or antibody.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="virus-neutralisation-tests">Virus neutralisation tests<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#virus-neutralisation-tests" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>When grown in various culture systems, viruses produce biological effects. Neutralisation of these effects by a specific antibody is used in the identification of viruses. Two examples of virus neutralisation tests are described below:</p>
<p>(i) Neutralization of cytopathic effect (CPE)</p>
<p>Neutralising antibodies react with their homologous virus by attaching to certain critical antigenic determinants on the virus particle. This renders the virus incapable of initiating infection in susceptible host cells. Viruses such as poliovirus produce characteristic cytopathic effects when grown in appropriate tissue culture systems. Patient's serum to be tested for antibodies to poliovirus is mixed with a known suspension of polio virus. After appropriate incubation for antigen-antibody binding to occur, the mixture is inoculated into a susceptible cell line. After incubation, absence of CPE in the cell line, shows that the patient's serum contains neutralising antibody to polio virus. CPE will be observed in the absence of antibody.</p>
<p>CPE neutralisation test can also be performed for the identification of isolated virus by treating it with a known antibody before inoculation into a susceptible cell line.</p>
<p>(ii) Haemagglutination inhibition (HAI) test</p>
<p>Some viruses have the ability to induce haemagglutination when combined in vitro with erythrocytes from specific animal sources. For example, rubella virus can agglutinate red cells from newborn chickens. However, it should be borne in mind that haemagglutination by viruses is not an antigen-antibody reaction, but a biological effect due to receptors on their surfaces for red cells. This activity can be neutralised by neutralising antibody to the virus.</p>
<p>Antibody to a haemagglutinating virus can be detected by first reacting patient serum with the virus. After appropriate incubation, the red cell suspension of susceptible species is added to this mixture. If inhibiting antibody is present in the patient's serum, haemagglutination will not occur. It is possible to determine the HAI titre of antibody by preparing serial dilutions of the patient's serum and mixing with a constant amount of viral suspension.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="toxin-neutralisation-tests">Toxin neutralisation tests<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#toxin-neutralisation-tests" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Exotoxins produced by some bacteria such as <em>Corynebacterium diphtheriae</em> or <em>Clostridium tetani</em>, are strongly antigenic and induce the formation of neutralising antibodies (antitoxins) in their host. Effects of toxin can be neutralised by antitoxins and can be demonstrated by either in vivo or in vitro tests. Neutralisation tests can be performed in vivo in animals by injecting into them a mixture of toxin and patient's serum. If an antitoxin is present in patient's serum, it should prevent disease or death of the animals.</p>
<p>An example of toxin neutralisation test in vitro is the Nagler reaction which is used for identification of toxin producing <em>Clostridium perfringens</em> from clinical specimens. The α-toxin of the pathogen produces an opalescence in medium containing egg-yolk. For the test, half of the petri dish containing egg-yolk agar is smeared with the antitoxin. The isolate is inoculated in a streak across the plate, starting from antitoxin-free area to the one seeded with antitoxin. After anaerobic incubation at 37°C, the colonies of <em>C. perfringens</em> in the antitoxin-free area show a zone of opacity while those on the antitoxin portion show no opacity due to neutralisation of the toxin (lecithinase) by the antitoxin.</p>
<p>Scanned by CamScanner</p>
<p>1170 Basic Immunology and Serodiagnosis</p>
<p>Enzyme Inhibition tests Enzymes are proteins which act on their specific substrates and bring about chemical changes. Due to their chemical nature, enzymes can also be antigenic. Enzyme inhibition tests make use of this phenomenon by reacting a specific antibody with its enzyme antigen which inhibits the enzyme's ability to react with its substrate.</p>
<p>The best example of this phenomenon is the detection of antistreptolysin O (ASO), which is an antibody to the haemolytic enzyme Streptosin O. Patient's serum which may contain the antibody is serially diluted and mixed with a constant amount of streptolysin O, followed by addition of a suspension of red blood cells. Neutralisation of streptolysin O by ASO will result in inhibition of haemolysis of the added red cells.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="labelling-techniques">Labelling Techniques<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#labelling-techniques" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>There are four types of techniques which involve labelling or tagging either antigen or antibody in order to detect or quantitate the presence of one of the reactants. These are:</p>
<ul>
<li>A. Immunofluorescence assay (IFA)</li>
<li>B. Radioimmunoassay (RIA)</li>
<li>C. Enzymeimmunoassay (EIA) and</li>
<li>D. Western Blot (Immunoblot)</li>
</ul>
<p>Immunofluorescence assays Fluorescence is the phenomenon exhibited by certain molecules or compounds known as fluorochromes. They absorb light energy of one wave length and emit the light energy of another wave length. If a fluorochrome receives the invisible ultra violet light, it will emit a light within the visible spectrum, for example, green.</p>
<p>Fluorescein is used as an isothiocyanate which makes its subsequent attachment to antigen or antibody easier. When fluorescein isothiocyanate is combined with antigen or antibody, it is referred to as a conjugate. Fluorescein conjugated with various antigens and antibodies are commercially available. It is necessary to determine the appropriate dilution of the conjugate for IFT to avoid non-specific staining. Optimum dilution is determined by trying different dilutions on a known positive antigen or antibody for each lot of conjugate.</p>
<p>The phenomenon of fluorescence, when used in antigen-antibody reactions, is known as immunofluorescence.</p>
<p>Application of Immunofluorescence (IFA) The IFA can be either on solid-phase (heterogeneous) or in liquid-phase (homogeneous). In the clinical laboratory, solid-phase IFAs are more commonly performed. There are three solid-phase techniques which are most frequently used. They are direct IFA, indirect IFA and sandwich IFA.</p>
<p>(i) Direct Immunofluorescence Assay Direct IFA can be used to identify an unknown antigen which can be attached to a solid phase, such as a microscope slide.</p>
<p>The clinical specimen which may contain a specific antigen is smeared on a glass slide. The air-dried smear is fixed with acetone for 1–2 minutes. This fixed antigen is then reacted with a known, fluorescein labelled antibody. Evidence of fluorescence in the smear under fluorescence microscope indicates a positive test for antigen in the specimen. (Fig. 4.19A).</p>
<p>Direct IFA is useful for rapid identification of causative agents such as bacteria; viruses and fungi in clinical specimens.</p>
<p>A disadvantage of this method is that a separate, specific conjugate needs to be prepared for every antigen to be tested and is expensive.</p>
<p>(ii) Indirect Immunofluorescence Assay In the indirect IFA, the reacting antigen and antibody are both unlabelled. The antigen-antibody complex is then detected by an anti-human immunoglobulin labelled with fluorescein isothiocyanate (FIT). (Fig. 4.19B). The indirect IFA can be used to detect either unknown antigen or antibody. The advantage of the indirect test is that the same conjugate with anti-human globulin can be used for all the tests.</p>
<p>(iii) Sandwich Immunofluorescence Assay Unknown antigen in the specimen can also be detected by the sandwich technique. Known unla</p>
<p>Scanned by CamScanner</p>
<p>Antigen-Antibody Reaction in Vitro 1171</p>
<p>In all immunofluorescence assays, it is essential to run known positive and negative controls with each test. This helps to guard against non-specific fluorescence, which may lead to false-positive results.</p>
<p>Helleled antibody, specific for the antigen, is attached to the solid phase. The specimen, which is being tested for the antigen in the medium, is then added.</p>
<p>After incubation and washing, FIT labelled specific antibody is added. If fluorescence is detected, it is an indication of the presence of antigen in the specimen. Here, the antigen is 'sandwiched' between unlabelled and labelled antibody. (Fig. 4.19C).</p>
<p>(A) Direct immunofluorescence</p>
<p>Specimen (unknown antigen) fixed to a slide.</p>
<p><img src="assets/images/image-20251219-b97daa18.jpeg" alt="img-47.jpeg">
UV light fluorescence</p>
<p>Known antibody with fluorescent label added. Incubate, wash, examine under UV light to see fluorescence.</p>
<p>(B) Indirect immunofluorescence</p>
<p>Known antigen fixed to a slide</p>
<p><img src="assets/images/image-20251219-41c3330d.jpeg" alt="img-48.jpeg">
Patient's serum, which may contain antibody, is added. Antibody binds to antigen. Wash.</p>
<p><img src="assets/images/image-20251219-1319dae0.jpeg" alt="img-49.jpeg">
UV light fluorescence
Anti-human IgG with fluorescent label added which binds to antibody in patient's serum, shows fluorescence under UV light.</p>
<p>(C) Sandwich technique</p>
<p><img src="assets/images/image-20251219-8de65960.jpeg" alt="img-50.jpeg">
Known antibody is fixed to a slide</p>
<p><img src="assets/images/image-20251219-8201ce71.jpeg" alt="img-51.jpeg">
Specimen (unknown antigen) added which binds to the antibody</p>
<p><img src="assets/images/image-20251219-bd342e09.jpeg" alt="img-52.jpeg">
UV light fluorescence
Antibody specific for the antigen with fluorescent label is added. Antigen sandwiched between two antibody molecules -shows fluorescence under UV light</p>
<p>Fig. 4.19 Immunofluorescence (A) Direct, (B) Indirect and (C) Sandwich techniques</p>
<p>Scanned by CamScanner</p>
<p>1172 Basic Immunology and Serodiagnosis</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="radioimmunoassay-ria">Radioimmunoassay (RIA)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#radioimmunoassay-ria" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Radioimmunoassay or RIA is another labelling technique used for the detection of antibody, or more commonly, antigen. It uses a radioactive label or tracer to assess the concentration of biological molecules. Tritium (H³), I¹³¹ or I¹²⁵ are commonly used as tracers.</p>
<p>RIA makes use of the principle of competitive binding between radiolabelled and unlabelled molecules of antigen to bind with a high affinity, specific antibody. The amount of unlabelled antigen present in the specimen is measured by its competitive effect on the labelled antigen for limited antibody sites.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ria-for-antigen-detection">RIA for antigen detection<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ria-for-antigen-detection" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The antigen to be detected in the clinical specimen, e.g. hepatitis-B surface antigen (HBs Ag) is radio-labelled with I¹²⁵.</p>
<p>The labelled antigen is allowed to react with the known specific antibody. The proportion of antigen-antibody is such that about 70% of antibody sites are bound by labelled antigen. A clinical specimen, containing the antigen under test, is added to this mixture. If present, the unlabelled antigen from the specimen competes with the labelled antigen for binding sites and may displace some labelled antigen.</p>
<p>After appropriate incubation period, labelled antigen bound to the antibody is separated from the unbound labelled antigen (see below). The change in the amount of radioactivity due to unlabelled antigen is measured using a scintillation counter (Fig. 4.20).</p>
<p>A standard curve is constructed with radioactivity obtained by adding various known amounts of unlabelled antigen to a constant amount of antibody-labelled antigen mixture. From this curve, the amount of antigen can be assessed from its radioactivity with the help of the standard curve.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ria-for-antibody-detection">RIA for antibody detection<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ria-for-antibody-detection" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The classic RIA procedure for antigen detection can be varied for the detection of antibody. In this case, the antibody, radiolabelled and unlabelled, competes for the antigen.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="techniques-for-the-separation-of-bound-and-free-labelled-molecules">Techniques for the separation of bound and free labelled molecules<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#techniques-for-the-separation-of-bound-and-free-labelled-molecules" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>It is essential to separate free and bound radioactive molecules at the end of the reaction before the measurement of radioactivity. The following techniques can be used for this separation:</p>
<p>(i) Farr technique The labelled antigen combined with antibody can be separated from the free labelled antigen by using 50% ammonium sulphate solution. This selectively precipitates immunoglobulin. This method is applicable only to antigens with molecular weight &gt; 30,000.</p>
<p>(ii) Use of anti-globulin serum The antigen bound to the antibody can be precipitated by the use of antiglobulin serum which will bind with the antibody molecules and form a precipitate.</p>
<p>(iii) Use of staphylococcal protein A Staphylococcal protein A has a high affinity for the Fc portion of immunoglobulin G (IgG), bringing about its precipitation along with bound antigen. This method can</p>
<p><img src="assets/images/image-20251219-5b206013.jpeg" alt="img-53.jpeg">
Fig. 4.20 RIA competitive binding assay</p>
<p>Scanned by CamScanner</p>
<p>Antigen-Antibody Reaction in Vitro 1173</p>
<p>be employed only if IgG antibodies are used in the test.</p>
<p>(iv) Solid phase RIA or Immunoradiometric Assay (IRMA) This is an RIA competitive binding assay on a solid phase such as the wall of a test tube, microtitre well or bead. Attachment of the radiolabe antigen to the solid phase facilitates separation of bound and free radiolabelled reactants merely by washing.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="advantages-and-disadvantages-of-ria">Advantages and disadvantages of RIA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advantages-and-disadvantages-of-ria" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>RIA is a very sensitive and specific method for the assay of various antigens and antibodies. Substances such as hormones or drugs, which can be antigenic in laboratory animals and produce specific antibody can be assayed by this method. With increasing use of monoclonal antibodies, RIA is proving to be very useful. Major disadvantages of RIA are the use of radioactive compounds which have a limited shelf-life and need special staff training for handling them. Counting radioactive emissions requires expensive equipment. If the radiation is not well monitored, it can be a potential health hazard.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="enzyme-immunoassay-eia">Enzyme Immunoassay (EIA)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#enzyme-immunoassay-eia" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Enzymes are molecules which function as catalysts for certain biochemical reactions. A small amount of enzyme can react with much larger amounts of substrate to produce detectable levels of breakdown products in a given time. Enzymes which bring about chromogenic or fluorescent changes in their substrates are selected for enzyme immunoassays.</p>
<p>Enzyme immunoassay (EIA) includes all the techniques where enzymes are used to label antigen or antibody reactions. EIA can be carried out entirely in solution, when it is called homogeneous enzyme-linked assay. When some of the reactants are adsorbed on a solid phase it is called heterogeneous enzyme-linked or enzyme-linked immunosorbent assay (ELISA).</p>
<p>Homogeneous assays do not involve washing stage and are very rapid, but are not very sensitive. They can be used only for small molecules. Heterogeneous enzyme assay or ELISA, on the other hand, are comparatively slow, requiring several incubation and washing stages, but are very sensitive and suitable for large molecules. Antibodies are conjugated or labelled with an enzyme by the addition of glutaraldehyde in such a way that the resulting conjugates retain both immunological and enzyme activity. They can be assayed by their ability to breakdown a suitable substrate. The most commonly used enzymes are alkaline phosphatase and horseradish peroxidase, with their respective substrates of p-nitrophenyl phosphate and o-phenylene diamine dihydrochloride. The colour change in the substrate due to the enzyme activity is assessed visually or in a simple spectrophotometer.</p>
<p>ELISA techniques can be used to detect either antigen or antibody qualitatively or quantitatively. The two main techniques of ELISA are (i) Indirect ELISA to detect antibody and (ii) Sandwich ELISA or Double antibody ELISA to detect antigen.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-indirect-elisa">(i) Indirect ELISA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-indirect-elisa" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>A known antigen is attached to a solid phase such as the wall of the test tube, a micro-titre plate well or a bead. It is reacted with the test sample which may contain antibody. The test is incubated and followed by a wash. Subsequently, an enzyme-labelled anti-human globulin is reacted with the antibody in the test sample that has attached to the antigen on the solid phase.</p>
<p>After incubation, the uncombined labelled anti-human globulin is washed off.</p>
<p>Retention of enzyme on the surface is detected by addition of appropriate substrate which changes colour after incubation. (Fig. 4.21).</p>
<p>The concentration of antibody in the test sample bound by the antigen on the solid phase is proportional to the intensity of colour. The reaction is stopped by changing the pH with acid.</p>
<p>Scanned by CamScanner</p>
<p>1174 Basic Immunology and Serodiagnosis</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-sandwich-antibody-or-double-antibody-elisa">(II) Sandwich antibody or double antibody ELISA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-sandwich-antibody-or-double-antibody-elisa" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This technique is used for the detection of antigen in the test sample. A known antibody is adsorbed on a solid phase, to which the test sample, which may contain the antigen, is added.</p>
<p>During incubation, the antibody captures or binds the antigen to the solid phase. After washing, enzyme labelled specific antibody is added. At this stage, the antigen is sandwiched between two antibody molecules, one on the solid phase and the other with the enzyme label.</p>
<p>On addition of substrate, a colour change indicates that the enzyme labelled antibody is present on the solid surface. This is due to the presence of antigen in the test sample (Fig. 4.21).</p>
<p>The enzyme activity is stopped after a fixed period by changing the pH with acid.</p>
<p>ELISA is now widely employed for the diagnosis of bacterial, viral and parasitic infections. Commercial kits are available for a wide range of diseases, for both antigen and antibody detection.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="western-blot-immunoblot">Western Blot (Immunoblot)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#western-blot-immunoblot" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Western blot is a very innovative, sensitive and specific technique for antibody detection, which uses an enzyme label at the final stage. It is a very useful tool to distinguish a specific antibody response to different molecular weight protein antigens from a single infectious agent. Western blot (WB) is the most commonly employed as confirmatory test for the human immunodeficiency virus (HIV) infection for detecting antibodies for individual HIV antigens. Steps in the performance of WB assay.</p>
<p><img src="assets/images/image-20251219-69a2c8e0.jpeg" alt="img-54.jpeg">
(A) Indirect ELISA</p>
<p>Known antigen adsorbed on solid phase</p>
<p>Patient's serum, which may contain antibody, is added. Antibody is bound to the antigen</p>
<p><img src="assets/images/image-20251219-e5e3007b.jpeg" alt="img-55.jpeg">
(B) Sandwich ELISA</p>
<p>Known antigen adsorbed on the solid phase</p>
<p>Patient's serum, which may contain antibody, is added. Antibody is bound to the antigen</p>
<p><img src="assets/images/image-20251219-7034c74c.jpeg" alt="img-56.jpeg">
Anti-human IgG conjugated with enzyme is added which binds to antibody in patient's serum</p>
<p><img src="assets/images/image-20251219-9f122429.jpeg" alt="img-57.jpeg">
Substrate for the enzyme label is added-coloured product</p>
<p><img src="assets/images/image-20251219-539130a3.jpeg" alt="img-58.jpeg">
Known antigen</p>
<p>Patient's serum, which may contain antibody, is added. Antibody is bound to the antigen</p>
<p><img src="assets/images/image-20251219-3ceb9b50.jpeg" alt="img-59.jpeg">
Patient's serum</p>
<p><img src="assets/images/image-20251219-0198de81.jpeg" alt="img-60.jpeg">
Known antigen, conjugated to enzyme, is added which binds to antibody in patient's serum</p>
<p><img src="assets/images/image-20251219-43fdbf29.jpeg" alt="img-61.jpeg">
Substrate for the enzyme label is added-coloured product</p>
<p>Fig. 4.21 Enzyme linked immunosorbent assay ((ELISA): (A) Direct, (B) Indirect and (C) Sandwich techniques.</p>
<p>Scanned by CamScanner</p>
<p>Antigen-Antibody Reaction in Vitro 1175</p>
<p>There are seven basic steps involved in the performance of WB.</p>
<p>(i) The antigen sample is prepared by ultracentrifugation of cell-free supernatant from an HIV-producing cell-line.
(ii) The proteins are separated by electrophoresis on a polyacrylamide gel.
(iii) These resolved proteins are transferred onto nitrocellulose paper by placing the polyacrylamide gel together with a nitrocellulose sheet between several sheets of absorbant paper and then soaked in buffer for 2-3 days.
(iv) The non-specific binding sites on the nitrocellulose paper are 'blocked' by placing them in a solution of dry milk (5%, w/v) or albumin, at 37°C for 1 hour. This nitrocellulose sheet can be cut into strips, so that each strip can be used for a separate test sample.</p>
<p>(v) Patient's serum is then added for immunoreaction with separated, bound proteins on nitrocellulose. Antibodies in patient's serum bind to their corresponding antigens.
(vi) Antigen-antibody binding is detected by addition of anti-human globulin labelled with either horseradish peroxidase or alkaline phosphatase.
(vii) When appropriate substrates are added, these enzymes produce coloured bands at the electrophoretic position of the corresponding HIV antigens.</p>
<p>Figure 4.22 illustrates the steps involved in WB. Interpretation of WB results for HIV. There are three major structural genes in HIV, and three</p>
<p><img src="assets/images/image-20251219-8e3af2c5.jpeg" alt="img-62.jpeg"></p>
<p>Scanned by CamScanner</p>
<p>Basic Immunology and Serodiagnosis</p>
<p>major products of each gene which are generally visualized in a WB. These are:</p>
<p>Envelope glycoproteins - gp 160, gp 120, gp 41</p>
<p>Polymerase proteins - p65, p53, p34</p>
<p>Group-specific antigen - p55, p24, p17.</p>
<p>(gag)</p>
<p>There are different criteria for interpretation of HIV WB test results. Generally, reactivity to at least one antigen from each group is considered positive.</p>
<p>&gt; <strong>Note</strong>
&gt; Southern blot is a similar technique used for nucleic acids instead of proteins.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="iii-miscellaneous-tests">III. Miscellaneous Tests<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#iii-miscellaneous-tests" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Other applications of antigen-antibody reaction in diagnosis include:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="a-complement-dependent-tests">A. Complement Dependent Tests<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-complement-dependent-tests" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>(i) Immobilisation test When motile bacteria are mixed with specific antiserum in presence of complement, they are rendered nonmotile (immobilised). This test is useful for the identification of bacteria such as <em>Vibrio cholerae</em> in stool specimen or for the detection of antibody to <em>Treponema pallidum</em> in patient's serum.</p>
<p>(ii) Immune adherence test When some bacteria react with their antibody in the presence of complement and some other cells such as red cells or platelets, they form aggregates which are seen to adhere to these cells.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="b-immune-electron-microscopy">B. Immune-electron Microscopy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-immune-electron-microscopy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>The clumping of virus particles by specific antibody can be visualized in the electron microscope directly e.g. rotavirus in stool, hepatitis-B virus in serum or adenovirus in respiratory secretions.</p>
<p>The clumping of virus particles by antibody can be more easily detected by electron microscopy when the antibody is conjugated with ferritin, which is an electron-dense substance from horse spleen.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="c-capsule-swelling-or-quellung-reaction">C. Capsule-swelling or Quellung Reaction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#c-capsule-swelling-or-quellung-reaction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>When capsulated bacteria such as <em>Streptococcus pneumoniae</em> are mixed with their respective type-specific antisera, swelling of the capsule occurs. This is one of the methods of serotyping based on the capsular antigens and is known as Quellung reaction. The results can be observed under the microscope.</p>
<p>Scanned by CamScanner</p>
<p>Chapter 5</p>
<p>Common Serodiagnostic Tests</p>
<p>Techniques of some serological tests which are commonly performed in a clinical laboratory are described here.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="detection-of-febrile-agglutinins">DETECTION OF FEBRILE AGGLUTININS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#detection-of-febrile-agglutinins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Febrile agglutinins are antibodies present in the sera of patients with some infectious diseases characterized by the presence of persistent fever of unknown aetiology. Such a condition is referred to as pyrexia of unknown origin (PUO). The antibodies are demonstrable <em>in vitro</em> by their ability to agglutinate corresponding bacterial antigens.</p>
<p>Febrile agglutination tests have been used in the diagnosis of infections with organisms such as</p>
<p>A. Salmonella species (Widal Test)
B. Brucella species (SAT—standard agglutination test)
C. Rickettsiae (Weil—Felix Test)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="a-widal-test">A. Widal Test<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-widal-test" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Widal test is a tube agglutination test for the detection of antibodies for the diagnosis of enteric fevers (typhoid and paratyphoid) caused by <em>Salmonella</em> species, namely, <em>Salmonella typhi</em>, <em>S. paratyphi A</em>, <em>S. paratyphi B</em> and <em>S. paratyphi C</em>. The 'O' (somatic or cell wall) antigens and 'H' (flagellar) antigens of each species are required for the test.</p>
<p><strong>Specimen:</strong> Patient's serum</p>
<p><strong>Note</strong> Antibodies to <em>Salmonella</em> antigens do not appear in the patient's serum until about the eighth day of fever. Therefore, a blood sample collected in less than one week after the onset of fever may give a false negative result.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Antigen Suspensions
(a) O antigens: <em>Salmonella typhi</em> (TO), <em>S. paratyphi A</em> (AO), <em>S. paratyphi B</em> (BO) and <em>S. paratyphi C</em> (CO) antigen suspensions. O or somatic antigens are obtained by treatment of appropriate bacterial suspension with alcohol to destroy the H antigens. The suspension can also be heated at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>100</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">100^{\circ}\mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">10</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> for 20-30 minutes to destroy the flagella, centrifuged and then resuspended in saline.
(b) 'H' antigens <em>Salmonella typhi</em> (TH), <em>S. paratyphi A</em> (AH), <em>S. paratyphi B</em> (BH) and <em>S. paratyphi C</em> (CH)
'H' or flagellar antigens are obtained by treatment of the respective bacterial suspension with formaldehyde to destroy O antigens and fix the flagella.</p>
<p>Scanned by CamScanner</p>
<p>1178 Basic Immunology and Serodiagnosis</p>
<table><thead><tr><th>Note</th><th>Stained antigen suspensions in a concentrated form with a colour code (blue for O, pink for H) are commercially available.</th></tr></thead></table>
<p>(ii) Physiological (0.85%) saline
(iii) Positive control serum: Polyvalent O and H antisera for Salmonella species.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="screening-test">Screening Test<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#screening-test" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Before performing the tube agglutination test, a screening test should be performed on the serum against each antigen listed above.</p>
<ul>
<li>Using an agglutination tile, place one drop (0.02 ml) of patient's serum into eight wells, one well for each antigen. Add one drop of appropriate antigen to each well. Two wells, for a positive control and a saline control, should be included for each antigen suspension.</li>
<li>Using separate wooden applicator sticks, mix the contents of each well, spreading over the entire well surface.</li>
<li>Rotate the tile at approximately 180/rpm for three minutes on a rotator or rotate manually.</li>
<li>Observe for agglutination, preferably in a transmitted light. The positive controls must show obvious agglutination, negative controls show uniform suspensions.</li>
<li>Any agglutination observed with patient's serum must be tested further by tube agglutination test.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="tube-agglutination-test">Tube agglutination test<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#tube-agglutination-test" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<ol>
<li>
<p>Set up ten (13 × 100 mm) test tubes for each antigen to be tested, namely TO, TH, AO, AH, BO, BH, CO and CH, or the antigens which are agglutinated by the patient's serum in the screening procedure.</p>
</li>
<li>
<p>Prepare doubling dilutions of patient's serum in saline, starting with 1:10 dilution for the H antigens as shown in the protocol as follows:</p>
</li>
<li>
<p>Pipette 0.1 ml of patient's serum in tube 1 (1:10 dilution), mix and transfer 0.5 ml to tube 2 (1:20 dilution). Continue serial two-fold dilution till tube 8, the dilutions range from 1:10 to 1:1280. Discard 0.5 ml from tube 8.</p>
</li>
<li>
<p>To tube 9, add one drop of the appropriate control serum.</p>
</li>
<li>
<p>Tube 10 serves as a saline control.</p>
</li>
<li>
<p>Dilute the appropriate antigen 1:100 (or according to manufacturer's instructions) with saline (e.g. 0.1 ml of antigen + 9.9 ml of saline).</p>
</li>
<li>
<p>Add 0.5 ml of dilute antigen to each tube (from 1 to 10) so that the final dilution ranges from 1:20 to 1:2560.</p>
</li>
<li>
<p>Repeat the same steps for each antigen to be tested.</p>
</li>
<li>
<p>Mix well. Incubate the tubes at 37°C waterbath for 18 to 24 hours.</p>
</li>
</ol>
<p>|  Note | If concentrated antigen suspension is used:
(i) Add one drop of the suspension to each tube of dilution.
(ii) Start serum dilutions from 1:20 to 1:2560.
(iii) The final dilution of the serum remains the same i.e. 1:20 to 1:2560.  |
| --- | --- |</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reading-results">Reading Results<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reading-results" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Observe the tubes for agglutination in good light. Read as</p>
<p>++++ Complete agglutination, clear supernatant
+++ Nearly complete agglutination, supernatant 75% clear
++ Significant agglutination, supernatant 50% clear</p>
<ul>
<li>Observable agglutination, supernatant as dense as the negative control</li>
</ul>
<ul>
<li>No agglutination, supernatant as dense as the negative control</li>
</ul>
<p>Scanned by CamScanner</p>
<p>Protocol for Widal tube agglutination test</p>
<table><thead><tr><th>Tube No.</th><th>1</th><th>2</th><th>3</th><th>4</th><th>5</th><th>6</th><th>7</th><th>8</th><th>9</th><th>10</th></tr></thead><tbody><tr><td>Saline (ml)</td><td>0.9</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td></td><td></td></tr><tr><td>Potient's Serum (ml)</td><td>0.1</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Discard 0.5 +</td><td></td><td></td></tr><tr><td>Dilution</td><td>1:10</td><td>1:20</td><td>1:40</td><td>1:80</td><td>1:160</td><td>1:320</td><td>1:640</td><td>1:1280</td><td>—</td><td>—</td></tr><tr><td>Positive Control Serum</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td></td><td>1 Drop</td><td>—</td></tr><tr><td>Dilute Antigen (ml)</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td></tr><tr><td>Final Dilution of Serum</td><td>1:20</td><td>1:40</td><td>1:80</td><td>1:160</td><td>1:320</td><td>1:640</td><td>1:1280</td><td>1:2580</td><td></td><td></td></tr></tbody></table>
<p>Scanned by CamScanner</p>
<p>1180 Basic Immunology and Serodiagnosis</p>
<p>|  Note | (i) H antigens cause an easily dissociable flaky agglutination, whereas O antigens cause hardly dissociable, fine granular agglutination.</p>
<p>(ii) The positive control should show ++++ agglutination, whereas negative (saline) control should show as an even cloudy suspension.  |
| --- | --- |</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reporting">Reporting<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reporting" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Report the titre of the serum for each antigen as the reciprocal of the highest dilution exhibiting + or greater agglutination.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="interpretation-of-results">Interpretation of results<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#interpretation-of-results" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In general, O-agglutinins appear towards the eighth day after the onset of fever, rise to a titre of about 400, and rapidly disappear after clinical cure. H-agglutinins appear about 10–12 days after the onset of fever, rapidly rise to a higher titre (800, to 1600), which decreases after the clinical cure. H-agglutinins can persist at a low titre (100 to 200) for several months, sometimes years after cure. Therefore, both O and H agglutinins of the infecting organism are present during the acute phase of the disease.</p>
<p>Generally, a titre of 80 or above is considered to be significant for H and O antibodies.</p>
<p>A second specimen of serum collected 10 to 14 days after the first should show a four fold rise in titre. This will indicate a true infection. If only O-agglutinins are observed in the first sample, this may correspond to the early stage of the typhoid or paratyphoid fever. The second sample will show both antibodies.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="causes-of-raised-o-or-h-titres-other-than-active-typhoid-or-paratyphoid">Causes of raised O or H titres other than active typhoid or paratyphoid<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#causes-of-raised-o-or-h-titres-other-than-active-typhoid-or-paratyphoid" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Antigenic relationships between Salmonella species: For example, Salmonella enteritidis has the same O antigen as S. typhi, and S. typhimurium has the same O antigen as S. paratyphi B. Infection with such organisms can lead to rise in O agglutinins. Therefore, raised titres of both O and H agglutinins is significant for the diagnosis of typhoid fever.</p>
<p>(ii) Anamnestic reaction: H antigens of Salmonella are shared by some unrelated organisms. Previous infections with such bacteria may show high titre of H-agglutinins in absence of Salmonella infection. This is a non specific reaction known as anammestic reaction.</p>
<p>(iii) Vaccination: If only H-agglutinins are observed for Salmonella typhi, S. paratyphi A and S. paratyphi B at comparatively low titres (approx. 200), the person has probably received TAB vaccine. TAB vaccine is given as a protection against S. typhi, S. Paratyphi A and S. paratyphi B.</p>
<p>(iv) Treatment with Chloramphenicol: If the patient with typhoid fever has been treated with chloramphenicol before the test, the O-agglutinins may not appear. In this situation, the diagnosis is based on a significant increase in the H-agglutinins in the paired sera (two samples taken seven to ten days apart).</p>
<p>(v) Other clinical conditions: Chronic liver disease and immunological disorders such as rheumatoid arthritis, rheumatic fever, or nephrotic syndrome may show raised O or H titres.</p>
<p>(vi) Basal Titre: In a geographical area where typhoid fevers are endemic, most members of such communities have moderately raised level of O and H agglutinins for Salmonella. The levels of these basal titres in respective communities should be known before interpreting the results of Widal test.</p>
<p>Widal test using microtitre plate: Widal test can be performed using smaller quantities in microtitre plate as shown in this protocol.</p>
<p>Scanned by CamScanner</p>
<p>Common Serodiagnostic Tests 1181</p>
<p>Protocol for widal test in a microtitre plate</p>
<table><thead><tr><th>Well No</th><th>1</th><th>2</th><th>3</th><th>4</th><th>5</th><th>6</th><th>7</th><th>8</th><th>9</th><th>10</th></tr></thead><tbody><tr><td>Saline (μ l)</td><td>285</td><td>150</td><td>150</td><td>150</td><td>150</td><td>150</td><td>150</td><td>150</td><td>150</td><td>150</td></tr><tr><td>Patient's serum (μ l)</td><td>15</td><td>150</td><td>150</td><td>150</td><td>150</td><td>150</td><td>150</td><td>150</td><td>150 (discard)</td><td></td></tr><tr><td>Serum dilution</td><td>1:20</td><td>1:40</td><td>1:80</td><td>1:160</td><td>1:320</td><td>1:640</td><td>1:1280</td><td>1:12560</td><td></td><td></td></tr><tr><td>Positive control serum (μ l)</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>1 Drop</td><td>-</td></tr><tr><td>Add 10 μl of antigen suspension (concentrated) to each well. Mix well by tapping the plate. Proceed as for the tube test</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Set up the test in the same way as for the other antigens (as Shown in the protocol for Widal test) except that the initial dilution of the serum is 1:5 (0.2 ml serum + 0.8 ml saline) instead of 1:20.</li>
<li>Add 0.5 ml of Vi antigen to each tube and incubate at 37°C for 18-24 hours.</li>
<li>Note the agglutination titre.</li>
</ul>
<p><strong>Detection of Vi agglutinins</strong> Some fresh isolates of <em>Salmonella typhi</em> show an evidence of a surface antigen, Vi. Vi antigen is poorly immunogenic. The Vi antibodies appear after O and H agglutinins, and the titres are generally low. Vi antibodies, therefore, are not very useful in diagnosis. However, Vi antibodies can be detected only when the person harbours <em>S. typhi</em> in the body. Epidemiologically, it is useful for the detection of carriers.</p>
<p>&gt; <strong>Note</strong>
&gt; The Vi agglutination test can be performed in a microtitre plate in the same way as for O and H antigens. Start with 1:5 as the initial dilution by mixing 60μl of serum in 240μl of saline.</p>
<p><strong>Interpretation</strong> Vi agglutinins occur in sera of 80-90% of <em>S. typhi</em> carriers. The carrier state should be confirmed by isolation of the pathogen.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="b-serodiagnosis-of-brucellosis-by-tube-agglutination-test">B. Serodiagnosis of Brucellosis by Tube Agglutination Test<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-serodiagnosis-of-brucellosis-by-tube-agglutination-test" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Brucellosis in man is caused mainly by <em>Brucella abortus</em> and <em>Brucella melitensis</em>. Infection with <em>Brucella</em> species produces an antibody response and antibodies start appearing in the blood about 10 - 15 days after the onset of the disease. IgM antibodies are the first to appear followed by IgG. Generally, very high titres of antibodies are observed in brucellosis which can give false negative results due to prozone phenomenon. The slide agglutination test for screening is therefore, not recommended.</p>
<p><strong>Specimen:</strong> Serum, collected 10 to 15 days after the onset of the disease.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Antigen suspensions Although <em>B. abortus</em> and <em>B. melitensis</em> can cause brucellosis, only core antigen can be used because of</p>
<p>Scanned by CamScanner</p>
<p>1182 Basic Immunology and Serodiagnosis</p>
<p>sharing of antigens and cross reactivity. <em>Brucella abortus</em> antigen gives coarser agglutination, and therefore, is preferred to that of <em>B.melitensis</em>.</p>
<p>The antigen suspension is prepared by inactivation of the organisms with 0.5% phenol saline and heating. It is also available commercially.</p>
<p>(ii) Phenol saline (0.5%): Add 0.5 ml of phenol to 99.5 ml of normal saline.
(iii) Positive control serum</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Follow the same procedure as for the Widal test using the two Brucella antigens and 0.5% phenol saline as diluent.</li>
<li>Incubate the tubes in 37°C water bath for 24 to 48 hours. This technique can also be performed in a microtitre plate using the same dilutions and volumes as for the Widal test.</li>
</ul>
<p>&gt; <strong>Note</strong>
&gt; Phenol saline is used because it acts as a preservative preventing the serum (at 37°C for 48 hours) from being contaminated. It also helps to prevent prozone effect.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="recording-results">Recording results<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#recording-results" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Examine the tubes, without shaking them.</li>
<li>Check the controls and record the results.</li>
<li>Record the titre as the highest dilution that shows visible agglutination.</li>
</ul>
<p><strong>Interpretation</strong> A titre of 80 and above indicates brucellosis. If the titre is less than 80, the test should be repeated with a second sample after 2–3 weeks. A two to four-fold rise in titre is indicative of current infection.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="sources-of-error">Sources of error<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sources-of-error" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Specimen collected in a pre-serological phase (less than 10-15 days after the onset) may give a false negative result.</p>
<p>(ii) Prozone phenomenon If the antibodies are present in high titres, the lower serum dilutions (1:20, 1:40 or 1:80) may show false negative results due to prozone phenomenon.
(ii) False negative result due to blocking antibodies: IgG blocking antibodies can prevent agglutination by IgM antibodies. This can be overcome by
(a) <em>Coomb’s Reagent</em>: Addition of Coomb’s reagent, (antihuman globulin) to the tubes will agglutinate the blocking antibodies.
(b) <em>2-Mercaptoethanol (2ME)</em>: 2ME selectively destroys IgM antibodies where as IgG antibodies are unaffected. Agglutination after 2ME treatment indicates presence of IgG antibodies. The 2 ME solution (0.05M) should be used in the test as the diluent instead of saline. A titre of 80 and above with 2ME strongly indicates chronic brucellosis.
(c) <em>Blocking test</em>: Add 1 drop of Brucella positive control serum to the first tube (1:20 dilution) and incubate at 37°C for 24 hours. No agglutination indicates presence of blocking IgG antibodies.</p>
<p>&gt; <strong>Note</strong>
&gt; Other serological tests for the serodiagnosis of brucellosis include complement fixation test, ELISA and indirect immunofluorescence test.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="c-well-felix-test">C Well-Felix Test<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#c-well-felix-test" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Well-Felix test is an example of heterophile antibody test. This is based on the antibodies produced in acute rickettsial infections which crossreact with somatic antigens of OX19 and OX2 strains of <em>Proteus vulgaris</em> and OX K strain of <em>Proteus mirabilis</em>.</p>
<p>Specimen Serum, collected after one week of infection.</p>
<p>Scanned by CamScanner</p>
<p>Common Serodiagnostic Tests 1183</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="rgents">Rgents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#rgents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Antigen suspensions: Somatic antigen suspensions of OX2 and OX19 strains of <em>Proteus vulgaris</em> and OXK stain of <em>P.mirabilis</em> are prepared by treatment with alcohol. These antigens are commercially available.
(ii) Positive control serum: consists of a polyvalent antiserum of <em>Proteus</em>.
(iii) Saline 0.85%.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Follow the same technique as for the Widal test using tubes or microtitre plate. Each serum specimen should be tested against the 3 antigens, OX2, OX19 and OXK.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="results">Results<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#results" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Record the titre of the serum against each antigen as for the Widal test.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="interpretation">Interpretation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#interpretation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>A single titre of 160 or above; or a four-fold rise in paired sera at the interval of 2–3 weeks is suggestive of a rickettsial infection. The reactivity of sera from patients with various rickettsial diseases is shown in Table 5.1</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="limitations-of-weil-felix-test">Limitations of Weil-Felix Test<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#limitations-of-weil-felix-test" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>(i) The test is not specific and less sensitive in early phases of the disease.
(ii) False positive results are obtained in individuals with <em>Proteus</em> infections and in infections such as leptospirosis, borreliosis, hepatic disease and in pregnancy. Specific serological tests for diagnosis of rickettsial infections include immunofluorescence, ELISA, haemagglutination, latex agglutination and complement fixation tests. Specific rickettsial antigens are prepared from infected cell cultures or chick embryo yolk sacs.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="antistreptolysin-o-aso-test">ANTISTREPTOLYSIN-O (ASO) TEST<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antistreptolysin-o-aso-test" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Streptolysin-O is an oxygen-labile haemolysin produced by many strains of group A,C and G streptococci. Streptolysin-O is immunogenic and induces antibody production in the host. Detection and titration of antistreptolysin-O antibodies is one of the most widely used methods of immunological diagnosis of post-streptococcal disorders such as rheumatic fever or glomerulonephritis. Conventional culture and identification methods are not possible in most cases because the organism is absent by the time the symptoms appear.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="principle">Principle<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principle" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The antistreptolysin-O (ASO) test is an enzyme inhibition or neutralisation assay. Patient's serum is serially diluted and incubated with the streptolysin O. Antibody, if present in the patient's serum, will neutralise the streptolysin O. Inhibition of the haemolytic activity of streptolysin O can be detected by the addition of red cells to this mixture.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="table-5-1-weil-felix-reactions">Table 5.1 Weil-Felix Reactions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-5-1-weil-felix-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<table><thead><tr><th>Disease</th><th>Agent</th><th>Proteus Antigens</th><th></th><th></th></tr></thead><tbody><tr><td></td><td></td><td>OX19</td><td>OX2</td><td>OXK</td></tr><tr><td>Rocky Mountain spotted fever</td><td>R. rickettsii</td><td>++++</td><td>+</td><td>-</td></tr><tr><td>Q fever</td><td>C. burnetii</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Endemic typhus</td><td>R. typhi</td><td>++++</td><td>+</td><td>-</td></tr><tr><td>Brill-Zinsser</td><td>R. prowazeki</td><td>-/-</td><td>-</td><td>-</td></tr><tr><td>Rickettsialpox</td><td>R. akari</td><td>++++</td><td>+</td><td>-</td></tr><tr><td>Epidemic typhus</td><td>R. prowazeki</td><td>-</td><td>-</td><td>+++</td></tr><tr><td>Scrub typhus</td><td>R. tsutsugamushi</td><td></td><td></td><td></td></tr></tbody></table>
<p>Scanned by CamScanner</p>
<p>1184 Basic Immunology and Serodiagnosis</p>
<p>Haemolysis of the red cells will indicate absence of ASO.</p>
<p>Specimen: Serum</p>
<table><thead><tr><th>Note</th><th>Do not use cloudy, chylous (streptolysin O is inhibited by cholesterol) or haemolysed sera.</th></tr></thead></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) ASO Buffer
Sodium chloride 7.4 g
Potassium dihydrogen phosphate (KH₂PO₄) 3.17 g
Disodium hydrogen phosphate (Na₂HPO₄) 1.8 g
Distilled water 1000 ml
Adjust the pH to 6.5 to 6.7 with NaOH.</p>
<p>(ii) Human group 'O' red blood cell suspension (5%)</p>
<p>(iii) Streptolysin O Reagent This is obtained from broth filtrates of Group A streptococci. It is commercially available in lyophilized form. It should be stored at 2-8°C. It should be reconstituted just before use with distilled water. It should not be subjected to vigorous shaking and should be used within one hour.</p>
<p>(iv) Antistreptolysin O control serum (standard) This is a positive control for the antibody titration.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Tube method</p>
<p>(i) Dilute the serum samples 1:10, 1:100 and 1:500 as follows.
(a) 1:10 dilution: 0.5 ml serum + 4.5 ml buffer
(b) 1:100 dilution: 1.0 ml of 1:10 dilution + 9.0 ml buffer
(c) 1:500 dilution: 2.0 ml of 1:100 dilution + 8.0 ml buffer</p>
<p>(ii) Reconstitute ASO control serum with 10 ml of distilled water; this is equivalent to 1:100 dilution.</p>
<p>(iii) Set up the test according to the protocol given in Table 5.2.</p>
<p>Microtitre Plate Method</p>
<p>Follow the same procedure as for the tube method using one tenth volumes i.e., 100 μl instead of 1.0 ml. After the second incubation, allow the plate to stand at room temperature for 1 hour before reading the results.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="results">Results<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#results" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Check the controls.
(a) Red cell control No haemolysis
(b) Streptolysin O control : Complete haemolysis
(c) ASO positive control Note the highest dilution showing complete absence of haemolysis. Inverse of this dilution is the titre of the control serum which must be as designated by the manufacturer. Usually this titre is 166 Todd units.</p>
<p>(ii) Record the titre of the patient's serum in the same way as for the ASO control.</p>
<p>Interpretation A titre of 200 Todd units or above is significant.</p>
<table><thead><tr><th>Note</th><th>(i) Testing of paired sera at an interval of 10-15 days is recommended.</th></tr></thead><tbody><tr><td></td><td>(ii) Todd units and International Units (IU) are roughly equivalent.</td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="5cbe9195">♦ SERODIAGNOSIS OF SYPHILIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#5cbe9195" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Serological tests for syphilis (STS) can be used independently or in association with the direct examination to diagnose syphilis. Depending on the nature of the antigen used, STS can be divided into two groups.</p>
<ol>
<li>Tests using non-treponemal antigen In these tests antigens such as cardiolipin, is used to detect 'reagin' antibody. The reagin antibody is non-specific and is found in the sera of patients with T.pallidum infection.</li>
</ol>
<p>Scanned by CamScanner</p>
<p>Table 5.2 ASO test</p>
<table><thead><tr><th>Serum Dilutions</th><th>1:10</th><th></th><th>1:100</th><th></th><th></th><th></th><th></th><th>1:500</th><th></th><th></th><th></th><th></th><th>Red Cell Control</th><th>SLO Control</th></tr></thead><tbody><tr><td>Tube</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>6</td><td>7</td><td>8</td><td>9</td><td>10</td><td>11</td><td>12</td><td>13</td><td>14</td></tr><tr><td>Add serum dilution, ml</td><td>0.8</td><td>0.2</td><td>1</td><td>0.8</td><td>0.6</td><td>0.4</td><td>0.3</td><td>1</td><td>0.8</td><td>0.6</td><td>0.4</td><td>0.2</td><td>0</td><td>0</td></tr><tr><td>Add buffer solution, ml</td><td>0.2</td><td>0.8</td><td>0</td><td>0.2</td><td>0.4</td><td>0.6</td><td>0.7</td><td>0</td><td>0.2</td><td>0.4</td><td>0.6</td><td>0.8</td><td>1.5</td><td>1</td></tr><tr><td>Shake gently to mix</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Add streptolysin O, ml</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0</td><td>0.5</td></tr><tr><td>Shake gently to mix.</td><td>Incubate at 37°C for 15 minutes</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Add 5 per cent red cell suspension, ml</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td><td>0.5</td></tr><tr><td>Shake gently to mix. Incubate at 37°C for 45 minutes, shaking tubes after first 15 minutes. Following incubation, centrifuge tubes for 1 minute at 1500 rpm.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Todd unit value</td><td>12</td><td>50</td><td>100</td><td>125</td><td>166</td><td>250</td><td>333</td><td>500</td><td>625</td><td>833</td><td>1250</td><td>2500</td><td></td><td></td></tr></tbody></table>
<p>Scanned by CamScanner</p>
<p>Basic Immunology and Serodiagnosis</p>
<p>These are non-specific tests because of the nonspecific nature of the antigen. Venereal Disease Research Laboratory (VDRL) test and rapid plasma reagin (RPR) test are the two most commonly used non-specific tests. Wassermann test, which is a complement fixation test (CFT), is outdated because it is complicated and time consuming.</p>
<p>The tests using non-treponemal antigen are not specific and biological false positive results may be observed in diseases such as rheumatoid arthritis, SLE, infectious mononucleosis, malaria and in pregnancy. Reagin antibody is usually present only during active disease.</p>
<p>Although false positive reactions are very common, non-treponemal tests are very useful for screening for syphilis. They are simple and easy to perform. Positive results must always be confirmed by one of the specific tests.</p>
<ol start="2">
<li>Tests using treponemal (specific) antigens These tests detect antibody to Treponema pallidum or its components, and therefore, are specific for the diagnosis of syphilis. They include:</li>
</ol>
<p>(i) Treponema pallidum immobilization test (TPI)
(ii) Fluorescent treponemal antibody absorption test (FTA-ABS)
(iii) Treponema pallidum haemoglutination test (TPHA)</p>
<p>The specific antibody may appear later than the reagin antibody, but once positive, the test may remain positive for life irrespective of the stage of the disease or cure.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="tests-using-non-treponemal-antigen">Tests Using Non-treponemal Antigen<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#tests-using-non-treponemal-antigen" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="1-vdrl-venereal-disease-research-laboratory-test-on-serum">1. VDRL (Venereal Disease Research Laboratory) Test on serum<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-vdrl-venereal-disease-research-laboratory-test-on-serum" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>Principle This is a non-specific flocculation test. A cardiolipin-lecithin-cholesterol antigen is mixed with patient's serum, agitated and examined microscopically for flocculation.</p>
<p>Specimen Serum.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) VDRL Antigen This is an alcoholic solution of 0.03% cardiolipin, 0.9% cholesterol and 0.21% lecithin. There should be no precipitate in the antigen.
(ii) VDRL Buffered Saline This is 1.0% saline solution at pH 6.0
(iii) Saline 0.85%
(iv) Controls Positive control sera
(a) Reactive
(b) Weakly reactive</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="qualitative-test">Qualitative test<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#qualitative-test" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>(i) Inactivate patient's serum at 56°C for 30 minutes.
(ii) Prepare the antigen emulsion as follows:</p>
<ul>
<li>Pipette 0.4 ml of buffered saline to a 30 ml bottle, so that it covers the bottom of the bottle completely.</li>
<li>Add 0.5 ml of the VDRL antigen, drop by drop, but rapidly (within six seconds), directly onto the saline solution while rotating the bottle continuously but gently.</li>
<li>Continue rotation of the bottle for 10 more seconds. Add 4.1 ml of buffered saline, close the bottle and shake for approximately 30 times in 10 seconds. The antigen suspension is now ready for use and should be used within 24 hours.</li>
</ul>
<p>(iii) Using a VDRL slide (a glass slide with 16 wells), add 0.05 ml (50 µl) of the control and patient's sera to each, appropriately labelled, wells.
(iv) Add one drop (1/60 ml) of antigen to each serum using a syringe calibrated to deliver</p>
<p>Scanned by CamScanner</p>
<p>Common Serodiagnostic Tests 1187</p>
<p>1/60ml per drop (e.g. 20 gauge needle without bevel)</p>
<p>(a) Rotate the slide for four minutes at 180rpm on a mechanical rotator or manually.
(b) Read the results microscopically immediately.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="results">Results<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#results" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Under the low power (10X) objective, the result should be graded as</li>
<li>Reactive, when medium to large sized clumps are seen</li>
<li>Weakly Reactive, when small clumps are seen</li>
<li>Non-reactive, if no clumps are seen.</li>
<li>The control sera must exhibit appropriate reactivity.</li>
</ul>
<p><strong>Reporting</strong> Report patient's serum as reactive, weakly reactive or non-reactive.</p>
<p>All patient's sera showing reactive or weakly reactive results must be tested quantitatively.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="b-quantitative-test">B. Quantitative Test<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-quantitative-test" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Prepare dilutions of the reactive or weakly reactive serum, ranging from 1:2 to 1:64 as follows:</li>
<li>Set up 6 test tubes.</li>
<li>Add 0.1ml of VDRL buffered saline to each tube.</li>
<li>Add 0.1ml of patient's serum (1:2 dilution) mix and transfer 0.1ml to tube 2 (1:4 dilution).</li>
<li>Repeat doubling dilutions till tube 6.</li>
<li>Transfer 0.05 ml of each dilution to a VDRL slide, appropriately labelled for each dilution.</li>
<li>Repeat the same procedure as for the qualitative test with each serum dilution. Include controls.</li>
<li>Read the results after rotating the slide for four minutes.</li>
<li>If 1:64 dilution is reactive, prepare a further range of dilutions and repeat the test.</li>
</ul>
<p><strong>Reporting</strong> Report the VDRL titre as the reciprocal of the highest dilution that is reactive, not weakly reactive.</p>
<p><strong>Interpretation</strong> In the presence of clinical symptoms a reactive VDRL test is highly suggestive. However, in the absence of symptoms, a reactive VDRL test may be due to latent or tertiary syphilis, or it may be a biological false positive. All reactive VDRL tests should be confirmed by more a specific tests such as FTA-ABS.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="2-vdrl-test-on-cerebrospinal-fluid-csf">2. VDRL Test on Cerebrospinal Fluid (CSF)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-vdrl-test-on-cerebrospinal-fluid-csf" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>The technique for VDRL test on CSF is the same as that for serum except that the CSF is not inactivated and the VDRL antigen needs to be sensitised with 10% saline.</p>
<p>To sensitise the VDRL antigen, add one part of the antigen to one part of 10% saline. Mix by inversion and allow it to stand at room temperature for five minutes, and not more than two hours. Perform the VDRL test as for the serum.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="3-rpr-rapid-plasma-reagin-card-test">3. RPR (rapid plasma reagin) card test<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#3-rpr-rapid-plasma-reagin-card-test" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>RPR is another non-treponemal flocculation test for the detection of reagin antibodies. The antigen is the VDRL antigen containing microparticulate carbon. This enhances the visual difference between a reactive and a non-reactive result. When a specimen contains reagin antibody, flocculation occurs which appears as macroscopic black clumps against the white background of the plastic coated card. A non-reactive specimen shows a uniform gray colour.</p>
<p><strong>Specimens</strong> Serum, or plasma with EDTA as anticoagulant.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Antigen Suspension The antigen suspension is commercially available.
(ii) Controls: Reactive and non reactive control sera
(iii) Saline 0.85%</p>
<p>Scanned by CamScanner</p>
<p>1188 Basic Immunology and Serodiagnosis</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="qualitative-test">Qualitative Test<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#qualitative-test" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Using a calibrated dropper or a micropipette, drop 0.05ml of the specimen on a circle of the test card.</li>
<li>Dispense the reactive and non-reactive control sera in the same way and label accordingly. Using separate mixing sticks, spread the sample and the controls over the entire area of the test circle.</li>
<li>Shake the antigen suspension well, add one drop (1/60ml, 0.016ml or 16μl) of the suspension to each circle, using a syringe with 20 gauge needle without bevel.</li>
<li>Rotate the card for eight minutes at 100rpm on a rotator, preferably in a humid atmosphere.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="results">Results<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#results" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Immediately after rotation, read results macroscopically in good light.</li>
<li>Record the results as</li>
</ul>
<p><em>Reactive</em>, when large clumps are visible in the test circle.</p>
<p><em>Weakly Reactive</em>, when small aggregates are visible around the periphery of the test circle.</p>
<p><em>Non reactive</em>, when there are no visible aggregates.</p>
<p>Check the control sera for appropriate results, and record the reactivity of the specimen. All reactive and weakly reactive specimens should be followed by a quantitative test.</p>
<p>&gt; <strong>Note</strong>
&gt; It is recommended that the test on weakly reactive specimens should be repeated because the small clumping at the periphery may also appear as a result of drying.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="quantitative-test">Quantitative test<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#quantitative-test" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Prepare the dilutions of the specimen as for the quantitative VDRL test i.e. 1:2 to 1:64.</li>
<li>Repeat the same technique as for the qualitative test with each dilution. Include known reactive and non-reactive controls.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="results">Results<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#results" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Immediately after the test, read results macroscopically in good light.</li>
<li>Record the titre of the serum as the reciprocal of the highest dilution that shows macroscopic aggregates.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="interpretation">Interpretation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#interpretation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>As in VDRL test, the diagnosis should be confirmed using a specific test such as FTA-ABS.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="advantages-of-rpr-card-test">Advantages of RPR card Test<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#advantages-of-rpr-card-test" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>(i) The RPR card test can be performed on both serum and plasma
(ii) Inactivation of the specimen is not required.
(iii) The antigen is ready to use, no dilution is required
(iv) The results can be read macroscopically.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="d61c7bfa">♦ TESTS USING SPECIFIC TREPONEMAL ANTIGENS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#d61c7bfa" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="1-fluorescent-treponemal-antibody-absorption-test-fta-abs">1. Fluorescent treponemal antibody absorption test (FTA-ABS)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#1-fluorescent-treponemal-antibody-absorption-test-fta-abs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p><strong>Principle FTA-ABS</strong> is an indirect fluorescent antibody test, specific for the detection of antibody to <em>Treponema pallidum</em>. It is used as a confirmatory test in the diagnosis of syphilis. Serum samples are absorbed by treponemal protein extract of Reiter strain to eliminate non-specific antibodies from the sample. Serum dilutions are incubated with <em>Treponema pallidum</em> antigen fixed to slides. In the presence of specific antibody in the serum, antigen-antibody complexes are formed. The slide is</p>
<p>Scanned by CamScanner</p>
<p>Common Serodiagnostic Tests 1189</p>
<p>washed and antiglobulin serum labelled with fluorescein (conjugate) is added. The conjugate attaches to the antigen antibody complexes, making them fluoresce under the fluorescence microscope.</p>
<p>Specimen serum</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="materials">Materials<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#materials" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Dark field fluorescent microscope
(ii) Microscope slides
(iii) Staining dish with removable slide carrier
(iv) Coverslips (No. 22 mm square)
(v) Moist chamber: Moistured paper inside a suitable cover-fitting slide board.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Treponemal antigen: A suspension of Nichol's strain of <em>T. pallidium</em> extracted from rabbit testicular tissue and containing a minimum of 30 treponemes per high power field. Store at 6-10°C. It may be lyophilized and kept at 6-10°C.
(ii) Substrate slide Each substrate slide has 5 to 10 wells 6mm in diameter. The wells are coated with treponemal antigen suspension in acetone, 10 µl to each well and stored at -20°C or lower temperature.
(iii) Sorbent (or Absorbate) A standard product prepared from cultures of Reiter's strain of <em>T. pallidium</em>. It is used to absorb non specific antigens. It may be purchased in lyophilised or liquid form and stored according to manufacturers instructions.
(iv) Fluorescein isothiocyanate conjugate (FITC) This is a fluorescein-labelled antihuman globulin conjugate which is usually available in lyophilised form and stored at 6-10°C. When rehydrated, it should be dispensed in about 0.3 - 0.5ml volumes and stored at -20°C. Once thawed, it should not be refrozen but kept at 6-10°C as long as acceptable reactivity is obtained with test controls.</p>
<p>(v) Phosphate buffered saline (PBS), pH 7.2</p>
<p>It contains</p>
<p>Sodium chloride (NaCl) 7.65g
Disodium hydrogen phosphate 0.724g
Potassium di-hydrogen phosphate 0.21g
Distilled water 1000ml</p>
<p>(vi) Tween 80 Tween 80 prepared as 2% solution in PBS is used as the conjugate diluent.
(vii) Mounting medium This comprises one part of PBS (pH 7.2) plus nine parts of glycerin (high grade).
(viii) Acetone</p>
<p>Preparation of antisera Test and control sera should be inactivated at 56°C for 30 minutes before use. Previously inactivated serum should be reheated at 56°C for 10 minutes. Bacterial contamination or excessive haemolysis may interfere with the test result; such sera should be rejected.</p>
<p>Controls The following controls are included in each test run:</p>
<p>(i) Reactive 4+ control: This means that the serum or dilution of it should show a strong 4+ fluorescence when diluted at 1:5 in PBS and only slightly at 1:5 in sorbent. Prepare as follows:</p>
<p>(a) Add 0.05ml of reactive control serum to 0.2ml of PBS and mix well (at least eight times)
(b) Add 0.05ml of reactive control serum to 0.2ml of sorbent. Mix well.</p>
<p>(ii) Minimally reactive (1+) control: Dilutions of reactive serum showing the minimal degree of fluorescence reported as "reactive" for use as reading standard. The 4+ reactive serum can be diluted down with PBS to be used as minimally reactive (1+) control.
(iii) Non specific serum controls: This may be a non syphilitic serum known to show 2+ non specific reactivity in the FTA test at a</p>
<p>Scanned by CamScanner</p>
<p>1190 Basic Immunology and Serodiagnosis</p>
<p>dilation of PBS of 1:5 or higher. Prepare as follows:</p>
<p>(a) Add 0.05ml of non specific control serum to 0.2ml of PBS. Mix well (at least eight times)
(b) Add 0.05ml of non specific control serum to 0.2ml of sorbent. Mix well (at least eight times)</p>
<p>(iv) Non specific staining controls:</p>
<p>(a) Antigen smear treated with 0.3ml PBS
(b) Antigen smear treated with 0.3ml sorbent</p>
<p>Controls (i), (iii), and (iv) are used to control reagents and test conditions. Control (ii) (minimally reactive) is used as the reading standard.</p>
<p>Table 5.3 shows control pattern grading for the FTA-ABS test.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="test-procedure">Test procedure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#test-procedure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(Refer to protocol on page 1192)</p>
<p>(i) Identify the antigen slides by numbering the frosted end with a lead pencil.
(ii) Number the tubes to correspond with test sera and control sera.
(iii) Prepare the controls: reactive (4+), minimally reactive (1+), and non specific control serum dilutions as described above.
(iv) Transfer 0.2ml of sorbent into a test tube for each test serum.
(v) Add 0.05ml of the inactivated serum with appropriate tubes and mix at least 8 times.
(vi) Cover the appropriate antigen well with 0.03ml of the reactive (4+), minimally reactive (1+) and non specific control dilutions.
(vii) Cover the appropriate antigen well with 0.03ml of the PBS and 0.03 ml of the sorbent for ‘non specific’ staining controls (a) and (b) respectively.
(viii) Cover each of the appropriate antigen well with 0.03ml of the test serum dilutions.
(ix) Place the slide(s) in a moist chamber.
(x) Incubate at 35-37°C for 30 minutes.
(xi) Rinse slides in PBS two times for five minutes each. Place the slides in slide carriers and rinse in staining dish containing fresh PBS. Agitate the slides by dipping them in and out at least ten times.
(xii) Place them on a clean paper towel and dry them with a hair dryer or air pump (not hot air).
(xiii) Dilute conjugate to its working titre.
(xiv) Add 0.03ml of diluted conjugate to each antigen well. Spread to cover the smear.
(xv) Repeat steps (ix), (x), (xi) and (xi).
(xvi) Mount the slide immediately. Place a drop of glycerol buffer on each smear.</p>
<p>Table 5.3 Control pattern grading for the FTA-ABS test</p>
<table><thead><tr><th>Reactive control:</th><th>Reaction</th></tr></thead><tbody><tr><td>a. 1:5 PBS dilution</td><td>R4+</td></tr><tr><td>b. 1:5 sorbent dilution</td><td>R(4+ to 3+)</td></tr><tr><td>Minimally Reactive (1+) control</td><td>R1+</td></tr><tr><td>Non-specific serum controls:</td><td></td></tr><tr><td>a. 1:5 PBS dilution</td><td>R(2+ to 4+)</td></tr><tr><td>b. 1:5 sorbent dilution</td><td>N</td></tr><tr><td>Non-specific staining controls:</td><td></td></tr><tr><td>a. Antigen, PBS and conjugate</td><td>N</td></tr><tr><td>b. Antigen, sorbent and conjugate</td><td>N</td></tr><tr><td>Test runs in which these control results are not obtained are considered unsatisfactory and should not be reported.</td><td></td></tr></tbody></table>
<p>Key. R → Reactive
N → Negative</p>
<p>Scanned by CamScanner</p>
<p>Common Serodiagnostic Tests 1191</p>
<p>(vii) Examine slides as soon as possible with fluorescent microscope, using the high power dry objective.</p>
<p>(viii) Check the non specific smears to ascertain the presence of treponemes.</p>
<p>(xix) Using the minimally reactive (1+) as standard, record the intensity of fluorescence of the treponemes.</p>
<p>(xx) Report as shown in Table 5.4.</p>
<p>Specimens showing 1+ or less should be retested. If on retesting, a specimen initially read as 1+ still shows intensity of fluorescence of 1+ or greater, then report as reactive. All other results on retest are reported as 'borderline'. An explanatory note should always accompany borderline results to explain why it is reactive or non reactive.</p>
<p>Table 5.5 shows a scheme for reporting FTA-ABS test results.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="2-treponema-pallidum-haemagglutination-tpha-test">2. Treponema Pallidum Haemagglutination (TPHA) Test<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-treponema-pallidum-haemagglutination-tpha-test" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>TPHA is a simple specific test for syphilis. The test is comparable to FTA-ABS in all stages of syphilis except in the primary stage when the TPHA is less sensitive than the FTA-ABS or the VDRL test. This test is rapid and reproducible.</p>
<p>Principle Patient's serum is diluted and mixed with tanned turkey or chicken or sheep red cells coated with inactivated antigen from Nichol's strain of <em>T.pallidum</em>, in microtitre plate. The antibody in the patient's serum reacts with the antigen sensitised red cells to give an agglutination depicted by a characteristic pattern in the wells as the agglutinated cells settle to the bottom.</p>
<p>The cell suspension contains an extract of the Reiter's treponeme which removes any cross reactive antibodies to non pathogenic treponemes. In the presence of specific antibody, cells settle as a 'mat' in the well; and in the absence of specific antibody cells form a compact cell button.</p>
<p>Non specific reactions are detected with control cells. These cells are also tanned turkey red cells but not coated with <em>T.pallidum</em> antigen.</p>
<p>TPHA test kits are commercially available from well established manufacturers. Because it is a simple test, the manufacturer's directions are easy to follow. Basically all of them contain the following:</p>
<ol>
<li>
<p>Sample diluent One or two bottles containing 20ml each of phosphate buffer pH 7.2 and 'normal' rabbit serum. This diluent usually contains 0.95% sodium azide as preservative. It is supplied ready to use.</p>
</li>
<li>
<p>Test cell suspension Two bottles containing 8.5ml each of a suspension of tanned turkey or chicken red cells sensitised with <em>T.pallidum</em> (Nichol's strain) antigen in a phosphate buffer base containing cell extracts of Reiter's treponeme. It usually contains 0.95% sodium azide as preservative. It is supplied ready to use.</p>
</li>
</ol>
<p>Table 5.4 Grading of results of FTA-ABS</p>
<table><thead><tr><th>Reading</th><th>Intensity of Fluorescence</th><th>Report</th></tr></thead><tbody><tr><td>2+ to 4+</td><td>Moderate to strong</td><td>Reactive (R)</td></tr><tr><td>1+</td><td>Equivalent to Minimally Reactive (1+) control</td><td>Reactive (R)</td></tr><tr><td>&lt;1+</td><td>Weak but definite, less than Minimally reactive (1+) control</td><td>Borderline (B)</td></tr><tr><td>-</td><td>None or vaguely visible</td><td>Non-reactive (N)</td></tr></tbody></table>
<p>Scanned by CamScanner</p>
<p>Protocol for FTA-ABS test</p>
<table><thead><tr><th></th><th>Reactive (4+) Control</th><th></th><th>Minimally Reactive (1+) Control</th><th></th><th>Non-specific Serum Controls</th><th></th><th>Non-specific Staining Controls</th><th></th><th>Test serum</th><th></th></tr></thead><tbody><tr><td>Antigen suspension (μl)</td><td>10</td><td>10</td><td>10</td><td>10</td><td>10</td><td>10</td><td>10</td><td>10</td><td>10</td><td>10</td></tr><tr><td>Dry in the incubator at 37°C</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Reactive (4+) Control in buffer (1:5)</td><td>30 μl</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Reactive (4+) Control in sorbent (1:5)</td><td></td><td>30 μl</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Minimally Reactive (1+) Control in buffer (1:5)</td><td></td><td></td><td>30 μl</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Minimally Reactive (1+) Control in sorbent (1:5)</td><td></td><td></td><td></td><td>30 μl</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Non-specific Serum Control in buffer (1:5)</td><td></td><td></td><td></td><td></td><td>30 μl</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Non-specific Serum Control in sorbent (1:5)</td><td></td><td></td><td></td><td></td><td></td><td>30 μl</td><td></td><td></td><td></td><td></td></tr><tr><td>Buffer</td><td></td><td></td><td></td><td></td><td></td><td></td><td>30 μl</td><td></td><td></td><td></td></tr><tr><td>Sorbent</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>30 μl</td><td></td><td></td></tr><tr><td>Test Serum in buffer (1:5)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>30 μl</td><td></td></tr><tr><td>Test Serum in sorbent (1:5)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>30 μl</td></tr><tr><td>Incubate in a moist chamber at 35 - 37°C for 30 minutes. Rinse twice in PBS for five minutes each. Dry.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Conjugate FITC (Working Dilution)</td><td>30 μl</td><td>30 μl</td><td>30 μl</td><td>30 μl</td><td>30 μl</td><td>30 μl</td><td>30 μl</td><td>30 μl</td><td>30 μl</td><td>30 μl</td></tr><tr><td>Incubate in a moist chamber at 35 - 37°C for 30 minutes. Rinse twice in PBS for five minutes each. Dry and Mount in glycerol. Examine under fluorescence microscope</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Expected Results</td><td>R 4+</td><td>R 4+</td><td>R 1+</td><td>R1+</td><td>R</td><td>N</td><td>N</td><td>N</td><td>?</td><td>?</td></tr></tbody></table>
<p>Key: R: Reactive, N: Non-reactive
Note: Interpret the results of the test serum by comparing with controls. If both the wells are reactive, the test serum is positive for FTA-ABS test. If only the buffer dilution is reactive, the test is non-specific.</p>
<p>Scanned by CamScanner</p>
<p>Common Serodiagnostic Tests 1193</p>
<p>Table 5.5 Reporting scheme for FTA-ABS</p>
<table><thead><tr><th>Test reading</th><th>Repeat</th><th>Report</th></tr></thead><tbody><tr><td>4+</td><td></td><td>R</td></tr><tr><td>3+</td><td></td><td>R</td></tr><tr><td>2+</td><td></td><td>R</td></tr><tr><td>1+</td><td>1+ or greater</td><td>R</td></tr><tr><td></td><td>&lt;1+ or -</td><td>B</td></tr><tr><td>&lt;1+</td><td>1+, &lt;1+, or -</td><td>B</td></tr><tr><td>-</td><td></td><td>N</td></tr></tbody></table>
<p>R = Reactive; B = Borderline; N = Non-reactive</p>
<ol start="3">
<li>
<p>Control cell suspension Two bottles containing 8.5ml each of a liquid stable suspension of unsensitised tanned turkey or chicken red cells. It usually contains 0.95% sodium azide as preservative. It is available in a ready to use form.</p>
</li>
<li>
<p>Reactive (Positive) control One bottle containing 2ml of diluted human serum with T.pallidum specific antibodies. It is usually supplied prediluted 1:20 and has a titre of 1:2560 +/- one doubling dilution. It usually contains 0.95% sodium azide as preservative. It is supplied ready to use.</p>
</li>
<li>
<p>Non-reactive (Negative) control One bottle containing 2ml of diluted human serum negative to T.pallidum. It usually contains 0.95% sodium azide as preservative. It is available in a ready to use form.</p>
</li>
<li>
<p>Materials required but not provided with the kit (i) Microtitre palte (U wells) with cover, and (ii) Microdiluters or micropipettes that can deliver 25μl, 75μl and 100μl.</p>
</li>
</ol>
<p>Specimens The TPHA test is designed to use only serum and CSF specimens. Plasma should not be used. Haemolysed, contaminated or lipaemic sera are not suitable for the test. Store serum samples at -20°C or lower temperature until required for use. Do not inactivate serum before use.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="test-procedure">Test procedure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#test-procedure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="a-screening-test-procedure">A. screening test procedure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#a-screening-test-procedure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>(i) Add sample diluent into wells of microtitre plate according to the following pattern for each sample to be tested.</p>
<p>Well 1 25μl</p>
<p>Well 2 100μl</p>
<p>Well 3 25μl</p>
<p>Well 4 25μl</p>
<p>(ii) Add 25μl of each serum sample into well 1.</p>
<p>(iii) Using microdiluters, or a micropipette or a multichannel pipette set at 25μl, dilute the sample as shown in Table 5.6.</p>
<p>(a) Mix the contents of the wells in row 1 by pipetting up and down 3 or 4 times and transfer 25μl to the wells in row 2.</p>
<p>(b) Mix and transfer 25 μl from the wells in row 2 to wells in row 3.</p>
<p>(c) Mix and discard 25 μl from the wells in row 3.</p>
<p>(d) Transfer a second volume of 25μl from the wells of row 2 to the wells of row 4.</p>
<p>(e) Mix and discard 25μl from the wells in row 4.</p>
<p>This will give a final dilutions of 1:80 in rows 3 and 4 (Table 5.6).</p>
<p><strong>Note</strong></p>
<p>Run reactive (positive) and non reactive (negative) controls exactly the same way as the test samples.</p>
<p>Scanned by CamScanner</p>
<p>1194 Basic Immunology and Serodiagnosis</p>
<p>(iv) Add one drop (75μl) of control cell suspension to wells of row 3. Shake the bottle well to fully resuspend the cell suspensions before use.</p>
<p>(v) Add one drop (75μl) of test cell suspension to wells of row 4. Shake the bottle well to fully resuspend the cell suspension before use.</p>
<p>(vi) Cover the plate and incubate at room temperature for 1-2 hours, or if preferred overnight in a vibration free position, away from direct sunlight and heat.</p>
<p>(vii) Examine the wells for agglutination patterns. Agglutination in well 3 and no agglutination in well 4 indicates a positive test.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="b-quantitative-test-procedure">B. Quantitative test procedure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#b-quantitative-test-procedure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>When the TPHA screening test gives a positive result, the samples may be qualitatively tested to determine the end point titres. The procedure is as shown in Table 5.7.</p>
<p>Examine the wells for agglutination patterns.</p>
<p><strong>Note</strong>
Run reactive (positive) and non-reactive (negative) controls similarly along with the tests.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="results">Results<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#results" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Agglutinated cells form a smooth, even layer covering the bottom of the well.</li>
<li>Non-agglutinated cells form a compact button in the centre of the well.</li>
<li>Weakly agglutinated cells form a characteristic ring pattern of a red circle.</li>
<li>Agglutination of the test cells but not the control cells indicates the presence of specific antibody to <em>T. pallidum</em>. Absence of agglutination with the test cells indicates that specific antibody to <em>T. pallidum</em> is absent or below the limit of detection.</li>
<li>The control cell pattern should be used as an indication of a negative pattern with test cell. This is because they give a more compact cell button.</li>
<li>The reactive control serum may give titre of up to 2560 and this varies from manufacturer to manufacturer.</li>
<li>If non-specific agglutination is observed with the control cells, the sample should be retested following an absorption step to remove non-specific antibodies.</li>
<li>TPHA test result is scored as 4+, 3+, 2+, 1+, +/- or – depending on the intensity and pattern of the agglutination. Most laboratories however, do report simply as ‘Reactive’ or ‘Non reactive’.</li>
</ul>
<p>Table 5.6 Summary of screening test procedure for TPHA</p>
<table><thead><tr><th>Well No.</th><th>1</th><th>2</th><th>3</th><th>4</th></tr></thead><tbody><tr><td>Diluent (μl)</td><td>25</td><td>100</td><td>25</td><td>25</td></tr><tr><td>Serum (μl)</td><td>25</td><td>25</td><td>25</td><td>25</td></tr><tr><td>Serum dilution</td><td>1:2</td><td>1:10</td><td>1:20</td><td>1:20</td></tr><tr><td>Control cells (μl)</td><td>–</td><td>–</td><td>75</td><td>–</td></tr><tr><td>Test cells (μl)</td><td>–</td><td>–</td><td>–</td><td>75</td></tr><tr><td>Final dilution</td><td>1:2</td><td>1:10</td><td>1:80</td><td>1:80</td></tr></tbody></table>
<p>Scanned by CamScanner</p>
<p>Common Serodiagnostic Tests 1195</p>
<ul>
<li>Quantitative tests giving a reactive result with test cells and no agglutination with control cells should be reported as Reactive along with the titre value as the highest dilution showing agglutination.</li>
</ul>
<p>Interpretation of result is shown in Table 5.8.</p>
<p>TPHA is highly specific. It may be negative in primary infections but can remain positive for life after that stage. It can be considered a satisfactory substitute for FTA-ABS as a confirmatory test. Because the reagents and equipments are comparatively cheap, and the control system easy to prepare, it has an advantage over the FTA-ABS.</p>
<p><strong>Note</strong></p>
<ol>
<li>
<p>Read the manufacturer's instructions carefully before performing the test.</p>
</li>
<li>
<p>Do not use kit beyond the expiry date given on the label.</p>
</li>
<li>
<p>The serum sample in the kit should be regarded as potentially infectious and capable of transmitting disease. Therefore, the usual precautions for handling blood products should be taken.</p>
</li>
<li>
<p>Do not mix reagents from different kits as reagents have been standardised to give a correct reaction.</p>
</li>
<li>
<p>Allow all reagents to attain room temperature before use.</p>
</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="serodiagnosis-of-viral-hepatitis">SERODIAGNOSIS OF VIRAL HEPATITIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#serodiagnosis-of-viral-hepatitis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>'Hepatitis' or inflammation of the liver is caused mainly by viruses, autoimmune diseases, chemical agents or irradiation. Many viruses such as herpes simplex virus, cytomegalovirus, Epstein-Barr virus, can induce liver inflammation. However, by convention, the word hepatitis refers to the disease caused by viruses which primarily affect the liver. Hepatitis or inflammation of the liver is mainly caused by hepatitis viruses. These viruses are:</p>
<p>(i) Hepatitis A virus (HAV), transmitted by faecal oral route.
(ii) Hepatitis B virus (HBV), transmitted by various parenteral routes including sexual and vertical (from mother to foetus).
(iii) Hepatitis C virus (HCV), transmitted mainly parenterally.
(iv) Hepatitis Delta virus (HDV), transmitted parenterally. This virus is only known to exist in co-infection with HBV.
(v) Hepatitis E virus (HEV), transmitted by faecal oral route.</p>
<p><strong>Table 5.7 Quantitative test for TPHA</strong></p>
<table><thead><tr><th>Rows</th><th>1</th><th>2</th><th>3</th><th>4</th><th>5</th><th>6</th><th>7</th><th>8</th><th>9</th><th>10</th></tr></thead><tbody><tr><td>Diluent (μl)</td><td>-</td><td>25</td><td>25</td><td>25</td><td>25</td><td>25</td><td>25</td><td>25</td><td>25</td><td>25</td></tr><tr><td>Serum</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Discard</td></tr><tr><td>1:10 dilution from row 2 of screening plate (μ l)</td><td>25</td><td>25</td><td>25</td><td>25</td><td>25</td><td>25</td><td>25</td><td>25</td><td>25</td><td></td></tr><tr><td>Control cells (μ l)</td><td>75</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td></td></tr><tr><td>Test cells (μ l)</td><td>-</td><td>75*</td><td>75</td><td>75</td><td>75</td><td>75</td><td>75</td><td>75</td><td>75</td><td></td></tr></tbody></table>
<ul>
<li>The starting dilution is 1:80</li>
</ul>
<p>Scanned by CamScanner</p>
<p>1196 Basic Immunology and Serodiagnosis</p>
<p>Table 5.8 Interpretation of TPHA results</p>
<table><thead><tr><th>Description of Haemagglutination Pattern</th><th>Reading</th><th>Interpretation</th></tr></thead><tbody><tr><td>Smooth mat of cells covering entire bottom of well, sometimes with folded edges.</td><td>4+</td><td>Reactive</td></tr><tr><td>Smooth mat of cells covering less area than 4+</td><td>3+</td><td>Reactive</td></tr><tr><td>Smooth mat of cells surrounded by a red circle of cells</td><td>2+</td><td>Reactive</td></tr><tr><td>Smooth mat of cells covering less area than for 2+ and surrounded by a more defined circle of cells</td><td>1+</td><td>Reactive</td></tr><tr><td>Button of cells having a small hole in the centre giving the appearance of a well defined ring with a fairly clear background around the ring.</td><td>+/-</td><td>Retest</td></tr><tr><td>Definite compact button of cells with or without a very small hole in the centre.</td><td>-</td><td>Non-Reactive</td></tr></tbody></table>
<p>There are various types of commercial kits available for the detection of antigens or antibodies for the diagnosis of hepatitis. Reagents, techniques and interpretation depend on the kit used, based on manufacturer's information and instructions. Some examples of commonly used kits are given below:</p>
<ol>
<li>Enzyme Immunoassay for Hepatitis—A Virus</li>
</ol>
<p>Principle The IgM antibody to hepatitis A virus in patient's serum is captured by anti-IgM coated on a solid phase such as polystyrene beads or wells of a microtitre plate. Addition of hepatitis A virus (HAV) antigen followed by anti-HAV conjugated with an enzyme results in the formation of a complex. This complex can be detected by the addition of specific substrate and is indicated by a colour change.</p>
<p>Anti - IgM (coated beads or microtitre plate)
+
HAV-IgM (Patient's serum)
+</p>
<p>HAV-Ag
+
Anti-HAV- Enzyme (conjugate)
+
Substrate
↓
Colour
Specimens Human serum or plasma</p>
<p>Reagents</p>
<p>(i) Beads coated with anti-human IgM
(ii) Hepatitis A virus antigen suspension
(iii) Conjugate (Antibody to HAV + horseradish peroxidase)—anti-HAV-HRPO
(iv) Specimen diluent
(v) Positive control serum - (HAV.AB-M)
(vi) Negative control serum
(vii) O-phenylenediamine dihydrochloride (OPD) tablets.
(viii) Diluent for OPD
(ix) Sulphuric acid 1N (stop solution)</p>
<p>Scanned by CamScanner</p>
<p>Common Serodiagnostic Tests 1197</p>
<p>(x) Normal saline (0.85%).
(xi) Wash solution</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Dilute patient's serum 1:200 by adding 10μl of serum to 1.990ml (2.0ml) of normal saline. This dilution should be used within 4 hours.
(ii) Label the reaction wells for controls (positive 3, and negative 2) and test sera. Prepare a worksheet.
(iii) Place 10μl of each control (undiluted) and 10μl of diluted specimens at the bottom of appropriate wells, using a separate tip for each.
(iv) Add 200 μl of specimen diluent to each well. Mix by tapping the tray.
(v) Carefully dispense one bead coated with anti-human IgM (from goat) in each well.
(vi) Gently tap and cover the reaction tray
(vii) Incubate the tray at 40°C for one hour.
(viii) Wash the beads with the wash solution.
(ix) Add 200 μl of HAV suspension to each well. Gently tap, cover and incubate at 15-30°C for 18 to 22 hours.
(x) Wash the beads again and add 200μl of anti-HAV-HRPO conjugate to each well. Gently tap, cover and incubate at 40°C for 2 hours.
(xi) Prepare OPD substrate solution about five to ten minutes before the end of incubation period by dissolving one tablet in 5.0ml of OPD diluent. This solution should be used within one hour of preparation. Do not use metal containers for the solution.
(xii) Appropriately label the assay tubes.
(xiii) At the end of the incubation period wash the beads again, and immediately transfer them to the corresponding assay tubes.</p>
<p>Note
To transfer the beads, align the rack of properly oriented tubes over reaction tray and holding them together, invert both so that the beads fall directly into the corresponding tubes.</p>
<p>(xiv) Add 300 μl of freshly prepared OPD substrate into each tube containing bead, and into two blank tubes for substrate blanks.
(xv) Incubate the tubes at 15-30°C for 30 minutes, preferably in the dark, for colour development.
(xvi) Stop the enzyme reaction by adding 1.0 ml of 1N sulphuric acid to each tube.
(xvii) Mix the contents by agitating the tubes.
(xviii) Immediately read the absorbance of each tube against the substrate blank at 492 nm using a spectrophotometer.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="calculations">Calculations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#calculations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Calculate the mean value for positive control (PCx). Calculate the mean value for negative controls (NCx).</p>
<p>PCx – NCx must be 0.400 or greater for the test to be valid. If not, the test should be repeated.</p>
<p>Calculate the cut-off as follows</p>
<div class="math math-display"><span class="katex-display"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML" display="block"><semantics><mrow><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">x</mi></mrow><mo>+</mo><mfrac><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">x</mi></mrow><mn>10</mn></mfrac><mo>=</mo><mtext>cut-off&nbsp;value</mtext></mrow><annotation encoding="application/x-tex">\mathrm{NCx} + \frac{\mathrm{PCx}}{10} = \text{cut-off value}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord mathrm">NCx</span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 2.0463em; vertical-align: -0.686em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.3603em;"><span style="top: -2.314em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">10</span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.677em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PCx</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.686em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord text"><span class="mord">cut-off&nbsp;value</span></span></span></span></span></span></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="results">Results<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#results" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>If a test sample has an absorbance within 10% ± of the cut-off value, it should be retested. e.g. If the cut-off value is 0.100, any test sample showing absorbance between 0.090 and 0.110 should be retested.</li>
<li>Any sample having an absorbance greater than the retest range (e.g. 0.110) should be reported positive for anti-HAV IgM.</li>
<li>Absorbances below the retest range (e.g. 0.090) should be reported as negative for anti-HAV IgM.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="interpretation">Interpretation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#interpretation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Presence of anti-HAV IgM in patient's serum indicates a current or recent infection with HAV. The test does not indicate the immune status to HAV because it does not measure anti-HAV IgG.</p>
<p>Scanned by CamScanner</p>
<p>Basic Immunology and Serodiagnosis</p>
<p>Note
Commercial kits for the above method are available.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="2-serodiagnosis-of-hepatitis-b">2. Serodiagnosis of Hepatitis B<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#2-serodiagnosis-of-hepatitis-b" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Hepatitis B virus (HBV) is a DNA virus, 42nm in size. It is also referred to as Dane particle. It contains a nucleocapsid core, the polypeptide component of which is known as the core antigen. The core antigen is surrounded by an outer coat, also called envelope. In the envelope, there is an antigen, termed hepatitis B surface antigen (HBsAg), and was formerly known as Australia antigen. Another antigen, the hepatitis B 'e' antigen (HBeAg) is also associated with the core of the virus. HBsAg and HBeAg may be detected in the sera of infected individuals. These antigens and their homologous antibodies are considered to be the specific markers of hepatitis B infection.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="sequence-of-hepatitis-b-markers">Sequence of Hepatitis B markers<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#sequence-of-hepatitis-b-markers" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Hepatitis B surface antigen, HBsAg is the first to appear after exposure to HBV. The presence of HBsAg indicates active infection. Persons with HBsAg in the serum are considered to be infectious and are unfit to be blood donors.</p>
<p>(ii) Hepatitis B 'e' antigen (HBeAg) appears shortly after HBsAg. It indicates a high degree of infectivity and is present during viral replication.</p>
<p>(iii) Antibody to the core antigen (anti-HBc), can be detected shortly after the appearance of symptoms. IgM core antibody indicates a current or recent infection whereas IgG antibody may persist for life and may indicate a current or past HBV infection.</p>
<p>Note
It is difficult to detect the core antigen because it is masked by the envelope.</p>
<p>(iv) Antibody to HBeAg (anti-HBe) appears shortly after HBeAg disappears from the serum. The presence of this antibody indicates that the infection is being resolved.</p>
<p>(v) Antibody to HBsAg (anti-HBs), appears after HBsAg disappears from blood and indicates a convalescent phase. It provides protective immunity.</p>
<p>Figure 5.1 and Table 5.9 shows the sequence of hepatitis B markers.</p>
<p><img src="assets/images/image-20251219-5615c6a7.jpeg" alt="img-63.jpeg">
Fig 5.1 Hepatitis markers in acute infection with hepatitis B virus</p>
<p>Scanned by CamScanner</p>
<p>Common Serodiagnostic Tests 1199</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="choice-of-methods-for-serodiagnosis-of-hepatitis-b">Choice of methods for serodiagnosis of hepatitis B<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#choice-of-methods-for-serodiagnosis-of-hepatitis-b" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Guidelines for the selection of tests for hepatitis B profile are shown in Fig. 5.2.</p>
<p>A large number of methods have been used for serodiagnosis of hepatitis B. The Ouchterlony double immunodiffusion, counter immuno-electrophoresis and complement fixation tests were the first and second generation tests. These are less sensitive than the newer, third generation methods such as enzyme immuno assays (ELISA), radioimmunoassay (RIA), latex agglutination and passive haemagglutination. ELISA is the method of choice due to its high sensitivity and ease of performance.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-detection-of-hepatitis-b-surface-antigen-hbsag-by-enzyme-immunoassay-eia-or-elisa">(i) Detection of Hepatitis B Surface Antigen (HBsAg) by Enzyme Immunoassay (EIA or ELISA)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-detection-of-hepatitis-b-surface-antigen-hbsag-by-enzyme-immunoassay-eia-or-elisa" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><strong>Principle</strong> Beads or wells of a microtitre plate coated with mouse monoclonal antibody to hepatitis B surface antigen (anti-HBs) are-incubated with patient's serum or plasma and with mouse anti-HBs conjugated with horseradish peroxidase (anti-HBs-HRPO). If patient's serum/plasma contains HBsAg, it simultaneously binds to both the solid phase antibody on the bead and the anti-HBs-HRPO conjugate. The substrate for HRPO, o-phenylenediamine (OPD) dissolved in hydrogen peroxide is then added to the beads. The presence of HBsAg in the patient's serum is detected by the colour change after the addition of a specific substrate.</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>Anti-HBs (Beads or microtitre plate)
</span>+
HBsAg (Patient's serum)
+
Anti-HBs- Enzyme (Conjugate)
+
Substrate
↓
Colour
Specimen Serum or plasma</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="Anti-HBs (Beads or microtitre plate)
+
HBsAg (Patient's serum)
+
Anti-HBs- Enzyme (Conjugate)
+
Substrate
↓
Colour
Specimen Serum or plasma" style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Beads: coated with mouse antibody to HBsAg (anti-HBs)
(ii) Conjugate: Mouse anti-HBs conjugated with horseradish peroxidase (anti-HBs, HRPO)
(iii) O-phenylenediamine dihydrochloride (OPD) tablets
(iv) Diluent for OPD: Citrate-phosphate buffer containing 0.02% hydrogen peroxide
(v) Sulphuric acid, 1N (stop solution)
(vi) Positive control (PC): Human HBsAg, 9ng/ml
(vii) Negative Control (NC): Human plasma, non reactive for HBsAg and anti-HBs</p>
<p><strong>Caution</strong> Handle all the reagents with the universal safety precautions for blood and body fluids to avoid infection with HBsAg.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Label the reaction wells for each specimen and controls (3 negative and 2 positive controls). Prepare a worksheet.
(ii) Dispense 200μl of each specimen, 200 μl of positive control wells and 200μl of negative control into appropriate wells.
(iii) Add 50μl of the conjugate (anti-HBs—HRPO) to each well.
(iv) Carefully dispense one bead to each well containing specimen or control.
(v) Gently tap the tray, cover with a seal and incubate at 40°C for 3 hours. Alternatively, incubate at room temperature for 16 hours.
(vi) Prepare OPD substrate 5 to 10 minutes before the end of incubation. Dissolve 1 tablet in 5.0ml of OPD diluent.
(vii) After incubation, wash the beads and transfer to properly identified assay tubes.
(viii) Add 300μl of substrate to each tube containing bead and into two empty tubes as substrate blanks.
(ix) Incubate at room temperature for 30 minutes, preferably in the dark.</p>
<p>Scanned by CamScanner</p>
<p>1200 Basic Immunology and Serodiagnosis</p>
<p>Table 5.9 Sequence of hepatitis B markers during acute hepatitis B infection</p>
<table><thead><tr><th></th><th></th><th>PHASES OF DISEASE</th><th></th><th></th><th></th><th></th><th></th><th></th></tr></thead><tbody><tr><td>Phase of infection</td><td>Early incubation</td><td>Late incubation</td><td>Early acute</td><td>Acute</td><td>Seroconversion in progress</td><td>Convalescent window</td><td>Early recovery</td><td>Recovery</td></tr><tr><td>Period</td><td>4-12 weeks (No symptoms)</td><td>1-2 weeks</td><td>2 weeks to 3 months</td><td></td><td></td><td>3-6 months</td><td>Years</td><td></td></tr><tr><td>Markers</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></tbody></table>
<ol>
<li>HBsAg | - | + | + | + | + | - | - | -  |
|  2. HBeAg | - | - | + | + | - | - | - | -  |
|  3. Anti-HBc (IgM) | - | - | - | + | + | + | + | -  |
|  4. Anti-HBc (Total) | - | - | - | + | + | + | + | +  |
|  5. Anti-HBe | - | - | - | - | + | + | + | +  |
|  6 Anti-HBs | - | - | - | - | - | ± | + | +  |</li>
</ol>
<p>Scanned by CamScanner</p>
<p><img src="assets/images/image-20251219-6ec07120.jpeg" alt="img-64.jpeg"></p>
<p>Fig. 5.2 Guidelines for selection of tests for Hepatitis B Profile</p>
<p>Scanned by CamScanner</p>
<p>1202 Basic Immunology and Serodiagnosis</p>
<p>(x) Add 1ml of 1N sulphuric acid to each tube to stop the reaction.
(xi) Read the absorbance of each tube at 492nm on a spectrophotometer using substrate blank as zero. The colour is stable for two hours.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="results">Results<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#results" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Determine the mean values for positive and negative controls respectively. For the test to be valid, the difference between them should be at least 0.400.</li>
<li>The cut-off value is the mean absorbance of the negative control plus the factor 0.050.</li>
<li>If the absorbance of patient's serum lies within ±10% of the cut-off value, it should be retested.</li>
<li>Specimens with absorbance above the cut-off value are considered reactive for HBsAg and those with absorbance below the cut-off value are non-reactive.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="ii-detection-of-hepatitis-b-surface-antigen-hbsag-or-australian-antigen-by-counterimmunoelectrophoresis-ciep">(ii) Detection of Hepatitis B Surface Antigen (HBsAg or Australian Antigen) by Counterimmunoelectrophoresis (CIEP)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ii-detection-of-hepatitis-b-surface-antigen-hbsag-or-australian-antigen-by-counterimmunoelectrophoresis-ciep" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><strong>Principle</strong> This technique involves migration of the test serum in an electric field between two known reagents, the antibody and the reference antigen. This method can detect both the antigen or the antibody if present in the patient's serum. Under the selected conditions of the medium and the buffer, the antibody migrate towards the cathode(-) while the antigen migrates towards the anode (+). A line of precipitation is formed indicating the presence of either antigen or antibody in patient's serum.</p>
<p><strong>Specimen:</strong> Serum</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Antibody to HBsAg (anti-HBs)
(ii) Reference HBsAg
(iii) Barbital buffer, pH 8.2 to 8.6</p>
<table><thead><tr><th>Sodium barbital</th><th>24.428g</th></tr></thead><tbody><tr><td>Sodium acetate</td><td>19.428g</td></tr><tr><td>0.1N HCl</td><td>270ml</td></tr><tr><td>Distilled water upto</td><td>3000ml</td></tr><tr><td>(iv) Agarose</td><td></td></tr></tbody></table>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Add 1g agarose powder to 100ml barbital buffer in a beaker.</li>
<li>Heat with stirring till it boils.</li>
<li>Pour, while hot, about 2 to 3 ml of agarose on a glass slide to make a layer 2mm in thickness.</li>
<li>Allow it to cool and become firm.</li>
<li>Make wells in the agarose as shown in Fig. 5.3. The wells should be 2 mm in diameter and the distance between the centres of two wells should be 8mm.</li>
<li>Place 25μl of each reagent in the wells as follows:</li>
</ul>
<p>(i) The reference HBsAg in the first set of wells near the cathode.
(ii) The test serum in the second set of wells in the middle.
(iii) The reference antibody (anti-HBs) in the third set of wells near the anode.
(iv) Place reference HBsAg and anti-BHs in adjacent wells as a controls.</p>
<ul>
<li>Pass a current of 5-6mA/cm for 45-60 minutes.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="results">Results<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#results" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>At the end of electrophoresis, a line of precipitation is observed where the antigen and antibody meet.</li>
<li>If the test serum contains antigen (HBsAg), a precipitation line appears between the reference antibody and the test serum. If the test serum contains antibody (anti-HBs), the precipitation line appears between the reference antigen and the test serum (Fig. 5.3).</li>
</ul>
<p>Scanned by CamScanner</p>
<p>Common Serodiagnostic Tests 1203</p>
<p><img src="assets/images/image-20251219-902a7086.jpeg" alt="img-65.jpeg">
Fig. 5.3 CIEP for HBsAg</p>
<ol>
<li>Control: precipitation between antiserum (●) and reference antigen (○)</li>
<li>Presence of antigen in the test serum.</li>
<li>Presence of antibody in the test serum.</li>
<li>Line of Precipitation (1).</li>
</ol>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="detection-of-other-hepatitis-b-markers">Detection of other Hepatitis B Markers<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#detection-of-other-hepatitis-b-markers" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>IgG and IgM antibodies to the core antigen (anti-HBc), antibody to the surface antigen (anti HBs) noitalics B'e' antigen (HBe) and its antibody (anti-HBe) are other markers for the diagnosis of hepatitis B. Their presence in patient's serum can be detected by enzyme immunoassays similar to the one described above for the detection of hepatitis B surface antigen (HBsAg). Commercial kits are available for each of the above tests with manufacturer's instructions.</p>
<p><strong>Hepatitis delta virus (HDV)</strong> Another complication that occurs with hepatitis B infection in some individuals is concurrent infection with hepatitis delta virus (HDV). It is necessary to test a patient's serum for antibody to delta virus (anti-HDV) if it is positive for hepatitis B surface antigen (HBsAg).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="significance-of-hepatitis-b-profile">Significance of Hepatitis B Profile<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#significance-of-hepatitis-b-profile" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Because hepatitis B virus is impossible to culture, knowledge of its mechanism has led to the development of diagnostic strategies to detect the various markers of HBV infection.</p>
<p>The first serological marker after the onset of HBV infection is HBsAg, which can be detected before the onset of symptoms. In acute hepatitis B infection, HBsAg reaches peak levels and declines gradually as the patient recovers. HBeAg can be detected one week after HBsAg, rises with HBsAg and disappears before HBsAg.</p>
<p>Anti-HBe appears after disappearance of HBeAg and indicates signs of recovery. IgM-anti-HBc appears during the acute phase of illness and drops to undetectable levels in one to six months. IgG-anti-HBc is produced during convalescent phase and persists for a long time there after.</p>
<p>Anti-HBs is never present along with HBsAg. It appears weeks or months after the disappearance of HBsAg. It persists for years and provides protective immunity against HBV infection.</p>
<p>Window period is the interval between the disappearance of HBsAg and the appearance of anti-HBs. During this period, IgM-anti-HBc may be the only indicator of recent infection detectable at that time.</p>
<p>In chronic hepatitis B infection, HBsAg and HBeAg or HBsAg and anti HBe persist at elevated levels for at least six months or up to a lifetime in some individuals.</p>
<p>IgM-anti-HBc levels decline after a few months and are replaced by IgG-anti-HBc. In most cases, Anti-HBe and anti-HBs are not produced until recovery eventually occurs.</p>
<p><strong>Selection of Tests for Hepatitis Profile:</strong> Fig. 5.2 suggests a scheme for selection of tests for a suspected case of hepatitis B infection.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="serodiagnosis-of-hiv-infection-and-aids">SERODIAGNOSIS OF HIV INFECTION AND AIDS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#serodiagnosis-of-hiv-infection-and-aids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Acquired immunodeficiency syndrome (AIDS), a disease which has now reached pandemic proportions, was first recognised in 1981. There are two related, but antigenically and genetically distinct viruses which cause AIDS. These are known as human immunodeficiency virus (HIV) 1 and 2 respectively.</p>
<p>Scanned by CamScanner</p>
<p>1204 Basic Immunology and Serodiagnosis</p>
<p>Transmission of HIV occurs by three major routes
(i) Sexual contact with an infected individual.
(ii) Parenteral exposure to infected blood or its components or other body fluids; or transplantation of infected tissue.
(iii) Vertical transmission from infected mother to infant.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="laboratory-tests-for-hiv-infection">Laboratory tests for HIV infection<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#laboratory-tests-for-hiv-infection" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>It is necessary to perform laboratory tests for HIV for various reasons.
(i) To diagnose and monitor patients.
(ii) To screen donated blood and blood products for infectivity.
(iii) To determine the prevalence of infection in a community.
(iv) To screen pregnant women.</p>
<p>HIV may persist in patients who have developed antibody to the virus. Therefore, serological tests are used for HIV screening. Isolation of the virus in cells culture is very difficult and not readily available. ELISA or agglutination tests are used for screening patients and blood donors. More specific procedures such as Western blot should be used to confirm positive screening tests. Western blot assays determine the presence of antibody to each of the several viral antigens including the core protein (p 24). The presence of antibody in the serum only means that the patient has been infected with HIV, but does not necessarily suffer from AIDS. HIV antibody positive individuals are infectious and are capable of transmitting the virus to others. Those at risk include blood product recipients, sexual partners and foetuses of pregnant women. Measurement of specific antibodies to various HIV antigens has a prognostic value and helps in determining the stage of the disease. For example, p24 antibody appears as HIV enters into a latent phase, and the antibody disappears as p24 antigen reappears and viral replication starts.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="elisa-for-hiv-antibody">ELISA for HIV Antibody<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#elisa-for-hiv-antibody" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>ELISA is the most widely used method for the detection of HIV antibody. Commercial kits with very high (98% – 99%) sensitivity and specificity are available.</p>
<p><strong>Principle</strong> HIV virus coated beads or microtitre wells are incubated with patient's serum or plasma. If patient's serum contains HIV antibody, it binds to the antigen on the solid phase. After washing the beads, or microtitre wells, antibody to human IgG conjugated with horseradish peroxidase is added to the antigen-antibody complex on the beads or wells. O-phenylene diamine (OPD) substrate with hydrogen peroxide is added to the bead. A yellow-orange colour after incubation indicates a positive test for HIV antibody.</p>
<p><strong>False positive results</strong> False positive results may be obtained due to the procedural, technical or test kit errors. False positive results may also be due to the presence of autoantibodies or HLA antibodies against antigens from the cell lines used to grow the HIV. Nonspecific positive results may also be obtained in some viral infections.</p>
<p>For these reasons, a positive ELISA test for HIV should be repeated in duplicate.</p>
<p><strong>Confirmatory tests for HIV antibody</strong> If the serum is reactive after retesting, it must be reconfirmed by a confirmatory test such as the Western Blot (WB) technique which detects antibodies to individual HIV antigens. WB technique is described in Chapter 4.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="torch-screening">TORCH Screening<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#torch-screening" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>TORCH screening is a set of serological tests required as a part of investigations performed during early pregnancy. The screening is valuable especially in women with a previous history of abortions or of clinical abnormalities in the child at birth or at a later date, premature delivery or stillbirth. TORCH screening includes tests for the detection of antibodies, particularly IgM antibodies, to
(i) Toxoplasma gondii (TO)
(ii) Rubella virus (R)
(iii) Cytomegalovirus (C)
(iv) Herpes simplex virus (H)</p>
<p>Scanned by CamScanner</p>
<p>Common Serodiagnostic Tests 1205</p>
<p>The screening is essential because most of these infections are asymptomatic or subclinical in the mothers, but the infectious agents are capable of passing through the placenta and infecting the foetus. The presence of IgM antibodies indicates a recent or current infection. Commercial kits are available for the detection of antibodies to the TORCH agents by ELISA technique.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="serodiagnosis-of-infectious-mononucleosis-im">SERODIAGNOSIS OF INFECTIOUS MONONUCLEOSIS (IM)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#serodiagnosis-of-infectious-mononucleosis-im" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Infectious mononucleosis is the most common symptomatic manifestation of infection by Epstein Barr virus. Symptoms of IM resemble those of infections caused by agents such as <em>Toxoplasma gondii</em> or <em>Cytomegalovirus</em>. Diagnosis of IM depends on the haematological picture of severe lymphocytosis with more than 20% abnormal lymphocytes, and on the detection of heterophile antibodies.</p>
<p>Heterophile antibodies are those antibodies which react with similar antigens from two or more unrelated species. The heterophilic antibodies of IM cross react with antigens on the surface of sheep, horse or ox red cells, but not with the antigens on guinea pig kidney cells. This differentiates them from other heterophile antibodies such as Forssman or serum sickness antibody (Table 5.10).</p>
<p>&gt; <strong>Note</strong>
&gt; Kits for the detection of specific EBV antibodies are commercially available.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="screening-test-for-the-detection-of-im-heterophile-antibodies-monospot">Screening Test for the Detection of IM Heterophile Antibodies (Monospot)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#screening-test-for-the-detection-of-im-heterophile-antibodies-monospot" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><strong>Principle</strong> This is a rapid slide test where patient's serum is treated with guinea pig kidney. There will be no absorption of IM heterophile antibodies (IMHA). Therefore, it will agglutinate with horse red cells. On the other hand, the IMHA is absorbed when the serum is treated with ox red cells, and so, there is no agglutination with horse red cells.</p>
<p>|  Part I IMHA + Guinea pig kidney</p>
<table><thead><tr><th>(Patient serum)</th></tr></thead><tbody><tr><td>→ IMHA not absorbed + Horse red cells</td></tr><tr><td>→ Agglutination</td></tr><tr><td>Part II IMHA + Ox red cells</td></tr><tr><td>(Patient serum)</td></tr><tr><td>→ IMHA absorbed + Horse red cells.</td></tr><tr><td>→ No agglutination</td></tr></tbody></table>
<p><strong>Specimen</strong> Serum or plasma.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Reagent I Guinea pig kidney antigen suspension preserved with 1% sodium azide.
(ii) Reagent II Ox erythrocyte stroma antigen suspension preserved with 1% sodium azide.
(iii) Horse red cell suspension preserved with chloramphenicol (1:3000) and neomycin sulphate (1:10000).
(iv) Positive control serum
(v) Negative control serum</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Place one drop of thoroughly mixed reagent I and II on two separate squares on a reaction card.
(ii) Add one drop of patient's serum or plasma to each square and mix well with separate wooden applicator sticks
(iii) Follow the same procedure with positive and negative control sera for each batch of test sera.
(iv) Add one drop of horse red cell suspension to each square; and mix each with a separate stick for about 10 stirring motions, without lifting or rocking the reaction card.
(v) Examine for agglutination within one minute after the final mixing.</p>
<p><strong>Results</strong> Record the results in both the squares (with reagents I and II) for each specimen and controls as agglutination, weak agglutination or no agglutination.</p>
<p>Scanned by CamScanner</p>
<p>1206 Basic Immunology and Serodiagnosis</p>
<p>Table 5.10 Heterophile Antibodies</p>
<table><thead><tr><th>Screening of Antibody</th><th>Reaction with</th><th></th><th></th><th></th></tr></thead><tbody><tr><td></td><td>Sheep rbc*</td><td>Horse rbc</td><td>Ox rbc</td><td>Guinea Pig Kidney</td></tr><tr><td>Infectious mononucleosis</td><td>+</td><td>+</td><td>+</td><td>–</td></tr><tr><td>Serum sickness</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Forssman-induced</td><td>+</td><td>+</td><td>–</td><td>+</td></tr></tbody></table>
<p>*rbc = red blood cells</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="interpretation-of-results">Interpretation of results<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#interpretation-of-results" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) If the agglutination is stronger with reagent I than with reagent II, the test is positive for heterophilie antibody for IM.</p>
<p>(ii) If the agglutination is stronger with reagent II than reagent I, the test is negative.</p>
<p>(iii) If no agglutination, or agglutination of the same strength appears with both the reagents, the test is negative.</p>
<p>(iv) If agglutination appears after one minute, it should be regarded as a negative test.</p>
<p>If this screening test is positive, the IM heterophile antibody titre should be determined by a quantitative test such as Paul Bunnell test.</p>
<p>&gt; Note
&gt; A simple screening test that uses latex particles is commercially available.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="paul-bunnell-test-for-infectious-mononucleosis-im-heterophile-antibody-titre">Paul-Bunnell Test for Infectious Mononucleosis (IM) Heterophile Antibody Titre<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#paul-bunnell-test-for-infectious-mononucleosis-im-heterophile-antibody-titre" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><strong>Principle</strong> IM heterophile antibody can agglutinate sheep red cells. This property is used to determine the titre of the IM heterophile antibody in patients serum. This test should be performed on sera which are positive with the screening test for IM heterophile antibody.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Normal saline (0.85%)</p>
<p>(ii) Sheep erythrocytes, washed 2% suspension in saline</p>
<p>(iii) Positive control serum with a known IM heterophile antibody titre.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Inactivate the sera by heating at 56°C for 30 minutes</p>
<p>(ii) Set up a row of 10 tubes for the test serum and another row of 10 tubes for the positive control serum.</p>
<p>(iii) Add 0.4ml saline to the first tube of each row and 0.25ml to tubes 2 to 10.</p>
<p>(iv) Add 0.1ml of test serum to the first tube (1:5), mix and transfer 0.25ml to tube 2. Continue in the same way till tube 9. Discard 0.25ml from tube 9. Tube 10 serves as a cell control</p>
<p>(v) Repeat the same technique for the positive control serum</p>
<p>(vi) Add 0.1ml of 2% sheep red cell suspension to each tube. The serial dilutions now range from 1:7, 1:14 ...1:1792 in the ninth tube.</p>
<p>(vii) Shake the tubes to mix and incubate at room temperature (15 to 30°C) for 2 hours.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="results">Results<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#results" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Examine each tube for agglutination, starting with the cell control, which should show no agglutination.</p>
<p>(ii) Record the titre of the positive control serum and should match the expected value ± one dilution.</p>
<p>Scanned by CamScanner</p>
<p>Common Serodiagnostic Tests 1207</p>
<p>(iii) Determine the titre the patient serum. Report the Paul-Bunnell titre along with the screening test result of the IM heterophile antibody test.</p>
<p>Interpretation Paul-Bunnel titre greater than 56 is considered significant.</p>
<p>Limitation of the test Since Paul-Bunnell test can be positive even with Forssman and serum sickness antibodies, the test must be performed in combination with the Monospot screening test.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="7ca20cce">♦ RHEUMATOID FACTOR (RF) SCREENING TEST<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#7ca20cce" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Rheumatoid arthritis (RA) is a chronic systemic inflammatory autoimmune disease which primarily affects the joints. The sera of most patients with RA contain rheumatoid factors (RF). RF are antibodies directed against the Fc portion of IgG molecules. However, they are not specific for RA and may also be present in other autoimmune diseases such as systemic lupus erythematosus (SLE). Other autoantibodies which may also appear in RA include antinuclear antibodies, anti-collagen antibodies, and cryoglobulins (immunoglobulins which precipitate at low temperatures).</p>
<p>One of the most useful (screening) laboratory tests involves the detection of rheumatoid factor. Rose-Waaler test was the first of the agglutination tests introduced for the detection of RF, and involves the agglutination of sheep red cells sensitised with rabbit IgG. The test is now obsolete. There are latex agglutination tests available which are easy to perform and are quite sensitive.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="rheumatoid-factor-rf-screening-test-using-latex-agglutination">Rheumatoid Factor (RF) Screening Test Using Latex Agglutination<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#rheumatoid-factor-rf-screening-test-using-latex-agglutination" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Principle Latex particles coated with IgG, react with patient's serum containing RF. The RF acts as an antibody to IgG and attaches to the Fc portion of IgG on the latex particles, to bring about visible agglutination.</p>
<p>Specimen: Serum</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Latex reagent: Polystyrene latex particles coated with human IgG
(ii) Glycine-saline buffer diluent (pH 8.2)
(iii) Positive control serum
(iv) Negative control serum</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="technique">Technique<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#technique" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Prepare 1:20 dilution of patient's serum by mixing 950μl of glycine saline buffer, and 50μl of serum.
(ii) Place one drop of the diluted serum on a properly labelled clean slide.
(iii) Place one drop each of the positive and negative control on two separate slides.
(iv) Mix the latex reagent thoroughly and add one drop to each serum.
(v) Mix with a separate wooden applicator stick.
(vi) Rock each slide slowly and observe for agglutination for two minutes.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="results">Results<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#results" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Positive control should show visible clumping in less than two minutes.</li>
<li>Negative control should not show clumping in two minutes.</li>
<li>Observe the test serum for the presence or absence of visible agglutination within two minutes.</li>
<li>Agglutination within two minutes indicates a positive test.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="quantitative-test">Quantitative Test<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#quantitative-test" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>If the screening test is positive, quantitative test should be performed by diluting the serum serially from 1:10, 1:20...1:2560 as follows: Add 0.9ml (900μl) of glycine-saline buffer to the first tube and 0.5ml to tubes 2 to 10.</p>
<p>(i) Add 0.1ml of the serum to the first tube, mix and transfer 0.5ml to tube 2.
(ii) Continue this process till tube 9 and discard</p>
<p>Scanned by CamScanner</p>
<p>1208 Basic Immunology and Serodiagnosis</p>
<p>0.5ml from tube 9 after mixing.</p>
<p>(iii) Perform a slide test on each dilution.
(iv) Alternatively, add 0.5ml of latex suspension to each tube, incubate at 56°C for 90 minutes and centrifuge at 2300 rpm for three minutes.
(v) Shake each tube gently and record agglutination.</p>
<p><strong>Result</strong> Report the titre as the reciprocal of the highest dilution which shows agglutination.</p>
<p><strong>Limitation of the RF test</strong> The rheumatoid factor is also found in normal individuals and in a variety of disease states. Therefore, a positive RF test is not considered diagnostic, but is suggestive of rheumatoid arthritis (RA). A negative RF test does not rule out the possibility of RA. Only 80 to 90 per cent of patients with RA give a positive RF test.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="detection-of-anti-nuclear-antibodies">DETECTION OF ANTI NUCLEAR ANTIBODIES<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#detection-of-anti-nuclear-antibodies" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Antinuclear antibodies (ANAs) are autoimmune antibodies which are directed against nuclei of tissue cells. ANAs can be produced against various constituents of the nucleus such as DNA, RNA or a number of nuclear proteins. Most ANAs are IgG or IgM in nature. They are found in the sera of patients suffering from SLE, in some viral infections and connective tissue diseases.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="indirect-fluorescent-antibody-ifa-test-for-the-detection-of-ana">Indirect Fluorescent Antibody (IFA) Test for the Detection of ANA<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indirect-fluorescent-antibody-ifa-test-for-the-detection-of-ana" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><strong>Principle</strong> The IFA test is based on the use of antiglobulin serum conjugates with fluorescein. Mouse liver or kidney cells are used as substrate nuclear antigens. These are fixed in the wells of a microscope slide. The ANA in the patient's serum bind to the nuclear antigens. This antigen-antibody complex is detected by the addition of antiglobulin-fluorescein conjugate. The ANA forms a sandwich between the nuclear antigen and the antiglobulin conjugate. This can be observed as a fluorescence under the fluorescent microscope.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="specimen-serum">Specimen Serum<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#specimen-serum" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="reagents">Reagents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#reagents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>(i) ANA mouse liver or kidney substrate slides. Each slide may contain 6 to 8 wells coated with the substrate.
(ii) ANA positie control serum.
(iv) ANA negative control serum.
(iv) FITC: Fluorescein isothionate conjugated with goat antihuman globulin.
(v) Phosphate buffered saline (PBS)
(vi) Mounting medium.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h3 level="3" id="method">Method<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#method" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h3></div>
<p>(i) Dilute the patient's serum 1:10 in PBS (0.1ml serum + 0.9 ml PBS).
(ii) Dilute the positive control 1:10, 1:50, 1:250 and 1:1250 in PBS
(iii) Prepare a worksheet and label the substrate slide.
(iv) Place 25 µl of each dilution of the positive control serum into wells 1,2,3 and 4 respectively.
(v) Place 25 µl of the negative serum into well 5.
(vi) Place 25 µl of the diluted patient's serum in one well.
(vii) Incubate the slide in a moist chamber for 20 minutes at room temperature.
(viii) Rinse each slide gently with 5 to 10ml of PBS. Apply running tap water above the wells so that each well is washed well. Do not apply the water directly on the wells.
(ix) Wash the slides in PBS in a staining dish for 10 minutes. Agitate the staining dish gently during the wash or use a magnetic stirrer.
(x) Remove the slide from the staining dish. Drain and blot the edges of the wells with a blotting paper. Do not touch the wells.</p>
<p>Scanned by CamScanner</p>
<p>Common Serodiagnostic Tests 1209</p>
<p>(xi) Immediately place the slide in a moist chamber. Dispense 25μl of FITC conjugate to each well.
(xii) Cover the moist chamber and incubate for 20 minutes at room temperature.
(xiii) Rinse and wash slide in the same way as (viii), (ix) and (x) above.
(xiv) Immediately apply one drop of mounting medium on each well and cover with a coverslip.
(xv) Examine each well on the slide under a fluorescent microscope using a high dry objective.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="results">Results<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#results" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(i) Check the controls for appropriate results.
Negative control: No green-gold fluorescence
Positive control: Strong green-gold fluorescence
(ii) Examine the test for the evidence of fluorescence.
(a) The test for antinuclear autoantibodies (ANA) is negative if no specific pattern of fluorescence is observed on the substrate.
(b) The test for ANA is positive when the substrate shows one or more of the following patterns of fluorescence:
(i) Homogeneous (Diffuse) This shows a uniform fluorescence throughout the nucleus. Moderately large irregular areas of more intense fluorescence may be seen.
(ii) Rim (Peripheral) The nucleus stains predominantly at the periphery, appearing as a rim.
(iii) Speckled Numerous, discrete, small or medium, uniform points of fluorescence are scattered throughout the nucleus.
(iv) Nucleolar The nucleolar pattern shows an intense homogeneous staining of the nucleoli often associated with a dull homogeneous fluorescence of the rest of the nucleus.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="titration-of-positive-specimens">Titration of positive specimens<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#titration-of-positive-specimens" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Titrate all specimens giving a positive test reaction using 1:10, 1:50, 1:250, and 1:1250 dilutions.</li>
<li>Determine the highest dilution producing a positive reaction.</li>
<li>Report the titre and the pattern of the positive reaction.</li>
</ul>
<p>&gt; <strong>Note</strong>
&gt; The same method can be adapted for the detection of other autoantibodies to the cell components such as mitochondria (AMA), smooth muscle (ASMA), parietal cell (APCA) and thyroid (ATA) antigens. Commercial kits are available for these tests.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="automation-in-serodiagnosis">AUTOMATION IN SERODIAGNOSIS<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#automation-in-serodiagnosis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Advances in the development of rapid, reliable assay methods have resulted in the introduction of automated equipments in serodiagnosis. Most of these machines employ the same principles as those used for the manual tests. Some of them make use of new techniques. For example, Abbott IMx and AxSym systems use microparticle enzyme immunoassay.</p>
<p>The automated machines are convenient to use and can perform two or more tests simultaneously. However, the machines and the reagents are expensive.</p>
<p>Scanned by CamScanner</p></div></div></div></div></div></div></div><div data-testid="stAppIframeResizerAnchor" data-iframe-height="true" class="st-emotion-cache-1dumvfu eht7o1d9"></div></section></div></div></div><div data-testid="portal" id="portal" class="st-emotion-cache-1q6lfs0 e19n7mk11"></div></div><div class=""></div></div>
  

</body></html>